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Given the challenge of addressing a growing non-communicable disease burden with 
limited health resources in developing countries, clinical pathways (CP) have been 
proposed as a strategy to optimize resource allocation in a climate of increasing 
healthcare costs. Ongoing reforms to China’s county-level public hospitals have 
generated an interest in developing evidence-based CP with a focus on controlling 
unreasonable medical costs, while at the same time raising the overall quality of 
healthcare services provided. An intervention project of evidence-informed CP on two 
selected disease areas (chronic obstructive pulmonary disease (COPD) and stroke) 
was conducted by China National Development Research Center (CNHDRC) in 2014. 
Since then, the implementation of CP project has received significant government 
interest, and has been seen as a model for replication across the country by the 
national health authority. However, the real impact of CP intervention in the short and 
long term is not yet clear. Therefore, an impact evaluation was considered necessary 
to identify the effectiveness and cost-effectiveness of implementing the CP in the 
pilot setting before being scaled up in other parts of the country and for other 
conditions.  
Stroke incidence has declined by over 40% in the past four decades in high-
income countries, but over the same period, incidence has doubled in low and middle-
income countries. Taking cerebral infarction (CI, a type of stroke) as an example, this 
study aims to understand the impact of the CP intervention on treatment effectiveness, 
and the use of resources in both short and long term. The study not only adds valuable 
evidence to the literature of CP management of CI, but also seeks to demonstrate the 




rural China taking into account contextually appropriate solutions to enable 
continuous improvement in intervention effectiveness.    
LITERATURE REVIEW 
A literature review focusing on effectiveness and cost-effectiveness of CP in 
management of in-hospital CI patients was undertaken by thesis author and a second 
reviewer, using a number of key databases (PubMed, Medline, Embase, Cochrane 
library and CINAHL) applying pre-defined keywords and subject headings. The 
Cochrane collaboration’s tool for assessing risk of bias was used to document the 
internal validity of individual studies. In addition, forest plots of selected outcomes 
across different studies were performed where heterogeneity was not judged to be a 
concern. Since there are high levels of variation in the nature of the disease and 
treatment depends greatly on local circumstances, the application of CP in 
management of in-hospital CI patients in the studies reviewed reveals conflicting 
evidence given the variety of settings studied, the diversity of aims, and variation in 
reporting outcomes. Some studies reported that the introduction of CP for a broad 
range of conditions can reduce the length of stay (LOS), in-patient complications, and 
total costs of acute hospital admissions while maintaining quality of care, improving 
patients’ outcomes, interdisciplinary cooperation and staff satisfaction. Conversely, 
there are studies reporting no or minimal measurable benefits regarding LOS, 
readmission to hospital, mortality rates and total costs, and no positive “return on 
investment”. Overall, the result of literature review does not provide a clear 
justification and firm conclusion for the implementation of CP for hospital-based CI 
management. A larger population scale study assessing the effectiveness and cost-






The study analysis was performed using quantitative data collected from a pilot site-
Hanbin county (in Shannxi province of China). First, descriptive statistics of the 
entire dataset and of selected subsets were provided, and data were examined to see if 
outcomes were distributed normally. Next, three major type of analysis were 
processed, namely: difference in difference (DID) after propensity score matching 
(PSM); interrupted time series (ITS); and Markov modeling. DID study design is 
commonly applied to evaluating observational data in order to address the problem of 
time-dependent trends in outcomes unrelated to the policy change, and PSM can 
balance the variation of patients’ characteristics using matching skills. ITS is an 
intuitive, practical and powerful analytical approach which is used here for evaluating 
longitudinal effectiveness of a time-limited intervention before and after a specific 
time point, using routinely collected longitudinal data. In terms of the ITS analysis, 
overall intervention effectiveness, based on a number of outcomes, was explored over 
a period covering 12 months before the intervention was introduced, and 36 months 
after the intervention was performed. For both the DID and ITS analysis, the primary 
outcomes of total hospitalization expenses and its components (medication expenses, 
radiology expenses, laboratory test expenses, diagnostic expenses and consultation 
expenses), LOS and utility value were analyzed. The Markov model is a routinely 
analytical tool in cost-effectiveness to simulate the disease trajectory and compare the 
relative costs and outcomes of an intervention against a relevant alternative. In this 
study, two Markov models were developed to identify the cost-effectiveness of CP 
management for patients admitted into hospital and discharged after CP management. 




comprehensive sensitivity analysis. Ethical approval was obtained from the 
University of Waterloo Research Ethics Committee (ORE#22396) for this research. 
RESULTS 
After several rounds of screening with specified selection criteria, 2,533 CI patients’ 
records were obtained and grouped into 4 subgroups. DID analyses result shows the 
impact of CP intervention is generally positive after removing potential confounding 
factors using PSM. Total hospitalization cost decreased, as did LOS, while European 
Quality of Life Scale-5 dimensions-3 Levels (EQ-5D-3L) based utility value 
increased. For ITS, the general tendency is similar for all primary outcomes. Results 
show that CP implementation slowed down the rate of increase of costs and LOS. 
However, most of the parameters were not statistically significant based on t-tests.  
For the Markov model-based cost-effectiveness analyses, the impact of CP 
intervention was observed to be not cost-effective in short term (21 days), but 
appeared to be cost-effective in long term (lifelong). For patients who are at stage of 
hospitalization, CP intervention of CI patients was not cost effective, and the ICER 
value was higher than the pre-defined threshold. However, the intervention of CP led 
to better health-related quality of life as indicated by higher utility value. For patients 
who are at the stable stage, namely being discharged by hospital, CP intervention of 
CI patients was the dominant strategy, whose ICER was much lower than the pre-
defined threshold. In conclusion, combing both acute and stable stages, the CP 
intervention is cost-effective as ¥30,071.79/QALY with higher costs and Quality-







In the literature, the application of hospital-based CP in management of acute stroke 
CI is associated with positive and negative effects, but this study reported more likely 
positive results in terms of selected primary outcomes and cost-effectiveness. The 
impact of the intervention could not only be attributed to the application of CP itself, 
but also its integration with awareness of standardized treatment among clinical 
practitioners, extensive training and support, and incentive management approaches. 
All these were combined with extensive stakeholder engagement given the ongoing 
China’s nationwide healthcare reform. It is clear and significant that the perceived 
importance of using evidence to inform practice has changed. But results of DID and 
ITS analysis should be regarded as provisional and a complex causal chain requires 
further investigation over a longer time period, with the collection of additional data. 
Development of the Markov model was a means to assess the long term effectiveness 
and cost-effectiveness of such a complex intervention to support evidence-based 
decision making. Much more can still be done in re-directing resources away from the 
county hospital sector towards community care in rural China. Further refinement is 
also possible using information technology innovations, including electronic 
pathways plug-ins into clinical decision support and patients’ health record systems, 
that can better monitor baseline activity and link compliance with preferred activities 
to appropriate reimbursement. The strength of the study is in applying statistical skills 
of DID, PSM, ITS and Markov model in analyzing the impact of CP effects. The 
limitation of the study is identifying confounding factors in explaining the casual 







The evaluation findings and lessons learned from the pilot will be widely discussed 
and disseminated to policy-makers to enable evidence-based decision-making for CP 
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Chapter 1  Introduction 
Summary of Chapter 
This chapter is divided into three major parts. The first part allows the reader to 
understand the general setting of the study by introducing China’s healthcare system 
and healthcare reforms, with particular focus on rural China. The second part focuses 
on the introduction of stroke as the disease targeted by the intervention, describes 
clinical pathways (CP), the study intervention, to understand the effective mechanism 
of CP and, finally, summarizes evidence in international communities. In addition, CP 
for cerebral infarction (CI, a subtype of stroke) is emphasized and introduced.  And, 
the CP intervention activities adopted in a pilot hospital in China are described and 
the purpose of the study is introduced. 
Part one: China’s healthcare system and healthcare reforms 
1.1. China healthcare system 
1.1.1. Overview of China 
China is the third-largest country geographically, with 56 ethnic groups inhabiting, 
whose mainland population of approximately 1.4 billion, equivalent to 18.4% of the 
world’s total (NHC, 2018). In the political context, China is a centralized 
administrative system under the leadership of the Communist Party of China (CPC). 
The administrative system has five tiers. In descending order, they are the State 
Council, provincial-level government (including minority autonomous regions, 
special administrative regions, and municipalities under direct central government 
control), city government, district or county government (in urban and rural areas 




In economic development, China experienced a planned economy phase similar 
to the Soviet Union, beginning with the birth of “new China” as founded by the CPC 
in 1949. In 1978, the central government started to implement the “Economic Reform 
Initiation” (ERI), which converted China to a socialist market economy. The 
transition of economic development brought a rapid growth and introduced change in 
every aspect of economy and society. Since the late 1980s, China has experienced 
rapid economic growth, with China’s real Gross Domestic Product (GDP) (Group, 
2019a)growing at an average annual rate of nearly 10% from 1979 to 2017(Service, 
2019). However, the income gaps between urban and rural areas, among regions, and 
between various groups of citizens, are widening(Policies, 2015). 
In terms of where people lived, rural areas hosted the majority of the Chinese 
population, which is why China was recognized as an agricultural country. After 
2012, the urban population outnumbered the rural population because rural migrants 
were rushing into cities for better job opportunities. By 2017, urban residents made up 
more than half of the Chinese population (58.5%)(NHC, 2018). In addition, the 
population of China is distributed unevenly, with higher density in eastern (relatively 
richer) areas and lower density on the (relatively poorer) western plateau. Moreover, 
China is facing a population aging problem. As of 2016, there were already 158.31 
million people over the age of 65(Group, 2019b), approximately 11.39% of the 
population(NHC, 2018). In short, in the last three decades, China has experienced 
dramatic economic and demographic transitions in urbanization, industrialization, and 
large-scale migration. Consequently, the Chinese healthcare system and the 
population's health status were affected significantly.  
 
3 
1.1.2. Health status in China 
In term of health status, the challenges of Chinese residents were changing from 
facing high birth rate, high death rate, low health spending, low health insurance 
coverage, and low life expectancy to tackling low birth rate, low death rate, expensive 
health spending, high health insurance coverage, and high life expectancy(Policies, 
2015). The health status glance of Chinese residents in 2017 can be seen in  
 
 
Table 1-1.  Meanwhile, China’s disease profile is shifting towards chronic disease due 
to economic, geographic and demographic (aging) transitions. Consequently, the 
healthcare system faces the challenge of transitioning from focusing on acute care and 
control of communicable disease to a system supporting prevention and rehabilitation 
stages and cost-effective management of non-communicable diseases. The disease 
risk factors related to lifestyle and social determinants have grabbed more attention 
from various stakeholders, including government and the general public. By 2016, the 
national authorities realized there was a need for an overall course management on 
healthcare rather than a focus on the treatment phase only. In 2016, the CPC Central 
Committee and the State Council released the “Healthy China 2030” blueprint, which 
covers areas such as public health services, environment management, the medical 
industry, food and drug safety, etc.(Xinhua). In recent years, “Healthy China 2030” 
was recognized as the national healthcare strategy for collection of all relevant 
resources towards improving the health status of Chinese and strengthening the 
healthcare system. In July 2019, the State Council announced a new national 
guideline proposing 15 special campaigns to intervene in health-influencing factors, 






Table 1-1 Health status of Chinese residents in 2017 
Description Value 
Birth rate 12.43‰ 
Mortality rate 7.11‰ 
Infant mortality rate 6.8‰ 
Life expectancy 76.7 years 
Prevalence rate of chronic disease in 2013 330.7‰ 
Health Insurance Coverage rate 94.2327% 
Resource: China health and family planning statistics yearbook 2018 
1.1.3. China’s healthcare system 
To understand the China’s healthcare system better, the relevant information can be 
considered in three related aspects: a health financing system, a health-service 
delivery system and a health supervision system (Policies, 2015). 
1.1.3.1. Financing system 
Healthcare is funded by the mix of general taxation, social insurance, private 
insurance, company-based health insurance schemes and out-of-pocket (OOP) 
payments. The total health expenditure (THE) is 5 trillion, 259.8 billion YUAN in 
2017 (as a percentage of GDP it reached 6.36%), while OOP expenses accounted for 
28.8% of THE (NHC, 2018). Although the OOP expenses has fallen from almost 60% 
in contrast to 2002, before rural residents were covered by a healthcare insurance 
scheme, the OOP rate is still higher than the government's expected goal, which is 
less than 20% of THE, as stated in the national healthcare strategy “Healthy China 
2030”(Council, 2017). Controlling the cost burden on households is a policy priority 
(Long, Xu, Bekedam, & Tang, 2013; H. Zhang, Hu, Wu, Yu, & Dong, 2015).  
At the time of the study, China operated three major healthcare social insurance 
systems: Urban Employees and Retiree Social Medical Insurance (UERSMI), Urban 
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Resident Social Medical Insurance (URSMI) and the New Rural Cooperative Medical 
Scheme (NRCMS). Each insurance scheme has disparate benefits packages, 
reimbursement rates and deductible amounts set at the city (UERSMI, URSMI) or 
county level (NRCMS), which vary due to differing levels of financing. Moreover, a 
medical financial assistance fund, paid for by the government and charitable 
donations, subsidizes premiums and OOP costs for those in financial need. The 
information for these insurance schemes can be found in Table 1-2.  
Rates of health insurance coverage have increased rapidly in recent years. 
Between 2003 and 2011, insurance coverage increased from 30% to 94% and average 
share of reimbursed inpatient costs rose from 14% to 47% over the same time period 
(Meng et al., 2012). In some well-funded regions such as Beijing, specialized 
operations (e.g., organ transplants) and innovative drugs (e.g., anti-cancer drugs) are 
included (L. Li & Fu, 2017) in the benefit directory, with higher reimbursement rates. 
In general, spending on medicines accounts for the biggest share of insurance 
payments among the three major insurance schemes, about 43% of THE (WHO, 
2011).  
Table 1-2 Information of three major healthcare social insurances 








workers in urban 
areas, financed by 
















expenses as UERSMI 




by rural household 











coverage depends in 
region) 
Resource: China health and family planning statistics yearbook 2018 
Exchange rate: 1CAD=5.2 YUAN. 
1.1.3.2. Supervision system 
The healthcare rights of Chinese citizens are defined in China’s constitution as 
follows: “Citizens of the People’s Republic of China have the right to material 
assistance from the state and society when they are old, ill or disabled. The state 
develops social insurance, social assistance and health services that are required for 
citizens to enjoy this right” (Council, 2017). The health authorities of multi-level 
governments are responsible for all the healthcare issues within a particular territory, 
under the leadership and technical guidance of health authorities at higher levels.     
At the time of the intervention, the supervision system was coordinated by the 
national health administration body called the National Health and Family Planning 
Commission (NHFPC), formerly the “Ministry of Health.” The NHFPC was replaced 
by the National Health Commission (NHC) in 2018. Other ministries, including the 
Ministry of Finance (MOF), the National Healthcare Security Administration (NHSA, 
founded in 2018 to manage diversity healthcare insurance system nationwide), and the 
Ministry of Civil Affairs (MCA), have responsibilities relating to financial processes 
and the accessibility of healthcare services 
Management of the healthcare system is delegated to mainland China’s 31 
provinces, municipalities and autonomous regions. Imitating the structure of the 
political management system, the health administration is organized in a hierarchy of 
four tiers, with NHFPC as the ultimate national healthcare authority (CNHDRC, 
2015). Provincial, municipal and city or county health bureaus are the main 
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administrative bodies at the regional level and generally mirror the organizational 
structure of the NHFPC. These regional bodies are responsible for implementing 
plans within their local areas (Policies, 2015). Healthcare services are also delivered 
at the township health center and village clinics (in rural areas) and community 
healthcare facilities (in urban areas), but there are no independent administrative 
bodies (CNHDRC, 2015). 
1.1.3.3. Healthcare delivery system 
Similar to healthcare systems worldwide, the Chinese healthcare delivery system is 
divided into a medical services system and a public health system.  
Medical services are delivered via various sizes of general hospitals, specialized 
hospitals, community or township healthcare facilities and village clinics. Ideally, the 
healthcare delivery system acts like a pyramid, in which a patient with minor or 
chronic diseases are managed through primary health care (community or township 
healthcare facilities and village clinics) and only acute and severe patients can be 
treated in hospitals with Acute and Emergency (A&E) and specialized professionals. 
However, the situation is the opposite in China. An integrated health care system 
composed of the primary healthcare system and hospitals sections is not yet well-
established, and the dual patient referral mechanism between upper-level health 
institutions and lower-level health institutions is absent. There were 310,563 hospitals 
in China in 2017, of which more than 90% were public hospitals (NHC, 2018). 
Hospitals are the dominant supplier of medical services in the Chinese healthcare 
system. Patients normally choose to go to hospitals directly rather than going to 
primary care institutions, such as village clinics or township healthcare centers. 
Barriers to the use of primary medical care include a lack of trust in the quality of 
non-hospital care and limited access to primary care facilities for large sections of the 
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population. In addition, hospitals can offer both inpatient and outpatient services 
simultaneously, which is convenient for patients. In 2009, more than 40% of the 
population did not have ready access to primary care centers (H. Wang, Gusmano, & 
Cao, 2011). More importantly, the reimbursement rate, acting as an economic 
leverage, is not significantly different between primary and advanced healthcare 
institutions. Therefore, given the belief by people that hospitals are more advanced 
and provide better service, people flock to hospitals, which are consequently 
overcrowded. The medical service delivery system was described as an upside-down 
pyramid, which is the opposite of the normal system. Consequently, hospitals are the 
major providers of medical services and this is reflected by the concentration of 
funding and resources going into the hospital sector. In terms of hospital type, 
generally, hospitals contribute most medical services and consume most health 
funding. They can be defined as secondary or tertiary hospitals depends on what they 
can treat.  Mental, maternal, child care, dental, oral and rehabilitation services can be 
provided by specialized hospitals, such as Maternal and Child Health Institutions 
(MCHI). And, every city and county has at least one traditional Chinese medicine 
hospital, which can provide herbal treatment, acupuncture and massage services 
(Policies, 2015).  
Public services are handled mainly by the China Center for Disease Control and 
Prevention (CCDC), whose four-tier management systems are organized and managed 
in the method of the four-tier hierarchical healthcare management authorities. In 
addition, community healthcare centers, township health centers and village clinics 
provide public health services, in urban and rural areas respectively. The NHC 
launched basic essential public services for both urban and rural populations, such as 
chronic disease control, vaccination, the creation of health profiles and health 
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promotion (Policies, 2015). MOF is responsible for the financing of public health 
services through national general taxation. The per capita cost of the basic and 
essential public health service package was 55 YUAN in 2018 (Website, 2018).  
Since the outbreak of Severe Acute Respiratory Syndromes (SARS) in 2003, the 
government has invested huge resources to strengthen infrastructure development and 
the professional capacity of public health emergency responses.  
Despite major achievements in terms of healthcare financial protection and 
accessibility, and meeting several key Millennium Development Goal (MDG) 
indicators, China has not reached universal health coverage (UHC) yet, and faces 
serious challenges preparing its health system to meet the population’s rising 
healthcare needs and expectations (CNHDRC, 2015). 
1.2. China rural healthcare system 
Healthcare delivery in China is divided into an urban healthcare system and a rural 
healthcare system. The rural healthcare system provides for approximately 576.61 
million people permanently living in rural areas, excluding the floating population 
that occasionally works in urban areas. This is approximately 41.5% of China’s 
population (NHC, 2018). 
The rural system is based on different levels of healthcare facilities: 
• Village clinics, staffed by general practitioners, provide preventive and basic 
primary care services and do not offer inpatient services (Barber, Michael, 
Henk, & Jin, 2014). 
• Township health centers accommodate primary care and limited specialized 
outpatient and inpatient services. 
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• County-level hospitals play a leading role in the local healthcare network, 
providing specialty care for both outpatients and inpatients, and referring 
patients as needed to advanced municipal and provincial hospitals. 
The rural healthcare system is given fewer resources than its urban counterpart.  
There are less than half the number of beds per capita in rural areas compared with 
urban areas (3.11 per 1,000 people in rural areas vs. 6.88 in urban areas) (NHC, 2018) 
and much less than half the number of healthcare workers per capita (3.77 health care 
practitioners per 1,000 people in rural areas vs. 9.70 in urban areas) (NHC, 2018). 
Key information about the rural healthcare system at the time of the study is 
summarized in Table 1-3 
Table 1-3 Facts of China's rural healthcare system in 2015 




National healthcare expenditure (% of GDP) 
3,531.24 billion 
YUAN (5.55%) 
Total rural healthcare expenditure 802.4 billion YUAN 
Healthcare expenditure per capita 2,327 YUAN 
Rural healthcare expenditure per capita 1,274 YUAN 
Healthcare 
Capacity 
NO. of rural healthcare facilities 825,176 
NO. of county-level hospitals 12,365 
NO. of township healthcare centers 36,902 
NO. of village clinics 645,470 
NO. of beds in rural healthcare facilities 3,411,793 
NO. of beds per thousand in rural healthcare 
facilities 
3.54 
NO. of beds in county-level general hospitals 2,051,612 





NO. of visits to county-level hospitals 626,004,112 
NO. of patients discharged from county-level 
hospitals  
21,717,888 
Average LOS at county-level hospitals 8.1 days 
Outpatient visits to township healthcare centers 1,000,675,370 
Inpatient admission to township healthcare 
centers 
37,326,053 
Inpatient discharge from township healthcare 
centers 
37,130,133 
Average LOS at township healthcare centers 6.3 days 
Outpatientvisits in village clinics 1,800,452,987 
Human 
resources 
NO. of health professionals  5,453,652 
Health professionals per thousand residents 3.77 
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NO. of Assistant doctors 1,460,827 
Assistant doctors per thousand residents 1.51 
NO. of Licensed doctors 1,044,095 
Licensed doctors per thousand residents 1.08 
NO. of Registered nurses 1,266,777 
Registered nurses per thousand residents 1.31 
NO of GPs in township healthcare center 432,831 
NRCMS Insured people 540million 
Per capita funding 490.3YUAN 
Total funding 302.528 billion 
No. of Reimbursements 1652.206 million 
Utilization rate of NRCMS fund 95.5% 
Health 
status 
Neonatal mortality 6.9% 
Infant mortality 10.7% 
Children under 5 years old morbidity 14.2% 
Maternal morbidity 
22.2 per ten 
thousand 




Average inpatient expenditure at county-level 
hospitals 
6,359.9 YUAN 
Average medicine expenditure of each inpatient 
visit at county-level hospitals 
2,427 YUAN 
Health expenditure per capita (% of 
consumption expenditure) 
753.9 YUAN (9%) 
Source: 2015 Statistical Yearbook for Health and Family Planning, NHFPC. 
Exchange rate: 1CAD=5.2 YUAN. 
Accessibility to health services for rural residents has improved in recent years 
since a new round of healthcare reform in 2009. The NCRMS covered approximately 
800 million people and required a household premium of 305 YUAN in 2012 (Zhu, 
Zhang, Yuan, & Tian, 2016). Summary of NRCMS can be seen in Table 1-4. 
Table 1-4 NCRMS summary between 2010 to 2017 













2010 836 96.00 156.57 1087 
2013 802 98.70 370.59 1942 
2014 736 98.90 410.89 1652 
2015 670 98.80 490.30 1653 
2016 275 99.36 559.00 657 
2017 133 100 613.46 252 
Resource: China health and family planning statistics yearbook 2018 
Exchange rate: 1CAD=5.2 YUAN 
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The decreasing number of rural residents being covered by NCRMS was caused 
by the conversion from NCRMS to URSMI as well as rapid urbanization in recent 
years. The NCRMS insurance scheme covered inpatient and catastrophic outpatient 
expenses, with further outpatient expenses covered depending on the region (W. C. 
Yip et al., 2012). Thus, the gaps in healthcare coverage in rural areas have declined 
and extensive healthcare insurance coverage of uninsured rural residents was seen as 
the largest achievements of health reform in the rural sector.  However, the chief 
characteristic of NRCM is “Low level and wide coverage”; challenges remain in 
terms of unaffordable healthcare services and quality of care in rural areas. 
Unaffordable healthcare services are a major social problem in rural China, 
especially as a cause of illness-related poverty. In the context of age-old distortions of 
healthcare service prices, the healthcare providers’ incomes relied on “markups” of 
inappropriate overprescribing, health devices, consumable health materials and 
laboratory tests, etc. This is done in response to revenue lost caused by governments 
caps on medical service prices - a 15% profit gain for drugs and 10% for medical 
devices (C. M. Yip, Hsiao, Meng, Chen, & Sun, 2010).  As time passes, such 
institutional weakness and environment seems rational and acceptable to balance the 
conflicts of interest among variable healthcare stakeholders. But these practices pose 
serious risks for patients. A study in Shaanxi province found that the household 
burden of chronic diseases was associated with healthcare payment-induced poverty. 
Furthermore, the likelihood of poverty caused by chronic diseases was higher in rural 
areas than in urban areas (Lan et al., 2018). In contrast to other developing countries, 
China is unique in high use of injections. At least three out of ten patients were 
prescribed injections, two to three times the WHO standard (Y. Li, Xu, Wang, Wang, 
& Lu, 2012).  
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Consequently, healthcare providers were financially incentivized to overuse 
more expensive and profitable services, medicines, health materials and laboratory 
tests. This led to high costs, inefficiencies, poor quality, and weak medical ethics (H. 
Wang et al., 2011; C. M. Yip et al., 2010). One study found that 30% of rural patients 
in China were prescribed infusions (8 bottles/person/year) in 2013, which is two to 
three times higher than the World Health Organization (WHO) standards (2.5-3.3 
bottles/person/year) (Y. Li et al., 2012). In 2012, medications costs accounted for 
54.9% and 48.2% of per capita outpatient and inpatient costs in township health 
centers of the rural healthcare system (CNHDRC, 2015). 
Beyond the unaffordable healthcare services, another key issue with the 
healthcare system in rural China is the lack of effective monitoring of the usage of 
medicine and medical devices. As a result, there are concerns that inappropriate 
behaviors by providers is not only fueling medical expenditures, but also affecting 
medical quality and patient safety. The problems are compounded by the limited 
clinical guidelines in the rural healthcare system and buy the low incomes of rural 
healthcare facilities that are heavily reliant on this markup. For example, another 
article found that Computerized tomography (CT) scanners and Magnetic resonance 
imaging (MRI) machines were being over-used in rural regions, which was resulting 
in high healthcare expenditures and unnecessary exposure of patients to radiology  (T. 
Liu & Jin, 2009). It is arguable that such misuse of resources may be at least partly 
due to the absence of practical guidelines and effective monitoring mechanisms. 
While the over use of medical services has attracted wide attention, shortages of 
medical services in rural areas of China cannot be ignored. For example, in diagnosis 
of COPD, the lung function test is compulsory, but most of the China rural healthcare 
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institutions cannot offer such services to support appropriate and accurate COPD 
diagnosis.  
Both of these problems can be traced to irregular behavior of physicians, 
imperfect management and irrational oversight measurements. There is a popular 
sentiment to adopt CP to improve care quality and health outcomes at a relatively low 
cost.   
1.3. Healthcare reform 
The Chinese healthcare system has gone through several phases of reform:1) between 
1949 and the late 1980s, healthcare reforms were focused on equality due to the 
planned economy. The Chinese government created a health system gradually, in a 
fashion similar to other communist states. In this period, the government owned and 
operated all community healthcare facilities and employed the community healthcare 
workforce (so-called “barefoot doctors”) to provide services for free. At that time, the 
Chinese rural health system was recognized by WHO as a model of service in 
developing countries; 2) from the late 1980s until the early 2000s, along with the 
introduction of market forces in all economic and social sectors, government scaled 
back its inputs to the health sector and exerted little control over the behavior of 
health care organizations. This change resulted in a vast majority of uninsured 
patients. Healthcare workers acted like private entrepreneurs. In response to a rapid 
growth in health expenditures and discontent with healthcare, the government 
introduced the NRCMS to mitigate the financial burdens of disease among rural 
residents. And 3) from the late 2000s, in response to rapid growth of healthcare 
expenditures,  healthcare reforms attempted to balance equality and efficiency with 
the quality of care and reasonable costs (H. Wang et al., 2011). 
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Since 2009, the national government officially abandoned experimenting with a 
healthcare system based predominantly on market principles and initiated a major 
new phase of healthcare reform that aimed to provide an affordable, equitable and 
accessible national health system to the public by 2020 (Reynolds & Mckee, 2012).In 
the new round of national comprehensive healthcare reform launched in 2009, and 
continuing through 2012, the government committed 850 billion YUAN. (The 
equivalent of 163.5 billion CAD, at an exchange rate of 5.2 YUAN = 1CAD.)  Five 
main independent parts were included in the reforms: 1) expanding health insurance 
coverage (with co-payments) to most of the population; 2) establishing a national 
essential medicine system; 3) strengthening the delivery system of basic public health 
services; 4) improving the primary healthcare operating system; and 5) conducting 
trials of public hospital reform (NHC, 2009). Out of five major reform parts, public 
hospital reform was recognized as the hardest part. Progress has been slower than the 
other four reform fields, since the change of behavior and interests of clinical 
practitioners from policy initiation to frontline practice is a complex and slower 
working mechanism. Within rural healthcare, this problem is bigger, more complex 
and more severe, given the county hospitals in a leading role, underpinned by the 
township health centers and village clinics. Because of low patient trust in village 
clinics and township health centers and the absence of effective management 
approaches in patient flow, the county-level hospitals in rural China are always 
overcrowded and excessively general in provision of treatments as patients often seek 
care at county-level hospitals for simple health problems. Although most Chinese 
counties have initiated tiered reimbursement systems, with higher reimbursement for 
care at village clinics and township healthcare centers, many patients continue to use 
county-level hospitals for minor conditions, NCD conditions, and rehabilitations. A 
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referral system is typically not in place(Barber et al., 2014). Therefore, the county-
level hospital is criticized as an important driver of increased healthcare costs and 
limited public access to qualified and standardized medical services. Meanwhile, 
faced with conflicting interests from variable governing stakeholders, county-level 
hospital reform remains one of the least understood areas of healthcare reform and 
progress has been slower than the other four reform fields described above. Thus, 
county-level hospital reform received the concern and attention of policy makers and 
was targeted as a key part to advance future healthcare reform plans. In 2012, the 
State Council issued the “Opinion on comprehensively Carrying Out County-Level 
Public Hospital Reform and The Instructions on Urban Public Hospital 
Comprehensive Reform’s Pilot Work.” This proposed to improve the quality of 
treatment through CP and electronic medical records, eliminate completely the bonus 
rewarded for over-prescription and standardize evidence-based clinical practice.  
The evolving rural health service system and associated health insurance 
schemes are helping to address the problem of accessibility and unaffordable care. 
Following the launch of the 2009 healthcare system reform, a three-tier rural 
healthcare delivery system composed of county-level hospitals, township health 
centers and village clinics was strengthened distinctly in most areas, and these 
institutions worked in coordination to meet the healthcare needs of local rural 
residents. These governance reforms for healthcare delivery and financing have made 
a significant difference in solving the problems of past services. For example, the 
accessibility changes in healthcare services for urban and rural residents can be 
summarized as Table 1-5. 




Year Visit rate within two 
weeks (%) 














2003 13.9 11.8 3.4 4.2 62 92.6 
2011 15.3 13.7 8.4 10.1 95.9 95.5 
Resource: Reports of the China’s health reform progress, 2013, NHC 
 
In terms of access to healthcare, reforms aimed to expand insurance coverage, 
and change reimbursement rates and government subsidies. By 2020, 97.5% of the 
rural population will be covered by the NRCMS (Cheng, 2013) and a package of free 
basic public health services will also be provided to reduce inequality. Although the 
expansion of health insurance has made medical services more affordable, challenges 
remain relating to inappropriate provider behavior increasing medical costs and 
reducing the quality of care. 
Two approaches to reform have previously been reported: eliminating the mark-
up alone and eliminating the mark-up alongside wider hospital reforms: 
• A review of hospitals in Zhejiang province showed that by cancelling markups 
and increasing service prices, drug spending per outpatient visit decreased by 
8.2% and drug spending per inpatient visit decreased by 15.4%, while service 
expenditures per visit increased by 23.0% for outpatients and 27.7% for 
inpatients (H. Zhang et al., 2015). 
• The integrated approach, known as the Sanming Model, after a city in Fujian 
province in southeast China (Fu, Li, Li, Yang, & Hsiao, 2017), involved not 
only addressing payment systems, but also restructuring the hospital 
governance structure and realigning physician incentives. This model was 
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shown to reduce drug expenditures for inpatients and outpatients (Fu et al., 
2017). 
Despite these reforms, overtreatment due to perverse financial incentives for 
providers as well as inadequate access to treatment for patients remain major issues in 
rural areas and are the focus of ongoing healthcare reforms. Interventions that can 
simultaneously address these issues and show measurable impacts on patient and 
provider-relevant outcomes should be investigated. 
Part two: overview of stroke and CP, and CP for cerebral infarction  
1.4. Stroke and cerebral infarction 
1.4.1. Clinical characteristics of stroke 
Stroke occurs when blood flow to the brain is restricted, causing the death of brain 
cells (Association, 2016). The impact depends on both the location and severity of the 
damage. The most important risk factors for stroke are high blood pressure, heart 
disease, diabetes, smoking and prior stroke (Prevention, 2019). 
Stroke can be categorized into two types: ischemic, which is caused by a lack of 
blood flow and accounts for 60-80% of strokes, and hemorrhagic, which is caused by 
bleeding (Health, 2019; Matthias et al., 2003; Yunhua et al., 2015). Ischemic strokes 
are further divided into thrombotic and embolic. In thrombotic stroke, a blood clot 
forms in an artery supplying blood to the brain. In embolic stroke, an embolism 
(blood clot or other material) travels through the bloodstream to an artery in the brain. 
CI is a major type of ischemic stroke resulting from a blockage in the blood vessels 
that supply blood to the brain (WIKIPEDIA, 2019a). A Chinese national surveillance 
program using CT scan results shows that on average, CI accounts for 62.4% of total 
stroke cases, ranging from 43% to 79% among patients with CT scan rate greater than 
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75% across ten cities (Wu et al., 2013; L.-F. Zhang et al., 2003). Thus, it was 
concluded that CI was the dominant subtype of stroke in Chinese populations. The 
frequency and proportion of CI is higher for people over 45 years old than younger 
people, but there is no significant difference between men or women (L.-F. Zhang et 
al., 2003).  
Treatment generally focuses on early intervention followed by rehabilitation. The 
2018 guidelines from the American Heart Association/American Stroke Association 
detail the first two weeks of care and cover 1) pre-hospital management, 2) urgent and 
emergency evaluation and treatment with intravenous and intra-arterial therapies, and 
3) in-hospital management, including prevention and treatment of 
complications(Powers et al., 2018). The guidelines emphasis the integration of pre-
hospital and in-hospital settings. 
1.4.2. Burden of disease (clinical burden and economic burden) 
Stroke is the second leading cause of death globally, leading to more than 5 million 
deaths per year, 11.1% of total deaths worldwide (Donkor, 2018; Lancet, 2018). 
Stroke has a significant impact on the health of patients and caregivers (Meng et 
al., 2012). Patients perceive that their physical function worsens over time, although 
they may be able to adapt and maintain a good quality of life. Caregivers’ health is 
also affected, particularly in terms of mental and emotional aspects of quality of life. 
On average, 0.27% of gross domestic product (GDP) was spent on stroke by national 
health systems, and stroke care, equivalent to around 3% of total healthcare 
expenditure (Evers et al., 2004). 
In China, age-standardized stroke prevalence and mortality rates were 1,114.8 
per 100,000 people and 114.8 per 100,000 person-years, respectively, in 2013 (W. 
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Wang et al., 2017). Stroke is the leading cause of years of life lost (YLL) and 
disability-adjusted life years (DALYs). There are geographical differences in stroke 
incidence in China: the Northeast has the highest incidence (486 per 100,000 person-
years), whereas the incidence rate is significantly lower (136 per 100,000 person-
years) in Southern China (Gao et al.; Liping, David, Wong, & Yongjun, 
2011).Furthermore, the same study found that the burden of Stroke in terms of YLLs 
and DALYs was higher in rural areas compared to urban areas. 
In 2003, national direct medical costs were 23.732 billion YUAN for ischemic 
stroke and 13.72 billion YUAN for intracerebral hemorrhage (Y. L. Wang et al., 
2007). Together stroke is the most costly disease in terms of medical expenditure in 
China and growth of spending on stroke exceeded the rate of GDP growth from 1993 
to 2003. In 2014, there were 1,705,459 CI patients who were discharged from 
hospitals (922, 992 from county-level hospitals) with an average LOS of 11.7 days 
(10.8 days for county-level hospitals) (Commission, 2015). In 2014, the average fee 
for CI hospitalization at county-level health institution was 8,841.4 RMB, accounting 
for 83.8% of annual income of rural residents (Commission, 2015). 
 Current levels of screening, prevention, treatment and rehabilitation are far from 
adequate in China. Research undertaken by the China National Health Development 
Research Center (CNHDRC) found that total hospitalization costs were particularly 
high with respect to stroke among some county-level hospitals. Also, patients who 
might be best managed in a community setting (i.e. a village health center), were 
being admitted unnecessarily to county level hospitals. These findings for stroke are 
in line with the general themes of overtreatment and under-use of community care in 
China, as outlined earlier in the chapter. 
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The stroke care pathway in China is not well integrated, which prevents patients 
from accessing comprehensive care (Z. Li, Jiang, Li, Xian, & Wang, 2019). This 
results in longer pre-hospital delay, low intravenous tissue-type plasminogen activator 
(tPA) use, poor adherence to medicines and low use of rehabilitation services (Bettger 
et al., 2017; Jiang et al., 2017; Zixiao Li et al., 2016). The lack of linkage across 
settings has also limited the ability to assess the outcomes and quality of stroke care in 
China (Z. Li et al., 2019). 
Consequently, there is an urgent need to explore and establish efficient 
integration systems for screening and prevention: stroke networks to disseminate 
health knowledge, advocate healthy lifestyles, conduct screening for people at high 
risk, undergo early diagnosis and intervention, focus on and strengthen primary 
prevention and secondary prevention, and improve the current situation with respect 
to treatment and rehabilitation. 
1.5. Clinical pathways 
CP, also known as “care pathways” “critical pathways” “care maps” or “integrated 
care pathways” are defined as patient-centered schedules of medical and nursing 
procedures, including assessment details for therapy and consultations designed to 
reduce variation in clinical practice, optimize patient outcomes, minimize resource 
utilization, maximize the clinical effectiveness of process of care, accommodate 
communication between patient and healthcare professionals and improve the quality 
of documentation (J. Kwan & Sandercock, 2002; Rotter et al., 2011; K. Vanhaecht, 
De Witte, Depreitere, & Sermeus, 2006).The characteristics of CP can be summarized 
as evidence-based, organized, goal-defined and time-managed (by hour for 
emergency care, by day for hospitalization or by visit for homecare), with 
interdisciplinary coordination and improved documentation coupled with payment 
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reform. While clinical guidelines and protocols can provide generic recommendations 
for specific conditions or interventions, CP outlines the best operational process for 
care within the local structure and supporting systems (K. Vanhaecht et al., 
2006).Thus, CP is a tool which translates the best available evidence and guidelines 
into multidisciplinary plans of best practice for people with particular conditions 
(CLINICAL, 2013). In addition, CP is a valuable tool for focusing on quality and 
coordination of care, It can apply to multi-disciplinary teams and cover interventions 
for prevention, treatment and rehabilitation (CLINICAL, 2013).   In practice, CP is 
developed in a particular setting to define the steps to be taken within the local 
structure, systems and time-frames. Sometimes, the healthcare service providers are 
required to follow and evidence CP steps in order to be reimbursed for delivery of 
patient care.  
CP was originally used to deal with medical errors and unnecessary variation 
observed in term of patient care and outcomes for certain conditions, as well as fast-
growing healthcare costs. CP reduced prolonged length hospitalization and 
unnecessary admissions (Crummer & Carter, 1993; Weingarten, 2001).The concept of 
CP was derived from industry practice and introduced to the health sector for the first 
time at the New England Medical Center (Boston, United States) in 1985, in response 
to inappropriate behavior including an escalating volume of care delivered and little 
focus on quality (Wikipedia, 2019b). In that scenario, the high volume and 
inappropriate variations in care contributed to inefficiency and resulted in 
inappropriate expenditures for labor, medication, laboratory procedures, supply chain 
redundancies and inefficient communication (Hipp, Abel, & Weber, 2016). 
Specifically, when variations of prescriptions are based on preference or interest 
rather than evidence-based decision making, the healthcare service provided will 
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increase risks to patient safety and lower the increase inefficiency in the utilization of 
healthcare funds (Hipp et al., 2016). Initially, early CP concentrated on simple 
conditions or surgical procedures, whose care had less variation in pathology and 
mature treatment in practice. They were easier to standardize in according with 
existing references and were shown to improve health outcomes and efficiency while 
reducing costs and variability (Crummer & Carter, 1993).   Later, CP began to be used 
to manage complex or chronic conditions such as stroke, diabetes, cancers, and 
palliative care. As an instrument to improve clinical processes, CP is being 
implemented across individual hospitals and healthcare systems in the USA, 
Australia, the UK and Singapore (Cheah, 2000).Over the past few decades, CP was 
increasingly used to decrease LOS and reduce unnecessary costs while maintaining or 
improving quality of care (K Vanhaecht et al., 2012).Some international studies have 
shown that the application of CP appears to shorten the length of hospitalization stays, 
lower mortality rates and in-hospital comorbidities, and all while maintaining quality 
of care, improving patient outcomes, interdisciplinary cooperation and staff 
satisfaction (Hanna et al., 1999; Isozaki & Fahndrick, 1998; Jacavone, Daniels, & 
Tyner, 1999; Mabrey, Toohey, Armstrong, Lavery, & Wammack, 1997; Maxey, 
1997).Therefore, CP, informed by evidence of best practice, has been recognized as 
an effective tool for enhancing individual health outcomes and reducing utilization of 
overall health resources. Consequently, CP may reduce medical service costs and 
improve the cost effectiveness of healthcare delivery, coping with changes in payment 
mechanism (Rotter et al., 2011; Y, 2012). A systematic review of CP working on 
stroke was conducted following routine approach, more details can be found in 
chapter 2.  
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1.6. Clinical pathway for cerebral infarction 
As proposed in the Helsingborg Declaration and by the American Heart Association, 
access to well-organized multidisciplinary care is recognized as one of the most 
effective treatment for CI patients (J. Kwan & Sandercock, 2002). However, 
variations in the organization and delivery of healthcare reduces the efficiency of 
recommended treatment. The CP can facilitate the process of general medical and 
nursing care, as well as coordinate and guide in an effective way the standardized 
collaboration of multidisciplinary professionals (J Kwan, 2007; Silke et al., 2012). 
In the acute-care hospitalization setting, CP is usually initiated at the time of 
admission and terminated when the patients are discharged or transferred to another 
setting (J Kwan, 2007; Silke et al., 2012). Within the acute stage, accessibility of 
timely and appropriate assessment, therapy, and early-stage rehabilitation are crucial 
for effective management of patients admitted to the hospital with acute CI; this kind 
of care can best be achieved through a coordinated and integrated approach across the 
healthcare continuum (Fagerberg, Claesson, Gosmanhedström, & Blomstrand, 2000). 
For example, in the hyper-acute phase of CI, an Emergency Clinical Pathway (ECP) 
can facilitate the decision to provide intravenous thrombolysis for eligible patients. In 
the first few days after admission, a CP can also ensure that all the important 
processes of care are provided, such as fever management, glucose monitoring and 
swallowing screening. In the stage of inpatient rehabilitation, the CP can then 
coordinate interdisciplinary communication between the physicians and nurses of the 
stroke unit and ensure a smooth discharge with clear instructions for follow-up (J 
Kwan, 2007). Additionally, a well-designed CP should take many factors into 
consideration during treatment, such as unpredictable courses of illness including the 
occurrence of complications and co-morbidities such as diabetes, hypertension, 
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infections, dehydration, incontinence, depression and dysphagia, etc. (David, Anne, 
Inigo, & Lalit, 2002; Martínez-Sánchez et al., 2010). In order to accommodate such 
challenges, “co-pathways” were designed to deal with the common co-morbidities or 
complications of CI in a more structured and organized manner. These can be shared 
across departments within the same health institution (Dykes, 1997; D. Sulch, ., I. 
Perez, ., A. Melbourn, ., & L. Kalra, . 2000). This setup should ensure that appropriate 
care is offered to treat the patient conditions at the right time. 
Part three: Overview of CP Intervention in pilot hospital and study 
objectives  
1.7. Intervention overview 
1.7.1. Rationale of intervention in the setting of rural China 
Within the China healthcare reform strategy, public hospital reform is recognized as 
the hardest job in balancing the conflict of interests between various stakeholders. As 
the major provider of medical services in Chinese healthcare system, there is evidence 
that hospital healthcare providers have been financially incentivized to over- or under-
provide healthcare services, and concerns remain that inappropriate behaviors by 
providers are fueling costs and affecting quality of care and patient safety. With it is 
large patient population and prolonged institutional weaknesses, the rural healthcare 
system was seen as the most complex and difficult sector in which to process changes 
in disease management. Due to weak disease management capacities in grassroots 
health institutes (township healthcare centers and village clinics) and the absence of 
effective management approaches to patient flow, large numbers of rural patients 
often seek care at county-level hospitals, which leads to overcrowding in those 
hospitals. The overcrowding and extensive use of treatments motivated by profit-
seeking rather than healthcare was criticized as an important driver of increased 
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healthcare costs and for settling up barriers to the access of quality medical services 
by the public Because of this, the reforms of county-level hospitals received great 
public attention and was seen as a sign of healthcare reform success.  Moreover, the 
State Council issued the “Opinions on Comprehensively Out County-level Public 
Hospital Reform Pilot Work” in 2012, which proposed to improve the quality of 
treatment through CP and encourage the exploration of different and innovative local 
models.   
The institutional weakness may at least be partly due to the absence of practical 
CP and effective monitoring mechanisms for the use of medicine and medical 
devices. Following the raising awareness of evidence-based medicine and the 
application of same decision-making in hospital management and clinical practice has 
evolved from being option-based to being based on sound scientific procedure (Rotter 
et al., 2011). This change provides the conditions and opportunities to introduce CP 
into rural public hospitals to strengthen the system and bring changes in behavior. 
Therefore, evidence-based CP not only has been introduced as a realistic option for 
optimizing diagnosis and treatment techniques for public hospitals, but also to provide 
sound scientific evidence for making policy decisions. 
Development of evidence-informed CP interventions has raised the interest of 
health authorities and rural medical institutions as a potential way to reduce variation 
in clinical processes and to help contain fast-growing medical costs while improving 
the quality of care. Trials of CP in rural pilot areas can provide real world evidence to 
help rural healthcare reforms take the next step. As the leading actor in the rural 
healthcare system, county-level hospitals were chosen as pilot sites because the 
county-level government has been given the authority as part of national health 
reform to create and define reform trials. By empowering local governments, project 
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interventions are more efficient and the potential risks posed by unexpected 
confounding factors, as well as outright failures, can be recognized and contained 
more quickly. In other words, if the reform trial within the county scale is not 
successful, the negative impact or intervention or risk factors can be controlled in 
scope. Conversely, successful experiences can be recognized by upper-level health 
authorities, and the pilot trial can be extended on a broader scale to benefit more 
people. This is also the usual method to push forward reform, given that China is a 
diverse country. This approach is described proverbially as “crossing the river by the 
feel of the stones”. 
1.7.2. The overview of intervention 
Resulting from extensive consultation and investigation with peers from the 
international community , the think tank of Chinese National Health Authority(NHC), 
China National Health Development Research Center (CNHDRC), in collaboration 
with the National Institute for Health and Care Excellence (NICE) International 
embarked on a pilot project to develop and implement evidence-informed CP for two 
high priority disease areas, chronic obstructive pulmonary disease (COPD) and stroke. 
The intervention was designed as a comprehensive reform in which CP is combined 
with other reforms, including capacity training sessions for clinical practitioners, 
management and development of data management systems, and incentive 
management approaches (not designed as a stand-alone pilot project.) The 
implementation of a CP with other supporting systems for selected conditions took 





Figure 1-1 Location of pilot sites in China 
The target counties were chosen based on predefined criteria: 1) strong 
willingness and enthusiasm to actively participate; 2) sound project management 
experience; 3) better support of information systems in county hospitals; 4) reflection 
of a diversity of economic conditions useful in dissemination and reproduction; and 5) 
minimization of potential confounding factors such as other, simultaneous reform 
trials which could interfere with assessments of this trial. Four candidate areas were 
selected as the pilot areas: Huangdao county of Shandong province (located in Eastern 
China and representative of high-income rural areas), Wen county of Henan province 
(located in middle China and representative of middle-income rural areas), Qianjiang 
county of Chongqing Municipality (located in Southwest China and representative of 
middle and low-income rural areas), and Hanbin county of Shaanxi province (located 
in Northwest China and representative of low-income rural areas).   
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After extensive engagement with various stakeholders (such as local 
practitioners, policy makers from rural health authorities and institutions, clinical 
consultants, senior policy makers from ministries, international counterparts, etc.), the 
research team outlined the intervention activities as per Figure 1-2. This divides the 
project activities into two major parts: preparation and implementation. Within each 
of the two parts, there were individual project activities designed to facilitate the 
development of the intervention. 
 
Figure 1-2 Overview of intervention activities 
Preparation stage: 
Target conditions were identified based on a broad-ranging situation analysis of 
the pilot areas, including a review of the literature, local socioeconomic and 
demographic information, health system indicators, analysis of the local disease 
spectrum, top-down analysis of the financial burden of disease, and consultation with 
clinical experts and local stakeholders. After comparing the burden of disease and 
corresponding economic burden across the four pilot areas, COPD and stroke were 
chosen as the target conditions for the intervention. According to local clinical 
demands, stroke was subdivided into three categories—cerebral hemorrhage, cerebral 








•2:Establisment of incentive 
policies





To fully consider professional competencies and local settings, existing clinical 
practice of the study sites was used to establish the baseline for CP development. To 
reach a consensus, amendments to existing practices and business processes were 
made iteratively, incorporating principles from national guidelines and comments 
from senior clinical experts on COPD and stroke. As a dynamic intervention, the CP 
contexts were optimized continuously to respond to changes in local setting and in 
response to other confounding factors. This is normally done during an update or as 
part of a review within each project year.  
There were two major components for each CP context template. One is the 
description of general principles and standards of procedure for treatment(Appendix 
A1), including, but not limited to, target conditions (diagnosis with International 
Classification of Diseases-10th Revision [ICD-10] code), diagnostic references, 
treatment options, LOS, inclusive and exclusive criteria, summary of recommended 
tests and medical principles of treatment, status at discharge, etc. The inclusion 
criteria are 1) primary diagnosis must be cerebral infarction (ICD10: I63) and 2) those 
patients with secondary diagnosis can be covered by the current CP if they do not 
need special treatment for their secondary diagnosis and if the secondary diagnosis 
does not have any impact on the implementation of cerebral infarction pathway. This 
general introduction serves as a simplified clinical guideline to outline the basic rules 
of standard procedure. The other component is a detailed list of daily-prescribed 
actions that might be taken by physicians (Appendix A2), which have been installed 
into hospital information systems for processing. In order to ensure the quality of 
service and physician adherence to the CP, the items were allocated into mandatory 
and optional categories according to their importance and feasibility in relation to the 
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condition. Specifically, mandatory items, such as  blood test, urine test, myocardial 
enzymes, coagulation function, are applied to all patients admitted into clinical 
pathway management and an explanation of decisions made must be recorded for 
review in some extreme cases. The optional items can be ordered by physicians 
depending on patient needs and will vary between cases, such as skull CT, oxygen 
inhalation, ECG monitoring, etc. 
Meanwhile, with the aim of more efficient delivery of care, an incentive 
mechanism was derived to motivate practitioners’ participation and improve the 
adherence of clinical staffs. If an extra bonus payment was proposed by hospital 
management on the basis of quality auditing, the doctors are able to receive benefits 
to subsidize their inputs, rather than from a “mark-up” on medicine and testing. 
Meanwhile, hospital management introduced a series of supportive management 
measures to assist with the implementation of CP in hospitals. These included linking 
monthly salary with volume and quality of patient managed by CP, drafting 
regulations on internal supervision and specifying related management rules. In short, 
the design of the incentive mechanism aimed to shift the behavior of healthcare 
providers from “more prescriptions, more income” to “reasonable prescriptions, better 
income”. 
In order to accommodate the routing monitoring and oncoming impact 
evaluation, the pilot hospitals created clinical management modules within the 
existing general hospital information system. They embedded digital pathway 
templates and achieved seamless links with the original hospital information 
systems(CNHDRC, 2015). Finally, patient-oriented project data, especially the 
expenditure data, could be tracked through the electronic management module at any 
time. Based on the monitoring results, supported by real world data, local 
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stakeholders’ sense of evidence-informed decision making was reinforced and 
encouraged access and use of evidence (CNHDRC, 2015).  
Building capacity was a crucial feature of the intervention and was repeatedly 
stressed throughout the course of the project lifespan (CNHDRC, 2015). There are 
two ways of building capacity. One is training clinical practitioners about CP content. 
The other is training to use the clinical management module tailored for the 
intervention. The first training aims to acquire an understanding of evidence-based 
treatment among clinical practitioners. This may vary from their long-term habits and 
practices. Another method is training to facilitate the physician use of supportive 
information systems, in order to improve working efficiency and strengthen the 
process of behavior change. Ultimately, these two types of training not only can 
increase adherence to CP in physicians and ease patient management, but can also 
facilitate route monitoring by providing evidence-based defaults for care delivery and 




Chapter 2  Systematic review of literature 
Summary of Chapter 
Introducing evidence-based CP is a potential solution to address practical problems 
described in the previous chapter: the high burden of CI; the overuse of healthcare 
services in China rural areas; and the poor quality of care in China’s rural healthcare 
system. Piloting CP in a rural area may provide evidence to guide the direction of 
further healthcare reform in China. 
However, since there is high variance in the nature of the disease and a 
dependence on local circumstances for treatment, the application of CP in 
management of in-hospital CI patients is associated with conflicting evidence. Some 
studies concluded that there was insufficient evidence to justify the advantages of CP 
implementation for acute CI management in terms of major clinical outcomes (J. 
Kwan & Sandercock, 2002). On the other hand, some studies stated that the CP can 
significantly improve the CI patients outcomes, such as 30-day mortality, LOS and 
hospital re-admission rates (Panella, Marchisio, Brambilla, Vanhaecht, & Di 
Stanislao, 2012). 
This systematic review aims to investigate the effectiveness of CP among 
patients admitted into hospital care with diagnoses of acute CI, compared to 
alternative treatments in Randomized Clinical Trials (RCT).  
2.1. Methods 
The systematic review was conducted based on principles of the Cochrane 
Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) standard (Higgins & Green, 2008; Moher, 2010). 
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The studies were screened independently by thesis author and a second reviewer 
(Mr. Zhonghan Li, research fellow from CNHDRC), using pre-defined inclusion and 
exclusion criteria to identify appropriate publications and process full text review. The 
second investigator has no conflicts with the study. Any conflicts between the 
interpretation of the thesis author and the second reader were accommodated by 
discussion in first, and third party judgement was designed to deal with the 
disagreement, but which was not applied in this literature systematic review.  
Four databases (Medline, Embase, Cochrane library and CINAHL) were 
searched for peer-reviewed articles according to the pre-defined “search strategies” in 
Appendix B1. Articles in Chinese language were not included but were used as a 
source for parameters in a chapter 5 to perform Markov modeling. Target peer-
reviewed articles were eligible and selected based on the following criteria:  
◆ Target population (the patients with diagnosed acute CI hospitalization with clear 
demographic and baseline characteristics) 
◆ Type of intervention (CP management, summarized as a structured hospital-based 
multidisciplinary plan of care and an intervention utilized to detail the steps to 
accommodate the recommendations of guidelines, protocols or inventories of 
actions in local structures.) 
◆ Type of outcomes (include LOS, number of deaths, Short form health survey with 
36 items (SF-36) general score, Barthel Index of activities of daily living (BI) 
score, time from dispatch to hospital, etc.) 
◆ Type of study: the titles, abstracts and keywords of studies were screened first. 
Full texts of selected publications were reviewed using pre-defined inclusion 
criteria and exclusion criteria. The PRISMA checklist was used to standardize the 
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reporting of this systematic review. The primary outcomes included length of 
hospitalization and mortality. The secondary outcomes were SF-36 health score, 
BI score, number of patients receiving the swallowing test and number of patients 
receiving the timely thrombolytic treatment. It was decided to focus this review 
on RCT study design because this represents among the highest levels of 
evidence (Medicine, 2019). 
Meanwhile, the exclusion criteria were outlined as below: 
● Non-English, duplicated and published papers before the year 2000; 
● Study implementing non-hospital-based (hospital-to-community-based or 
community-based) stroke care; 
● The papers omitting introduction of RCT design; 
● No full text papers or papers with difficult data access; 
● Papers referring to study protocols, systematic reviews or meta-analyses. 
2.2. Analysis 
Meta-analysis was conducted for the pre-defined primary and secondary outcomes by 
using Review Manager 5.3. The Mantel-Haenszel statistical test was performed for 
testing heterogeneity using a random effect model and a forest plot was used to 
interpret the synthesis of findings. We defined the amount of heterogeneity by using 
the I2. An I2 value less than 50% indicates high homogeneity, and I2 value greater than 
50% means substantial heterogeneity. The P-value lower than 5% for the Chi-square 




2.3.1. Study characteristics 
One thousand, eight hundred and eighty-four articles were found in the target 
database (Medline, Cochrane Library, EMBASE, CINAHL) and nine articles were 
selected for this systematic analysis according to inclusion criteria. The screening 
process is shown in Figure 2-1. The nine included articles were conducted in both 
developed and developing countries. Participants were randomly assigned to 
intervention and control groups to receive different health interventions. Selected 
studies used various outcomes to assess the effectiveness of hospital-based CP 
management for acute CI. Although the CP management in different papers were 
diverse, they all have CP management principles, such as high-priority process of 
care1 (PoC), evidence-based treatment protocols, emergency clinical pathway2(ECP) 
procedures, etc. 
No statistically significant difference on heterogeneity was found on the baseline 
of the demographic and clinical characteristics in the included papers. The 
demographic analyses included gender, age, marital status, level of education, 
employment status, time from onset of symptom, risk factors, and co-morbidities. The 
characteristics of the selected studies are summarized in Appendix B2. 
 
                                                 
1Process of Care (PoC) : process of care refers to an evidence based action or intervention performed 
during the delivery of patient care (Hoffman, 2019). 
2Emergency clinical pathway (ECP) : The implementation of an evidence-based acute stroke care 
pathway for Emergency Medical System personnel, associated with continuing medical education 




Figure 2-1 PRISMA flow chart showing study selection 
2.3.2. Primary outcomes 
LOS was reported as the primary outcome in the four studies. One of the studies 
reported LOS separately for intracerebral hemorrhage and transient ischemic attack or 
cerebral infarction. According to included studies outcomes, the meta-analysis 
showed that the average LOS in CP group is 2.02 days lower than control group 
though significant heterogeneity. (I2 =91%, mean difference= -2.02, 95% CI -2.66, -
1.38; p<0.00001) (Figure 2-2). 
 Database: Medline (PubMed and Ovid) (1303), Cochrane Library (236), EMBASE (via 





Articles screened on the basis of title and abstract 
N=602 
Excluded: N=1282 
Non-English n=166; No full text n=69;  
Duplication n=846; Years before 2000 n=201; 
Included N=62 
full text review 
Excluded: N=540 
Non-RCT: n=278;  
Study protocol n=209;  
Systematic review n=26;  





Clinical trial for new drug and treatment: n=28; 
Community-based rehab care: n=18 
Conference material without detailed data: n=7; 




Figure 2-2 Forest plot of length of stay 
Five articles reported mortality or number of death events as outcomes. Based on 
included studies outcome, CP favors the aggregated intervention group where the 
number of deaths is 0.56 times that of the control group (I2 =25%, OR=0.56, 95% CI 
(0.45, 0.70), p<0.00001) (Figure 2-3). 
 
Figure 2-3 Forest plot of Mortality 
2.3.3. Secondary outcome 
SF-36 health score (both mental and physical components) was reported as an 
outcome in two studies. For the SF-36 health score, mental and physical components 
were analyzed separately. The general SF-36 scores in the intervention group (CP 
group) is 1.38 units higher than control group in the condition of significant 
heterogeneity (mean difference=1.38, 95% CI (0.53, 2.22), p=0.001, I2=77%) (Figure 
2-4). It was not possible to perform the Mantel-Haenszel test on the mental  and 




Figure 2-4 Forest plot of SF-36 score 
The BI score was reported in different grades in six studies. This systematic 
review included the studies in which BI score 90 days after discharge was greater than 
50. Analysis shows that the CP group is less likely favor the aggregated intervention 
group in the condition of significant heterogeneity. (OR=0.72, 95% CI (0.56, 0.93), 
P=0.01, I2 =81%) (Figure 2-5). 
 
 
Figure 2-5 Forest plot of number of patients whose BI score greater than 50 after 
90 days of discharge 
2.3.4. Risk of bias assessment 
All the included, randomized controlled studies were evaluated in adequacy and 
quality from six domains by the Cochrane Collaboration risk-of-bias tools. They are: 
sequence generation, allocation concealment, blinding of participants and personnel 
and outcome assessors, incomplete outcome data, selective outcome reporting, and 
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other potential threats to validity. The article can be assessed as low risk if it meets all 
six criteria. Two papers (Middleton et al., 2011; D. Sulch, I. Perez, A. Melbourn, & L. 
Kalra, 2000) were ranked as low risk by the reviewer because they meet all six 
domains of assessing risk of bias. The bias assessment of each individual study is 
summarized in Figure 2-6 and Figure 2-7. Detailed statements about the assessment of 
risk of bias are shown in Appendix B3. 
 
Figure 2-6 Risk of bias graph 
 
 
Figure 2-7 Summary of risk of bias 
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2.3.5. Review of cost-effectiveness studies 
In order to inform the cost-effectiveness analysis, a further literature review of cost-
effectiveness models relating to stroke clinical pathways was undertaken to inform its 
structure and inputs (see Appendix B1).  
The identified six articles using MESH terms relating to cost-effectiveness of 
stroke clinical pathways. Of these articles, five were excluded since they did not use a 
cost effectiveness model. This left Wardlaw et al., which employed a  decision tree 
approach to investigate whether computerized tomography (CT) is cost-effective in 
acute stroke in Scotland (Wardlaw et al., 2004).While the study did not calculate an 
ICER, the most cost-effective strategy was to scan all patients immediately, which 
cost Great Britain Pound (GBP) 9,993,676 and generated 1,982.4 QALYs across 
1,000 patients. 
The main limitations of the study were its geographic scope, meaning its findings 
may not be generalizable to other healthcare systems, and the sensitivity of the results 
to several assumptions such as the proportion of patients that would reach the hospital 
in time to be considered for thrombolysis. 
2.4. Discussion 
The definition of CP was not unified terminologically. However, four studies used the 
terms “clinical pathway” “care pathway” or “practical protocol” to describe their 
intervention. The interventions in individual studies were highlighted and reviewed in 
line with the characteristics of CP, which may appear to have differences in terms of 
the target condition, method of design, stages of treatment, course of illness, location 
of use, etc. CP management is carried out in multiple treatment stages of stroke across 
different departments of hospital services, such as emergency care, (emergency room 
[ER] /emergency medical service [EMS] /mobile stroke unit [MSU]), the stage of 
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hospitalization treatment (e.g. stroke unit [SU], mobile service across various 
specialists interdisciplinary stroke team, or conventional wards), and the stage of 
earlier rehabilitation (e.g. inpatient rehabilitation unit). The presence of statistical 
heterogeneity of selected outcomes based on eligible data limited the development of 
quantitative meta-analysis. However, the overall estimates of effect in the presence of 
such heterogeneity are still available to interpret the general correlation between the 
intervention and outcome changes. Although this study included nine RCT studies, 
there is no conclusive evidence among the studies. This makes it difficult to generate 
a consistent conclusion in terms of the impact of CP on health outcomes. Six studies 
reported positive findings in RCT in condition of limited settings; but the other three 
studies concluded that CP cannot generally provide additional benefits over 
conventional treatment. It is probable that the CP were initiated and conducted with 
different aims in different settings, which complicates the interpretation of the results. 
From the six studies with positive results for CP, two main findings can be 
summarized. First, CP can improve the adherence of pre-defined, high-priority PoC, 
and can improve mortality and trends with independence. (but the causal factors of 
these changes were not clarified.) (Cadilhac et al., 2004; Drury et al., 2014; Middleton 
et al., 2011; Panella et al., 2012; Sulch, Evans, Melbourn, & Kalra, 2002). Second, CP 
management is able to improve the accuracy of pre-hospital diagnosis, reduce the 
response time from alarm to therapy decision, and improve effective emergency 
treatment in acute CI settings (De Luca et al., 2009; Walter et al., 2012).However, the 
other three studies suggest concerns about the limitations of CP:  
1) The reduction in death or institutional care was only observed in the short 
term, such as after three months of hospitalization. This effect did not remain after 
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one-year of hospitalization (Fagerberg, Claesson, Gosman-Hedstrom, et al., 2000; 
Sulch, Melbourn, Perez, & Kalra, 2002; D. Sulch et al., 2000). 
2) In two studies, the interdisciplinary stroke team didn’t show benefits in 
inpatient rehabilitation (Ferri et al., 2011; D. Sulch et al., 2000). CP has included 
standard inpatient rehabilitation care, but CP may lack the flexibility responding to 
the complexities of disease and diversity of patients’ needs (Mahoney & Barthel, 
1965; Sulch, Melbourn, et al., 2002; Torp et al., 2006). In order to maximize the 
effectiveness of CP in future pilot studies, there are some lessons that should be 
learned in dealing with the potential challenges during implementation:  
1) The CP optimizes healthcare procedures, which is more likely to be effective 
if the basic structure of the CI service is already in place. Therefore, CP should be 
introduced as part of an overall quality improvement scheme rather than as a stand-
alone intervention (Ringel & Hughes, 1996). Also, CP is a dynamic process. Adapted 
within a specific context, it should be continuously reviewed and evaluated in light of 
updated clinical evidence and local capacity, e.g., human resources and medical 
hardware infrastructure. CP is an important component of continuous quality 
improvement in clinical practice (Cheah, 2000). 
2) CP should be strengthened in the hyperacute stage rather than stable stage, i.e. 
rehabilitation. Three studies found CP is less positive for inpatient rehabilitation. CI 
or stroke rehabilitation patients are often medically stable and managed by a 
coordinated multidisciplinary team within a well-structured service; hence CP is less 
likely to provide additional benefits. This finding also provided new evidence to 
support the comments derived from the Cochrane Review (J. Kwan & Sandercock, 
2002), which concluded that the evidence supports the use of CP for the management 
of acute stroke rather than stroke rehabilitation  (J. Kwan & Sandercock, 2002).In 
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addition, pre-hospital CP in hyperacute stroke should be emphasized and 
strengthened. Animal experimental and clinical evidence shows that the time to 
efficient treatment is the primary determinant of better health outcomes for acute CI 
(Jamal et al., 2013).In particular, the pre-hospital CP of acute CI management can 
accommodate earlier detection and treatment provided by paramedical staff, or 
referral to a specialist center without delay once the initial diagnosis is made.  
3) CP must be flexible to accommodate clinical practice while still prioritizing 
patient safety. In order to successfully integrate CP into practice, there needs to be a 
balance between physician autonomy and prescription and evidence-based 
procedures. A well-defined CP includes inclusion criteria that reflect the usual care 
required by most of the patient population. It is significant to design exclusion criteria 
because of deviation from the CP due to unexpected events. For example, patient 
progress towards projected outcomes can be earlier or later than expected, or the 
patient can fail to meet project outcomes or require unplanned, additional intervention 
(Cheah, 2000). 
4) CP is a multifaceted management tool that requires educational programs and 
training workshops in order to make improvement of personnel capacity and structure 
changes. The objective is to build consensus among different stakeholders and attain a 
consistent understanding of the basic terms, concepts, objectives, content, procedures, 
principles and variances of CP. It is also necessary for health personnel be trained in 
combining CP with hospital information systems. A computerized CP can issue “real 
time alerts” to effectively reduce medical errors.  When desired, a short-term pilot 
study can be carried out to examine the feasibility of new CP methodologies 
correcting errors or omissions, improving staff competence and reducing the bias of 




The meta-analysis done by other counterparts shows that hospital-based CP provides 
positive and negative results for acute CI (J Kwan, 2007; J. Kwan & Sandercock, 
2002). However, this review reported a higher likelihood of positive results in relation 
to CP effectiveness in conditions of significant heterogeneity, when compared 
through randomized controlled trials with conventional medical treatments. Given the 
disease burden of CI and the urgent need for healthcare reform, evidence-based CP 
and related supporting systems can be a potential solution to lower fast-growing 
medical costs and improving quality of medical services in rural China. An impact 
evaluation should be conducted based on an evidence-informed CP pilot study to 







Chapter 3  Study rationale 
Summary of Chapter 
This chapter aims to clarify the study rationale and study objectives based on the 
aforementioned background and reviewing of literatures. Detailed study questions 
will be identified clearly as well, to facilitate the entire study. 
3.1. Study rationale 
There are two major reasons for conducting this study: one is related to research 
improvement, and the other is to practical application: 
3.1.1. Address knowledge gaps in literatures 
Based on the results of the systematic literature review, the use of CP in ischemic 
stroke management or CI remains inconclusive because of contradictory evidence. In 
terms of research, this evolutional study addresses at least two existing gaps in the 
literature on CP management for CI inpatients. The number of studies that have 
focused on CI in CP management is fairly small, meaning that there is little validation 
of the intervention’s impact beyond certain subtypes of ischemic stroke. Additionally, 
this will be the first study to use a comprehensive and logical assessment tool to 
statistically describe the overall effects and estimate the cost-effectiveness of CP 
intervention in the setting of China’s rural healthcare system. From a methodological 
perspective, the use of Interrupted Time Series (ITS) for this work is a practical and 
potentially powerful approach for evaluating the longitudinal effects of an 
intervention. Cost-effectiveness analysis is an increasingly used form of economic 
evaluation in supporting evidence-based decision-making. Analysis using Incremental 
Cost Effectiveness Ratio (ICER) in comparison with score-paired control group can 
deliver robust results and is easier to translate to stakeholders. There are few studies 
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conducting cost-effectiveness analysis (CEA) using the Chinese general population-
based value set of European Quality of Life Scale (EQ-5D-3L). The adoption of 
Chinese general population-based EQ-5D-3L social value set can favor the internal 
validity of study efficiency and reflect the rural China setting. 
3.1.2. Demonstrate real-world impact of CP intervention 
The implementation of the CNHDRC CP project has received significant government 
interest and has been seen as a model for replication by NHC. The practical purpose 
of this study is to test the actual impact of CP in the rural Chinese healthcare system. 
It is necessary to identify the benefits and challenges of implementing CP in the pilot 
setting before implementation is explored in more areas. The implementation body, 
CNHDRC, is the policy-making think tank of the national health authority. Both the 
positive and potential negative implications can generate convincing evidence to 
inform national health policy in a timely manner and help change clinical practice, 
physician remuneration mechanisms and payment reforms. 
Due to limited resources, this study was necessarily limited to one pilot site. 
However, its results may be more broadly applied to China’s rural healthcare system. 
Additionally, the development and optimization of contextually appropriate CP will 
be a dynamic progress; the evaluations can assist with the continued improvement of 
CP implementation. 
3.2. Study objectives 
The general objective for this impact evaluation is underpinned by testing the overall 
effectiveness and cost-effectiveness of CP interventions in CI disease management 
using mixed methods in the setting of one selected pilot area. Based on the existing 
knowledge gaps, as well as the concerns of project stakeholders, the specific research 
objectives were formulated respectively: 
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1) To evaluate the CP intervention effects of CI on the pre-defined primary 
outcomes, in term of both clinical effectiveness and financial burden.  
2) To assess the cost-effectiveness of CP compared to the usual care received by 
inpatients patients with CI.  
3.3. Study questions 
1) What is the overall effectiveness of CP in the management of inpatient CI 
patients in rural China? 
2) Is CP cost effective, compared to usual care in the management of CI, against 
possible confounding factors in rural China, from a healthcare perspective, as 
measured by incremental cost per quality-adjusted life-year (QALY)? 
3.4. Study hypothesis 
It is hypothesized that in the context of healthcare system in rural China: 
• CI inpatients managed by CP have better health outcomes than inpatients 
receiving usual treatment; 
• CP intervention is cost-effective in comparison with a conventionally-treated, 




Chapter 4  Methodology 
Summary of chapter 
In this chapter, the analytical approaches will be introduced and demonstrated. 
Meanwhile, the data resources, primary outcomes and analytical plan also will be 
presented. Three statistical approaches were adopted to undertake the data analysis: 
difference in difference (DID) after propensity score matching (PSM); interrupted 
time series (ITS); and Markov model of the short and long term cost-effectiveness of 
the CP intervention. DID is commonly applied by using observational data to estimate 
the absolute intervention change using pre-defined primary outcomes, and PSM can 
balance the variation of patients’ characteristics using matching skills. ITS is an 
intuitive, practical and powerful analytical approach which is used here for evaluating 
longitudinal effectiveness of a time-dependent intervention before and after a specific 
time point using routinely collected data. Markov model is a commonly used 
technique to evaluate cost-effectiveness, which is able to simulate the disease 
trajectory and compare the relative costs and outcomes of alternative interventions 
(CP and non-CP). 
4.1. Grouping of patients 
In order to estimate the impact of the CP on the costs and outcomes of CI care, four 
comparison groups were created initially as depicted in Figure 4-1. “Before/ 
treatment” refers to the group of patients before introduction of the CP who supposed 
to be eligible for the CP; “Before/ control” refers to the group of patients before 
introduction of the CP who would not supposed to be eligible for the CP, “After/ 
treatment” refers to the group of patients after introduction of the CP who followed 
the CP; and “After/ control” refers to the group of patients after introduction of the CP 




Figure 4-1 Grouping of patients 
Patients were classified into the groups as follows: 
- After the intervention, patients were assigned to treatment and control groups 
based on inclusion criteria defined in developing CP and agreed by senior 
stroke professionals and local stroke practitioner together. 
- Before the intervention, neurology physicians of the pilot hospital performed a 
retrospective review of medical records to assign patients to treatment and 
control groups based on the inclusion criteria of clinical pathway. Actually, 
this process can be seen as a simulation progress to adopt the CP criterial 
among patients before introducing intervention. 
4.2. Primary outcomes 
The following measures of resource use and health outcomes were collected for 
patients managed by the CP or conventional treatment: 
• Healthcare resource use: LOS as defined as the number of inpatient days in 












• Healthcare costs: Total hospitalization expenses and major components 
(medication expenses, radiology expenses, laboratory test expenses, 
consultation expenses and diagnostic expenses); 
• Health-related quality of life (HRQoL): EQ-5D-3Lbased utility value. 
Based on the rounds of discussions with stakeholders and the availability of data, 
only the following data were extracted from hospital information system to meet the 
analytical requirements, which are: gender, age, type of insurance, inpatient ID, 
diagnosis of discharge, ICD-10 code of discharge diagnosis, discharge status, 
admission date, discharge date, LOS, comorbidity information, accessibility of CT, 
MRI or color doppler services, total hospitalization expenses, medication expenses, 
radiology expenses, laboratory test expenses, consultation expenses, diagnostic 
expenses, admittance of CP treatment, etc. 
As defined as direct healthcare expenses, the total hospitalization expenses 
include all the corresponding expenses of services and medicines provided by the 
hospital during the patients’ stay. Total hospitalization expenses can be broken down 
to the following components: medication expenses, radiology expenses, laboratory 
test expenses, consultation expenses and diagnostic expenses. 
Medication expenses include the expenses of medicines in relation to 
thrombolytic therapy, such as urokinase, antiplatelet agents, anti-atherosclerotic 
drugs, and free radical scavenger, drugs for improving cerebral perfusion, supportive 
treatment, and dilatation drug. 
Radiology expenses include the expenses of imaging services, such as skull CT, 
skull MRI, chest x-ray, CT angiography, abdominal ultrasonography, magnetic 
resonance angiography (MRA), and carotid ultrasonography. 
 
52 
Laboratory test expenses include the expenses of biochemical examination of 
blood, urine, stool, liver function, renal function, electrolyte, blood glucose, blood 
lipid, myocardial enzymes, coagulation function, homocysteine(HCY), blood gas 
analysis, and infectious disease screening (AIDS, syphilis, hepatitis B or C). 
Consultation expenses include the personnel charge for clinicians’ routine 
consultation and nursing care, such as nursing assessment on admission, instruction 
on diets, measuring blood, pressure, temperatures and pulse. In addition, the expenses 
of medical consumables, such as injection syringes and gauze, were included. 
Diagnostic expenses include the use of common medical monitoring equipment 
in relation to oxygen inhalation, Electrocardiography (ECG) monitoring, blood 
pressure monitoring and sputum suction, etc. 
EQ-5D-3L based utility value: along the process of preparation before official 
intervention kick-off, the EQ-5D-3L data of hospitalized patients admitted with 
cerebral infarction was collected from Jun 2013 to accommodate DID, ITS and cost-
effectiveness analysis. Data of EQ-5D-3L was being collected at time point of 
discharge for CP and non-CP patients. The trained nurses explain and accommodate 
the survey in face-to-face interviews. The Chinese EQ-5D-3L value set (G. G. Liu, 
Wu, Li, Chen, & Nan, 2014) was applied to calculate the utility value scores. More 
details can be found in section 4.3.3 
LOS here means the hospitalization days of CI patients receiving treatment in 
hospitals. The LOS has been estimated with difference of admission date and 




4.3. Data resource and process 
RCT design is rarely possible to assess the impact of policy changes. Time series 
designs have been argued to be the strongest, quasi-experimental design to estimate 
intervention effects in non-randomized settings (Wagner, Soumerai, Zhang, & Ross-
Degnan, 2002). 
Data for this study was drawn from the CNHDRC CP Project for two targeted 
diseases. The project covered four representative pilot county-level areas across 
western, middle and eastern China. This study focuses on a detailed analysis of the 
data in one county, Hanbin county in Shaanxi province, western China. The selection 
reasons are as follows: 
• It was the first pilot county to initiate the CP intervention, and therefore had 
the largest dataset available; 
• Local practitioners had a strong interest in understanding the impact of 
intervention.  
• A workable hospital information system was available to accommodate high-
quality data collection.  
Hanbin General hospital, as one of the few hospitals in the county qualified to 
receive stroke patients, acted as the implementation agency under the direction of 
the local government. 
4.3.1. Data collection 
Study time period:1st June 2013 to 31st May 2017, which represents one year before 
and three years after the implementation of the CP on1st June 2014. 
The choice of study period was based on criteria for ITS design, which 
recommends that there should be at least 10 pre-intervention and 10 post-intervention 
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data points (Fretheim & Tomic, 2015). This provides at least 80% power to detect a 
change when the autocorrelation between variables is about 2 (Ramsay, Matowe, 
Grilli, Grimshaw, & Thomas, 2003). 
Sample size: Inpatients admitted to Hanbin General Hospital who were 
diagnosed with CI were included in the study. CI was defined by ICD-10 codes 
I63.901 (multiple cerebral infarction), I63.902 (cerebral infarction), I63.903 (lacunar 
infarction), and I63.301 (sequelae of cerebral infarction) (Walter et al., 2012). 
Sample size considerations were based on the number of observations and time 
points at which data would be collected. As a pilot observational study, the selection 
of study sites and overall sample size were partly driven by pragmatic considerations. 
The sample size in ITS analysis depends on the number of CI hospitalized patients 
treated at the pilot hospital in Hanbin over the four-year period. The sample size for 
DID and CEA is dependent on the stringency of PSM. 
4.3.2. Data source 
Patients’ medical records 
Data was extracted from the electronic medical records of all hospitalized patients 
admitted as inpatients to Hanbin General hospital with cerebral infarction as defined 
by the ICD-10 codes described in Section 4.3.2 during the study period1st June 2013 
to 31st May 2017. 
The list of comorbidities was adopted from Diagnosis and treatment of 
complications of cerebral infarction (S. zhang & wu, 2016), which outlined the 
common comorbidities in relation to the severity of infarction in the condition 
evaluation from clinical view. For instance, those patients who were sent on to a 
 
55 
referral hospital quickly or stayed in hospital for an unusually long time because of 
their particularly (generous) insurance coverage would not fit the clinical pathway 
EQ-5D-3L measurement  
The EQ-5D-3Lis a generic preference-based measure of HRQoL. It is a 
standardized, self-reported, and easy-to-use instrument which allows comparisons 
across health conditions and treatments. It is widely used in economic evaluation and 
recommended by several Health Technology Assessment (HTA) agencies around the 
world. 
The EQ-5D-3L has been shown to be valid and responsive measure of HRQoL in 
stroke patients (Dorman, Waddell, Slattery, Dennis, & Sandercock, 1997; Pickard, 
Johnson, & Feeny, 2005). It consists of two segments, the EQ-5D descriptive system 
and the EQ visual analogue scale (EQ-VAS). The descriptive system consists of five 
single-item dimensions, each of 3 levels (Table 4-1). The EQ-VAS records the 
respondent’s self-rated health on a vertical, visual analogue scale where the endpoints 
are labeled ‘Best imaginable health state’ and ‘Worst imaginable health state’. This 
information can be used as a quantitative measure of health outcomes as reported by 
the individual respondents. 
Table 4-1 EQ-5D-3L descriptive system 
 No problems  Some Problems Extreme problems 
Mobility 1 2 3 
Self-care 1 2 3 
Usual activities 1 2 3 
Pain/Discomfort 1 2 3 




The EQ-5D-3L descriptive system gives a 5-digit health profile with 243 
possible health states. This profile may be converted to a health state utility value 
using a country-specific valuation tariff. The China tariff was used to convert patient 
health profiles to health state utility values (Luo et al., 2017).The China valuation 
study was conducted in a sample of 5,939inhabitants over 15 years and older over, 
and the estimation relies on multi-stage, stratified, clustered random skills using the 
time trade-off (TTO) technique (Lang et al., 2018). 
The EQ-5D-3L was administered to hospitalized patients admitted with CI from 
June 2013 (prior to implementation of the CP) when discharging. After 
implementation of the CP, the EQ-5D-3L was administered at discharge for both for 
CP and non-CP patients via face-to-face interviews with trained nurses. 
4.3.3. Data processing 
A pre-requisite for participation in the study was the implementation of an electronic 
prescription system within the hospital. Such a system not only facilitates the data 
collection for project monitoring and evaluation, but also encourages the process of 
physicians’ behavior change. 
To support efficient data linkage, all prescriptions information issued for patients 
participating in the CP was automatically mapped into a CP digital management 
module for both before and after introduction of the CP. For non-CP managed 
patients, all patient data could be tracked down through the routine hospital 
information system. 
To minimize bias and ensure comparability of data across different departments 
of the hospital (emergency room, internal medicine department and the joint 
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department of Chinese & Western medicine), all data collection techniques, 
procedures, and data collection forms were standardized. 
The most robust approach for ensuring accuracy and reliability of data collection 
is double data entry, where data from the entire sample is collected separately by two 
researchers, and compared for verification purposes before analysis. However this 
approach is associated with significant financial and resource costs (Büchele, Och, 
Bolte, & Weiland, 2005). For practical reasons, double data entry was not possible in 
this study. Instead, two researchers trained in the standardized extraction approach 
extracted data in duplicate from 5% of randomly selected records, and these data was 
compared to assess the overall reliability of data extraction. This process was done 
with the help of a junior researcher from CNHDRC. 
4.4. Statistical methods 
To achieve the research objectives, a mixed methods approach with three distinct 
analytical methods was adopted: 
• Difference-in-difference analysis (DID) after propensity score matching 
(PSM). DID was used to calculate the change in costs and outcomes before 
and after intervention on groups receiving CP and standard management 
matched by PSM; 
• Interrupted time series (ITS). ITS was used to calculate the change in costs 
and outcomes before and after intervention on groups receiving CP and 
standard management; 
• Cost-effectiveness analysis (CEA) using a Markov model. Markov model was 
used to estimate the short and long-term cost effectiveness of the CP compared 
with standard management. 
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These methods are considered appropriate for evaluating health policy 
interventions with observational data (Craig et al., 2010). Taken together, these 
analyses will be used to assess the impact of the CP on several outcomes relevant to 
patients.  
In order to confirm the appropriate statistical techniques, the data was first tested 
for normality. As the total sample size over 2,000, the Kolomogorov-Smirnov (K-S) 
test was used to test the normality of the continuous variables. The K-S test is an 
empirical distribution function in which the theoretical cumulative distribution 
function of the test distribution is contrasted with the empirical distribution function 
of the data(D, A, & E, 2006).Statistical analysis was conducted using SAS version 9.4 
(SAS Institute Inc. North Carolina, USA). 
4.4.1. Difference-in-difference 
DID study design is commonly applied to observational data to address the absolute 
effect in outcomes related to the policy change (Dimick & Ryan, 2014). DID 
normally uses a comparison group that is experiencing the same trends but is not 
exposed to the policy change. 
In a DID analysis, one cannot assume random assignment to avoid bias from 
unmeasured confounders. DID designs assume confounders that vary between groups 
do not vary over time and that confounders that vary over time do not vary by group. 
Therefore, a major assumption of DID is the parallel trends assumption, in which the 
trends in outcomes between the treated and comparison groups are the same prior to 
the intervention. See illustration of DID in Figure 4-2. 
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Figure 4-2 Illustration of DID 
The DID analysis was carried out in support of observations of PSM-matched 
patients. The approach is consistent with British Medical Research Council guidelines 
for using natural experiments to evaluate population health interventions. The 
approach has been previously applied to stroke service redesign in England (Morris et 
al., 2014). 
Total hospitalization expenses and its components (radiology expenses, 
laboratory testing expenses, diagnostic expenses and consultation expenses) were 
calculated for the four subgroups: “Before/ treatment”, “Before/ control”, “After/ 
treatment”; and “After/ control”. DID is employed to offset natural change before and 
after intervention, to allow us to state the absolute difference (the difference-in-
difference) using Excel 2016 (Microsoft, Seattle USA). 
Due to challenges associated with establishing causal relationships in 
observational research designs, a number of approaches are available to help to 
validate the assumptions of DID (Wing, Simon, & Bello-Gomez, 2018). In particular, 
this study employed PSM as described below. 
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4.4.2. Propensity Score Matching (PSM) 
In observational studies, the assignment of treatments to intervention or control group 
is typically not random. When randomization is not available for treatment allocation 
to subjects, causal inference cannot be made as it is not possible to determine whether 
the differences in outcomes are attributed to the treatment itself or to unobserved 
differences between subjects on other characteristics (Rosenbaum & Rubin, 1983). 
PSM is a statistical correction strategy for observational studies, where data bias 
and confounding factors potentially exist. PSM attempts to reduce, but not completely 
eliminate, the influence of confounding factors that could bias an estimate of the 
treatment effect when obtained simply by comparing outcomes among units that 
received the treatment versus those that did not(Austin, 2011). 
PSM attempts to ensure that the treated and comparison groups have similar 
characteristics. The propensity score is the estimated probability for each individual in 
the study to be assigned to the group of interest for comparison, conditional on all 
observed confounders (Baek, Park, Won, Yu, & Kim, 2015). Subjects with the same 
or similar propensity scores can be considered to have the same or a similar 
distribution of all confounding variables used in constructing the propensity score. 
Propensity scores are generally calculated using logistic regression, which is a 
model used to predict the probability that an event occurs. The propensity score is a 







=𝛼 + 𝛽𝑥𝑖 
where: 




𝑒(𝑋𝑖) = 𝑏0 + 𝑏1𝑋1 + 𝑏2𝑋2+𝑏3𝑋3 + ⋯ + 𝑏𝑖𝑋𝑖 
where b0 is the intercept; bi are the regression coefficients; Xi are the treatment 
variables and covariates (random variables); xi is the observed value of variables. 
In logistic regression, the dependent variable is binary, Zi=1 is the value for the 
treatment and the value for the control is Zi=0.  





Suppose we get the value of bi using maximum likelihood techniques, we can get 
a value of ?̂?(𝑥𝑖) as the specific propensity score for individual subjects from either the 
intervention or control stream. 
Once we have calculated the estimated propensity score for each subject from 
both CP and non-CP groups, we can match the treated subjects with subjects who 
have the same or most similar propensity score but did not receive treatment. (See 
example in Figure 4-3) 
 
Figure 4-3 Example of PSM Nearest Neighbor Matching 
This example implies the application of Nearest Neighbor Matching, where the 
absolute difference between the estimated propensity scores for the control and 
treatment groups is minimized within in certain width of caliper. Caliper means 
maximized value width between paired data, less width more accuracy. In this 
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example, the control and treatment subjects are randomly ordered. Then the first 
treated subject is selected along with a control subject with a propensity score closest 
in value to it. 
𝐶(𝑃𝑖) = min
𝑗
|𝑃𝑖 − 𝑃𝑗| 
where 𝐶(𝑃𝑖) represents the group of control subjects j matched to treated subjectsi 
based on the estimated propensity score; 𝑃𝑖 is the estimated propensity score for the 
treated subjects I; 𝑃𝑗 is the estimated propensity score for the control subject j. 
The PSM included patient characteristics of age, gender and severity of 
comorbidities. The list of comorbidities was drawn from information available in the 
Diagnosis and Treatment of Complications of Cerebral Infarction(S. zhang & wu, 
2016). The matching of patients is based on the types rather than number of 
comorbidities. 
Nearest neighbor matching without replacement, meaning that each sample being 
matched can only be used once, was adopted in the PSM analysis; one to one 
matching was selected whose caliper in our study was equal to 0.05.  
Descriptive statistics summarizing the characteristics of patients included and 
excluded in the matching were reported for age, gender, comorbidities (diabetes, 
hypertension, coronary heart disease, atherosclerosis, dyslipidemia, insufficient blood 
supply to the brain, pulmonary infection). PSM was performed using Stata version 
15.0 (Stata Corp. Texas, USA). 
4.4.3. Interrupted Time Series (ITS) Analysis 
ITS has been described as the “next best” approach for dealing with interventions 
when randomization is not possible or clinical trial data are not available” 
(Kontopantelis, Doran, Springate, Buchan, & Reeves, 2015). In an ITS design, data 
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was collected at multiple timepoints before and after an intervention is introduced to 
detect whether the intervention has a significant effect over and above the underlying 
trend. 
There are several issues associated with analyzing longitudinal data (Lagarde, 
2012). For example: 
1) There may be a natural trend in the data that occurs independently of the event 
of interest or other observable events. This will result in a natural change in 
the outcome of interest over time. 
2) Data may not meet the requirement of Ordinary Least Square (OLS) that error 
terms be uncorrelated. Adjacent data points in time are typically more likely to 
be close to each other than points that are further from each other (first-order 
correlation). 
3) There may be regular patterns in the data due to seasonal effects. Without 
controlling for these changes, the real effect may be masked. 
ITS allows for the statistical investigation of potential biases such as those 
described above in the estimate of the effect of the intervention (Ramsay et al., 2003). 
To detect autocorrelation, a plot of residuals against time was visually inspected. 
Randomly scattered residuals would suggest that there is no autocorrelation. 
Secondly, the Durbin–Watson statistic, was used to test for serial autocorrelation of 
the error terms in the regression model. 
By observing a series of same outcomes at equalized-interval multiple time 
points before and after the introduction of an intervention, the approach aims to 
demonstrate the immediate and gradual effects of the intervention, given the degree to 
which the intervention alters the outcome of interest. The greatest benefit of this 
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approach is the fact that it is able to distinguish the effects attributed to intervention 
itself out of segmental change. It can identify whether there is an instantaneous or 
delayed effect; whether the impact is temporary or sustained; and whether factors 
other than the intervention could account for the observed interruptions. 
The time period is divided into pre-intervention and post-intervention segments, 
and levels (intercepts) and slopes of observational outcomes are estimated in each 
segment, where “intercept” means the value of the observed outcomes at the 
beginning of a given time interval, and “slope” means the rate of change of outcomes 
over the time. Therefore, the “change in level” demonstrates the abrupt effect of 
introducing an intervention, and “change in slope” can show trend changes in the 
value of observed outcomes before and after the intervention. (See Figure 4-4) 
The regression approach allows the statistical modeling of interrupted time series 
data to achieve statistical power with a relatively short time series using routinely 
collected observations at multiple regular time points from before and after an 
intervention (Lagarde, 2012). Outputs indicate the degree to which the intervention 
altered the outcome of interest, both immediately and over time. 
The general specification of a segmented linear regression of ITS data is: 
𝑌𝑡 = 𝛽0 + 𝛽1 ∗ 𝑡𝑖𝑚𝑒 + 𝛽2 ∗ 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 + 𝛽3 ∗ 𝑐ℎ𝑎𝑛𝑔𝑒 𝑜𝑓 𝑠𝑙𝑜𝑝𝑒 + 𝜀𝑡 
β0 is the intercept;β1 is the slope prior to the intervention (baseline trend), 
representing the change over time before the intervention was implemented;β2 is the 
change in the level immediately after the intervention (level change); β3 is the change 
in the slope from the pre- to post- intervention periods (trend change).The expected 
trend of prior to intervention, which can be seen as the comparison group in the post-




Figure 4-4 Illustration of Interrupted Time Series 
There are no control counties that can be paired with the Hanbin county due to 
the absence of appropriate control counties unaffected by healthcare reform. Thus, the 
use of ITS was deemed a suitable alternative method for a situation in which 
randomization was not a practical option. ITS was conducted across the time periods 
before and after CP implementation on the monthly mean values of pre-defined 
outcomes (LOS, total hospitalization expenses, broken down expenses and EQ-5D-3L 
utility value) to describe the overall effects of the intervention.  
Measurements were collected on a monthly basis over a period of four years (12 
months before implementation and 36 months after implementation). 
ITS was used to fit the regression models to LOS, total hospitalization expenses, 
and expenses related to medications, radiology, laboratory test and diagnostics, and 
health professional consultation time, before and after intervention.           




Where 𝑌𝑡  is the total hospitalization expenses(including medication expenses, 
radiology expenses, laboratory test expenses, diagnostic expenses and consultation 
expenses) of patients with CI in one visit; X1 is a categorical time variable, recording 
the number of months between the beginning of the study and  month “t” (the starting 
time in this study was 1stJune 2013 and the ending time was 31stMay 2017); X2 is the 
intervention variable which is a dummy variable(X2 =0 means before intervention, X2 
=1 means after intervention); X3 is a categorical variable, recording the number of 
months of time t after intervention, X3= 0 before intervention and X3=X1 after 
intervention. In this model, β0 is the estimate of baseline level of outcome indicators; 
β1 is the slope before intervention, that is, the estimate of monthly change of outcome 
indicators before intervention; β2 is the estimate of change of level of outcome 
indicators after intervention compared with before intervention; β3 is the estimate of 
change of slope, that is, the change of trend of outcome indicators after intervention 
compared with before intervention. Value of (β1+β3) is the slope after intervention. 
This model can estimate the change of intervention level and trend under the control 
of baseline level and trend, which is a significant advantage of piecewise regression 
analysis. Ɛt is the error term, which indicates that the random effects which cannot be 
explained by the model include the random errors of normal distribution and the error 
term of time (t). 
Model assumptions were checked using diagnostic plots, based on the estimated 
residuals. An appropriate model for the data was one where residuals were 
independent and normally distributed having a mean of 0 and constant standard 
deviation. The F value and R2 value are key indicators to check for model adequacy. 
In terms of the F test, by convention, a p-value smaller than 0.05, is considered 
acceptable. R2 gives the percentage contribution of the independent variables to the 
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observed response. These tests were undertaken for each modeled outcome. Statistical 
analysis was performed using SAS version 9.4 and Stata version 15.0. 
4.4.4. Cost-effectiveness Analysis (CEA) 
CEA is employed to compare the relative costs and outcomes of an intervention to 
help payers and policy-makers decide whether they should implement a new 
technology or service (Drummond, Sculpher, Claxton, Stoddart, & Torrance, 2015). A 
common metric of CEA is the incremental cost-effectiveness ratio (ICER), which is 
calculated as the change in cost divided by the incremental effect of the new 
intervention compared to current standard of care. 
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡𝐶𝑃 𝑔𝑟𝑜𝑢𝑝 − 𝐶𝑜𝑠𝑡𝑁𝑜𝑛−𝐶𝑃 𝑔𝑟𝑜𝑢𝑝





The ICER may be visualized on a cost-effectiveness plane as shown in Figure 4-
5. Interventions falling into the bottom-right or the top-left quadrants are clearly cost-
effective and cost-ineffective respectively. Interventions falling into the top-right or 
bottom-left quadrants may be cost effective depending on the willingness to pay 




Figure 4-5 Cost-effectiveness plane 
Development of model 
In order to project CEA analysis and inform the decision making, steps in 
developing Markov model were followed as Figure 4- 6: 
 
Figure 4- 6 The steps of Markov model development 
In order to clarify the details of modeling, each step was processed under careful 
considerations and actions: 
4.4.4.1. Decision problem 
Target population 
The analysis considered two target CI populations: “acute” inpatients and “stable” 




























More Effective Less Effective 
Intervention is DOMINANT 
(Win-Win) 
Control is DOMINATED 
(Lose-Lose) 
More Costly/More Effective 




The intervention under consideration is CP applied for CI hospitalization patients 
in Hanbin county. 
Comparators 
The comparator considered in the model is conventional treatment (non-CP 
management). 
Outcomes 
The primary outcome of interest is the ICER, as measured by incremental cost 
per QALY; this approach is in line with the China Pharmacoeconomics Evaluation 
Guideline (G. Liu, Hu, & Wu, 2011), which clarifies that a cost-utility analysis should 
be conducted. Additional outcomes reported include: 
• Total costs 
• Break-down costs 
• Total QALYs 
Mortality rate was excluded as outcome measure given the Chinese culture. Patients 
prefer to die at home rather than hospitals, which would underestimate the mortality 
of CI patients.  
Perspective 
This perspective of the analysis is that of the local Healthcare System in Hanbin 
County. Only direct medical costs including expenses occurred in outpatient and 
inpatient services of hospital and initiate project investment were considered. The 
analysis excludes indirect costs, the costs of lost productivity, transportation costs, 




The cost-effectiveness analysis adopts a lifetime time horizon. This approach is 
considered appropriate as CI can affect both mortality and morbidity, and is 
associated with long term sequalae. The cycle length is set to one day for inpatients in 
the “acute” stage, while the cycle length is one year when patients are at stable stage. 
The half-cycle correction had been performed. 
Discounting 
Costs and outcomes are discounted at 5% (G. Liu et al., 2011), which is in line 
with the recommendations of the China Pharmacoeconomics Evaluation Guideline. 
4.4.4.2. Modelling 
Model type and structure 
Markov models are typically appropriate for chronic progressive conditions and have 
been previously applied to model stroke service redesign (Briggs, Sculpher, & 
Claxton, 2006; Hunter et al., 2018). The model was developed in Excel 2016 
(Microsoft, Seattle USA). 
As displayed in Figure 4-7 & Figure 4-8, two separate Markov simulations are 
used to reflect the application of CP in CI patients at acute and stable stages. This will 
capture the impact of CP in both short and long term. A Markov model allows 
patients to move between other disease management states over a fixed period of time 
(the Markov cycle). In line with the practice in Hanbin, patients at acute stage are 
included in CP based on inclusion criteria. They are discharged after the completion 
of CP. As the maximized LOS of hospitalized CP patients in dataset is 21 days in 
Hanbin, the flow between cycles in acute stage model (Figure 4-7) is determined by 
the probability per 1-day cycle, to transition to the next cycle (indicated by the 
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arrows). For patients at stable stage, the cycle length is one year (Figure 4-8).Patients 
in either model must be in one of three distinct and mutually exclusive disease 
management states: outpatient, inpatient and death. 
As illustrated in Figure 4-7 & Figure 4-8, in each 1-day or 1-year cycle, the 
patients can either remain in the same cycle or move to the next cycle. In addition, at 
any cycle, patients may die and move to the death state. By definition, the model 
assumed that any events and transitions between disease management states occur at 
the end of each cycle and therefore a half cycle correction is applied. This ensured 
that events and movements happen, on average, in the middle of the cycle. As a result, 
the continuous nature of events is approximated (Sonnenberg & Beck, 1993). 
The overarching result of the cost-effectiveness analysis is the combination of 
two Markov models, where patients at the acute stage go into hospitalization managed 
by CP or not. After the completion of CP, patients are discharged by the hospital and 
go into stable stage. This study simulates both short and long term effect of CP to 
estimate the overall effect of the CP management for CI patients. Disaggregated 
results are also illustrated to clarify results of intervention in short and long term. 
 





Figure 4-8 Model structure for CP application in CI patients at stable stage 
Costs incurred in the outpatient state are those associated with disease treatments 
after discharge, which was derived from clinician consultation. These include 
medication expenses, radiology expenses, laboratory test expenses and consultation 
expenses of each visit. In the inpatient state, patients incur expenses associated with 
medical management, which was from PSM analysis results after intervention. These 
include medication expenses, radiology expenses, laboratory test expenses, 
consultation expenses and diagnostic expense. Death expenses are excluded based on 
the model’s perspective. 
Utilities are applied to each disease management state, which are derived from 
EQ-5D-3L measurement on patients in Hanbin. 
4.4.4.3. Sensitivity analysis 
One way sensitivity analysis 
Parameter uncertainty was tested using one way sensitivity analysis. All model 
parameters are systematically and independently varied over a range determined by 
the 95% confidence interval, or +/- 20% where no estimates of precision were 




Probabilistic sensitivity analysis 
Probabilistic sensitivity analysis (PSA) was used to estimate joint parameter 
uncertainty. All parameters are assigned distributions and varied jointly. 1,000 Monte 
Carlo simulations were recorded. The distribution of parameters was known, and 
parameters in corresponding distribution was randomly drawn in each simulation. 
Results were plotted on the cost-effectiveness plane and a cost-effectiveness 
acceptability curve (CEAC) was generated. 
4.5. Discussion and potential methodological limitations 
There are a number of issues and challenges that need to be considered undertaking 
the analysis and interpreting the findings: 
• The pathways are complex interventions, which comprise not only the CP 
themselves, but also incentive management mechanism, training and general 
awareness rising on the importance of evidence-based methods. This 
highlights the importance of engagement with stakeholders that will help 
contextualize any quantitative findings and support an overall assessment of 
transferability.   
The pathways are not completely based on clinical evidence for practical reasons 
– a degree of tailoring was needed to reflect local conditions and constraints. This will 
affect interpretation of the findings including considerations of transferability. 
Identifying the separate impact of the confounding factors will not be possible, 
although there may be some suggestive findings. This again emphasizes the 




Chapter 5  Research findings 
Summary of chapter 
In this chapter, two major analytical components are introduced, which are statistical 
description of raw data set, and statistical analysis of selected patients. In term of 
statistical description, the subjects of raw data set, selection process of the appropriate 
patients, grouping of selected patients, and statistical test of primary outcomes are 
introduced sequentially. In term of statistical analysis, three major types of analysis 
results are reported using the approaches as descried in chapter three, which are DID 
after PSM, ITS, and Markov model. 
5.1. Selected patient cohort 
Originally, the Hanbin General hospital management extracted all the hospitalized 
patients’ records covering the period from 1st June 2013 to 31st May 2017(12 months 
before and 36 months after the CP intervention time-point as 1st June 2014), whose 
total number of individual records is 52,328. In consideration of patient privacy, the 
hospital information management staff first de-identified the patient data, then 
processed the patient selection based on the study criteria: major diagnosis at 
discharge including both of infarction diagnosis description in Chinese and ICD-10 
code starting with “I63”, which were I63.901 (multiple cerebral infarction), I63.902 
(cerebral infarction), I63.903 (lacunar infarction), and I63.301 (sequelae of cerebral 
infarction). The de-identified patient records were passed onto the researcher to 
undertake further data cleaning, in term of confirmation of diagnosis, duplication of 




Note that the outlier data of LOS and total hospitalization expenses, representing 
efficiency and expenses measurements respectively, were identified using the inter 
quartile range (IQR). Taking LOS as an example, the data set of LOS was sorted in 
increasing order and cut into 4 equal sizes as quartiles (25%, 50%, 75% and 100%), 
the IQR was defined as difference between highest value of Q3 and highest value of 
Q1 (IQR=Q3-Q1). Data falling beyond the range [lower value than Q1-1.5IQR, 
higher value than Q3+1.5IQR] were considered outliers and were removed from the 
analysis. This approach is normally applied in the statistical description of continuous 
variables.164 patients were removed as extreme values in term of LOS and total 
hospitalization expense, of which 95 patients were removed as outliers on LOS and 
115 patients were removed as outliers on the total hospitalization expenses. To be 
noted, some outliers offended on both criteria. In terms of those patients who were 
removed as outliers, some of them were sufficiently severe that they were sent on to a 
referral hospital very quickly and recorded an extreme small number of LOS, and 
some of them stayed in hospital for an unusually long time because of their generous 
insurance coverage. Using the IQR measurement, these patients were not the target 
population of CP management and would have confounded evaluation of impact of 
the intervention. Finally, 2,533 patients were seen as the sample size for performing 
analysis. 
The illustration of selection process of appropriate patients (also referred to as 





Figure 5-1 The process of data cleaning 
5.1.1. Basic information about general selected patients 
The descriptive summary of the selected patients can be found in Table 5-1: 
Table 5-1 Descriptive summary of the selected patients 
Subjects Description Proportion 
(%) 
Sample size (NO. of patients) 2533  
Age (Mean ± standard deviation, Median) 66.06±9.69,66.00  
Gender Male  1266 49.98 




Department of accident 
and emergency 
938 37.03 
Department of Neurology 954 37.66 
Combination Department 
of traditional Chinese and 
western medicine 
641 25.31 
Type of health 
insurance  
Health insurance for urban 
employees  
107 4.22 
➢ Major diagnosis including infarction description text 
in Chinese and ICD-10 code start with “I63”, two 
premises should be satisfied simultaneously. Finally, 
2,706 eligible patients were targeted.   
◼ 2,746 patients were targeted initially according 
to the Chinese text description containing 
“infarction” 
◼ 2,731 patients were targeted initially according 
to the ICD-10 code starting with “I63” 
52,328 patients for all conditions 
➢ 0 patient was removed in duplication screening of 
hospitalization ID 
2,706 patients were identified in cross-validation 
 
2,706 patients with cerebral infarction were 
rolled over 
 ➢ 1 patient was removed as discharge date info was 
missing  
➢ 8 patients were removed as the discharge date was out 
of the covering period (1st June 2013-31st May2017) 
2,697 patients were left over 
➢ 164 patients were removed as the outlier in term of 
LOS and total hospitalization expenses 
◼ 95 patients were removed as outlier on the LOS  
◼  115 were outliers on hospitalization expenses 
Some were outliers on both 
2,533 patients were targeted finally 
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Subjects Description Proportion 
(%) 
Health insurance for urban 
residence  
99 3.91 
New cooperative rural 
insurance 
2277 89.89 
Health care financial aids  14 0.55 
100% covered by 
employer (e.g. Public 
servant)  
16 0.63 
100% self-payment  5 0.20 
Others  15 0.59 
Comorbidities Diabetes 196 7.74 
Hypertension 1807 71.34 
Coronary heart disease 863 34.07 
Atherosclerosis 1770 69.88 
Dyslipidemia 511 20.17 
Brain offering blood 
insufficiency 
1344 53.06 
Pulmonary infection 125 4.93 
Total hospitalization expenses (Mean ± standard 
deviation; Median) 
4379.65±1396.15 4055.30 
Medication expenses (Mean ± standard deviation; 
Median) 
2085.70±867.15 1943.05 
Radiology expenses (Mean ± standard deviation; 
Median) 
355.76±228.07 344.39 
Laboratory test expenses (Mean ± standard 
deviation; Median) 
640.24±274.69 561.39 
Consultation expenses (Mean ± standard 
deviation; Median) 
480.39±399.52 334.68 
Diagnostic expenses (Mean ± standard deviation; 
Median) 
399.74±202.01 385.00 
LOS (Mean ± standard deviation; Median) 10.88±3.70; 10 
CT 1953 77.10 
MRI  424 16.74 
Color doppler  1670 65.93 
Discharge status Cure 61 2.41 
Improvement  2435 96.13 
Not improved 20 0.79 
Death  4 0.16 
others  13 0.51 
The average age of the patient group is 66 years old, consistent with the China 
Stroke Prevention and Treatment Report (2015) which states that people aged over 65 
has the highest risk to be admitted for infarction in China (L. Wang, Wang, & Peng, 
2015). The gender distribution is balanced, although in the population at large, males 
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account for a larger proportion (58% vs. 42%) (L. Wang et al., 2015). In this county 
hospital, the CI patients were managed over three different clinical departments: the 
emergency department usually received acute onset patients; the Department of 
Neurology hosted the stable patients from outpatient or the Emergency department; 
and the Combination Department of traditional Chinese and western medicine 
provided extra rehabilitation assistance for less serious or recurrent hospitalized 
patients treating by Traditional Chinese Medicine (TCM). Thus, in such county 
hospital, the distribution of patients is diverse. In terms of the insurance type, China 
has not achieved universal health coverage yet, and the patient with different identity 
or occupation have been covered by different type of healthcare insurance. In the 
county areas, the NRCMS which serves rural residents dominates accounts for nearly 
90% of hospitalized CI patients. In term of the expenses, the medication expenses 
took the largest share of total hospitalization expenses, one reason is the medication is 
the major approach in treatment of CI, another reason is that the clinicians have an 
incentive to prescribe drugs for profit-chasing. Mortality is quite low here which has 
two explanations, one is the patients with severe CI would be transferred upwards to 
an advanced level hospital, and another reason is the dying patients desired to die at 
home rather than in hospital, which was driven by Chinese traditional culture.  
5.1.2. Grouping of selected patients 
To facilitate the detection of intervention impact, the selected patients were divided 
into four subgroups: treatment group of patients before intervention (referred to as 
Before/Treatment), control group of patients before intervention (referred to as 
Before/Control), treatment group of patients after intervention (referred to as 
After/Treatment), and control group of patients after intervention (referred to as 




Table 5-2 Number of patients in subgroups 
 Treatment Control 
Before 359 116 
After 1,330 728 
The number of patients in post-intervention groups is larger than pre-intervention 
due to different time periods of data collection (12 months before intervention and 36 
months after intervention). The grouping of patients in term of before-intervention 
was facilitated by neurology physicians from the pilot hospital, who reviewed the 
patients’ medical records in order to retrospectively assign patients to CP and non-CP 
pathways using the inclusion criteria of the CP applied in the period of after-
intervention. The total sample size is 2,533 patients. The “control arm” including 
“before/control” and “after/control” for the purposes of this study had a total sample 
size is 844 patients. The “treatment arm” (patients who would have been eligible for 
CP management and patients who were actually managed according to the CP) had a 
total sample size is 1689 patients, including subgroups of “before/treatment” and 
“after/treatment”. 
5.2. Statistical description of data set 
5.2.1. Normality test of selected variables 
Based on the theory of cumulative distribution function, the Kolmogorov-Smirnov 
test (K-S test) is one of the most useful and general nonparametric tests of normality 
for the continuous data, which can be used to test the normality of one sample 
(Wikipedia, 2019c). In this study, we adopted the K-S test to verify the normality of 
the general sample data set of 2,533 selected patients. Accordingly, the null 
hypothesis H0 of K-S test in this study is that the distribution of sample is normal. If 
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the p value is less than 0.05, this means the null hypothesis will be rejected and the 
sample data is not normally distributed. Conversely, a p value greater than 0.05 means 
the null hypothesis will be accepted and the sample data is normally distributed. The 
Shapiro-Wilk test (S-W test) is a similar nonparametric approach as K-S test to 
identify the normality of a sample of continuous data. The effective logic of S-W test 
is similar as K-S test, which provides p value. If the p value is less than 0.05, the null 
hypothesis of normal distribution will be rejected. Conversely, if the p value greater 
than 0.05, the null hypothesis will be accepted and the distribution of sample data set 
is normal. In statistics, the advantage of K-S test application is if the total size of 
sample is over 2000. If sample size less than 2000, we will perform S-W test instead.   
The summaries of the normality tests were synthesized in Table 5-3. 
Table 5-3 Normality test results for selected variables 




Shapiro-Wilk test Shapiro-Wilk test 
  D p Value W p Value W p Value 
Age 0.04  <0.01 0.99  <0.0001 1.00  0.0104 




0.13  <0.01 0.89  <0.0001 0.99  <0.0001 
medication 
expenses 
0.11  <0.01 0.92  <0.0001 0.98  <0.0001 
Radiology 
expenses 
0.09  <0.01 0.95  <0.0001 0.96  <0.0001 
laboratory test 
expenses 
0.12  <0.01 0.90  <0.0001 0.91  <0.0001 
consultation 
expenses 
0.14  <0.01 0.82  <0.0001 0.84  <0.0001 
Diagnostic 
expenses 
0.09  <0.01 0.95  <0.0001 0.87  <0.0001 




Clearly, the above table shows that the K-S normality tests were highly 
significant (p<0.01) for all target variables, which means the distribution of general 
sample is skewed. Meanwhile, a similar conclusion can be obtained for treatment arm 
and control arm, in which the S-W test normality tests were highly significant 
(p<0.05) for all target variables. This means the distributions of treatment arm and 
control arm are skewed. This is consistent with visual diagnostic of the data through 
histograms.   
5.2.2. Significance test of selected variables for control arm and treatment arm 
In here, the age, gender, type of comorbidities, consultation expenses, diagnostic 
expenses, laboratory test expenses, LOS, medication expenses, radiology expenses, 
utility values and total hospitalization expenses are all continuous data and were 
selected as target variables. In term of continuous variables, the Wilcoxon rank sum 
test should be performed to explore the significant difference between groups 
statistically. In term of categorical variables, the Chi square test or Fisher exact test 
should be performed to explore the significant difference between groups statistically. 
The significance difference test between control arm and treatment arm was processed 
and reported in Table 5-4. 
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Table 5-4 Significance test between control and intervention arms 
  
Treatment group（n=1689） Control group(n=844) Z/X2 value P Value 
N % N % 
Age mean±std,median 65.10±9.71,64.00 67.97±9.35,68.00 6.973  0.000 * 
Gender           13.244  0.000 * 
  Male 888 52.58% 379 44.91%     
  Female 801 47.42% 465 55.09%     
Complications               
  Diabetes 124 7.34% 72 8.53% 1.115  0.291  




557 32.98% 306 36.26% 2.692  0.101  
  Atherosclerosis 1,154 68.32% 616 72.99% 5.809  0.016 * 









66 3.91% 59 6.99% 11.401  
0.001 * 
Total hospitalization expenses   4432.28±1282.95,4008.63 4274.31±1594.41,4288.09 -1.312  0.190  
Medication expenses   2161.83±822.96,1943.84 1933.35±931.43,1940.10 -5.081  0.000 * 
Radiology expenses   346.82±222.71,340.21 373.62±237.57,349.87 2.616  0.009 * 
Laboratory test expenses   607.95±227.20,549.80 704.87±342.05,626.93 6.125  0.000* 
Consultation expenses   490.72±400.44,346.00 459.73±397.11,323.95 -2.956  0.003 * 
Diagnostic expenses   402.09±179.52,394.33 395.03±240.84,375.00 -2.528  0.012 * 
Length of stay   11.43±3.32,11.00 9.78±4.16,10.00 -9.411  0.000 * 
Utility   0.4284±0.0504,0.4356 0.2500±0.0299,0.2494 -41.081 0.000* 
Note: * means the P value less than 0.05.
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Based on the significance test results above, we can see that there is a 
statistically significant difference between treatment and control arms in terms of age, 
gender, hypertension, atherosclerosis, pulmonary infection (p value is less than 0.05). 
The control group is older, more likely to be female, and more likely to have 
atherosclerosis or pulmonary infection. More importantly, in term of the reporting 
variables, the total hospitalization expenses, and many of the components of the total, 
including medication expenses, radiology expenses, laboratory test expenses, 
consultant expenses, diagnostic expenses, LOS, utility values, are significantly 
different (p value is less than 0.05). Meanwhile, the mean of total hospitalization 
expenses in treatment arm are higher than in control arm, and LOS is longer, but the 
utility values of treatment arm is higher than in the control arm. To sum up, a 
discrepancy of baseline characteristics in two arms is observed. The corresponding 
distributions and description of selected variables in general cohort, control arm and 
treatment arm can be seen graphically in Appendix C1. 
5.3. Statistical analysis of data set 
Three analytical strategies were applied to estimate the impact of intervention from 
quantitative perspective, which are DID after PSM, ITS, and Markov model. In this 
part, the corresponding analytical results will be presented and described. To be 
emphasized, the primary outcomes in statistical analysis are: total hospitalization 
expenses, medication expenses, radiology expenses, laboratory test expenses, 
consultation expenses, diagnostic expenses, LOS and utility values. The LOS and 
utility values are treated as indicators of treatment quality in the analysis.  
5.3.1. DID in support of PSM 
5.3.1.1. Results of PSM 
In order to improve the comparability of the two groups, PSM analysis was 
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undertaken targeting the characteristics of four grouped patients, in term of age, 
gender, type and number of comorbidities. The matching of patients between paired 
groups is in consideration of type and number of comorbidities, rather than number of 
comorbidities only. 
Nearest neighbor matching without placement was adopted in such PSM analysis, and 
one to one matching was chosen whose caliper in our study equals to 0.05. The results 
of PSM analysis before and after can be found in the 
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Table 5-5 Baseline characteristics of grouped patients before intervention introduced prior to PSM 
Before PSM 
Treatment group（n=359） Control group(n=116) Z/X2 value P Value 
N % N % 
Age Mean ± std, median 65.57±10.08,65.00 69.70±10.74,69.50 3.521  0.000  
Gender      2.994  0.084  
  Male 168 46.80% 65 56.03%     
  Female 191 53.20% 51 43.97%     
Complications               
  Diabetes 31 8.64% 10 8.62% 0.000  0.996  




113 31.48% 35 30.17% 0.070  0.792  
  Atherosclerosis 211 58.77% 66 56.90% 0.127  0.721  








12 3.34% 11 9.48% 7.174  
0.007  
Total hospitalization expenses   4620.61±1296.65,4099.54 3476.98±1690.54,2901.35 -7.391   
Medication expenses   2334.87±866.78,2083.95 1611.97±977.86,1341.41 -7.388   
Radiology expenses   318.08±214.34,283.23 313.42±221.29,283.23 -0.204   
Laboratory test expenses   462.93±137.57,440.50 414.27±145.91,402.07 -3.373   
Consultation expenses   597.08±458.05,465.90 400.94±369.21,262.09 -5.175   
Diagnostic expenses   415.51±189.38,428.96 358.60±332.53,340.70 -3.625   
Length of stay   12.98±3.70,12.00 9.18±4.62,9.00 -7.764   
CT   227 63.23% 65 56.03% 1.917   
MRI   51 14.21% 15 12.93% 0.119   
Color doppler   171 47.63% 42 36.21% 4.627   
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Discharge options           29.717   
  Cure 22 6.13% 3 2.59%     
  Improvement 334 93.04% 102 87.93%     
  Not improvement 1 0.28% 10 8.62%     
  Death 1 0.28% 1 0.86%     
  Others 1 0.28% 0 0.00%     
Utility   0.3492±0.0298,0.3491 0.2473±0.0295,0.2440 -16.201   
 
Table 5-6 Baseline characteristics of grouped patients before intervention introduced after PSM 
After PSM 
Treatment group（n=108） Control group(n=108) Z/X2 value P Value 
N % N % 
Age 
mean ± std, 
median 
68.98±9.00,70.00 68.84±10.60,68.00 
-0.109  0.913  
Gender           0.297  0.586  
  Male 55 50.93% 59 54.63%     
  Female 53 49.07% 49 45.37%     
Complications               
  Diabetes 11 10.19% 10 9.26% 0.053  0.818  




35 32.41% 35 32.41% 0.000  1.000  
  Atherosclerosis 65 60.19% 64 59.26% 0.019  0.890  





45 41.67% 49 45.37% 0.301  0.583  





expenses   
4495.66±1149.91,4081.03 3499.11±1708.93,2940.11 
-5.422   
Medication expenses   2225.88±688.56,2046.77 1624.81±992.08,1341.41 -5.494   
Radiology expenses   307.40±202.22,283.23 317.84±217.44 283.23 0.229   
Laboratory test expenses   460.59±130.71,435.55 411.76±140.97,398.81 -2.932   
Consultation expenses   601.35±473.32,523.98 406.31±377.41,262.09 -3.933   
Diagnostic expenses   413.08±181.00,428.96 361.27±340.14,340.70 -2.894   
Length of stay   12.83±3.68,11.50 9.27±4.61,9.00 -5.694   
CT   74 68.52% 59 54.63% 4.403   
MRI   11 10.19% 15 13.89% 0.700   
Color doppler   51 47.22% 39 36.11% 2.743   
Discharge options           9.798   
  Cure 7 6.48% 2 1.85%    
  Improvement 100 92.59% 98 90.74%    
  Not improvement 0 0.00% 7 6.48%    
  Death 1 0.93% 1 0.93%    
  Others 0 0.00% 0 0.00%    










Table 5-5 & Table 5-6 showed the baseline characteristics of grouped patients 
(“Before/treatment” subgroup and “Before/control” subgroup) before and after the 
applying of PSM approach. Following application of PSM (Table 5-6), there were no 
statistically significant differences between the matched pairs of patients in the 
“Before/treatment” subgroup and the “Before/control” subgroup by age, gender and 
type and number of comorbidities. The application of PSM has allowed for potential 
confounding caused by observable characteristics to be eliminated. 
The illustration of the matching patients before intervention introduced can be seen in 
Figure 5-2.  
 
 
Figure 5-2 The result of PSM for stage of before intervention 
In the above figure, the blue areas (“Untreated” defined by statistics software 
automatically) indicate the 108 paired patients used for matching out of 359 CI 
patients in group of “Before/Treatment”, who would have been eligible for the CP. 
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The red areas (“Treated: on support” defined by statistics software automatically) 
indicate the 108 paired patients out of 116 infarction patients who were not eligible 
for CP. The green area (“Treated: off support” defined by statistics software 
automatically) means the unpaired patients in the group of “Before/Control”. In 
general, we can see symmetry between the blue and red areas, which indicates the 





















Table 5-7 Baseline characteristics of grouped patients after intervention introduced prior to PSM 
Before PSM 
Treatment group（n=1330） Control group(n=728) Z/X2 value P Value 
N % N % 
Age Mean ± std, median 64.97±9.60,64.00 67.69±9.08,67.00 6.285  0.000  
Gender               
  Male 633 47.59% 400 54.95% 10.170  0.001  
  Female 697 52.41% 328 45.05%     
Complications               
  Diabetes 93 6.99% 62 8.52% 1.569  0.210  




444 33.38% 271 37.23% 3.063  0.080  
  Atherosclerosis 943 70.90% 550 75.55% 5.102  0.024  








54 4.06% 48 6.59% 6.409  
0.011  
Total hospitalization expenses   4381.45±1274.95,3951.39 4401.35±1542.10 ,4379.48 1.792   
Medication expenses   2115.12±804.71,1907.76 1984.56±914.12,1996.05 -1.990   
Radiology expenses   354.59±224.36,344.39 383.22±238.81,349.87 2.669   
Laboratory test expenses   647.09±230.76,585.56 751.18±341.58, 678.13 6.251   
Consultation expenses   462.01±378.51,322.41 469.10±400.81,333.09 -0.599   
Diagnostic expenses   398.47±176.67,387.57 400.83±222.53,375.00 -0.837   
Length of stay   11.02±3.08,10.00 9.87±4.07,10.00 -6.092   
CT   1,053 79.17% 608 83.52% 5.701   
MRI   252 18.95% 106 14.56% 6.301   
Color doppler   933 70.15% 524 71.98% 0.760   
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Discharge options           44.968   
  Cure 28 2.11% 8 1.10%    
  Improvement 1,302 97.89% 697 95.74%    
  Not improvement 0 0.00% 9 1.24%    
  Death 0 0.00% 2 0.27%    
  Others 0 0.00% 12 1.65%    
Utility   0.4497±0.0290,0.4491 0.2504±0.0300,0.2496 -37.560   
 
Table 5-8 Baseline characteristics of grouped patients after intervention introduced after PSM 
After PSM 
Treatment group（n=724） Control group(n=724) Z/X2 value P Value 
N % N % 
Age Mean ± std, median 68.17±8.83,67.00 67.62±9.05,67.00 -1.056  0.291  
Gender           0.400  0.527  
  Male 384 53.04% 396 54.70%     
  Female 340 46.96% 328 45.30%     
Complications               
  Diabetes 51 7.04% 62 8.56% 1.161  0.281  




274 37.85% 268 37.02% 0.106  0.745  
  Atherosclerosis 550 75.97% 546 75.41% 0.060  0.806  








45 6.22% 44 6.08% 0.012  0.913  




Medication expenses   2136.68±806.95,1936.80 1983.96±916.19,1996.05 -2.426   
Radiology expenses   354.85±218.96,344.39 383.73±238.59,349.87 2.190   
Laboratory test expenses   666.32±245.28,612.53 750.12±341.57,677.33 4.212   
Consultation expenses   483.50±395.01,337.16 469.92±401.70,333.95 -1.460   
Diagnostic expenses   392.70±172.54,386.21 400.96±222.36,375.00 -0.284   
Length of stay   11.18±3.14,10.00 9.89±4.07,10.00 -6.009   
CT   563 77.76% 604 83.43% 7.423   
MRI   133 18.37% 106 14.64% 3.653   
Color doppler   497 68.65% 521 71.96% 1.905   
Discharge options           25.949   
  Cure 18 2.49% 8 1.10%    
  Improvement 706 97.51% 694 95.86%    
  Not improvement 0 0.00% 9 1.24%    
  Death 0 0.00% 2 0.28%    
  Others 0 0.00% 11 1.52%    





Comparing before and after PSM, we can see that the samples are more balanced after 
PSM. Prior to PSM, age, gender, hypertension, atherosclerosis and pulmonary 
infection are significantly different (p value less than 0.05) in the two groups (see 
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Table 5-7). After adjusting with PSM, these differences are no longer significant (see 
Table 5-8).Then we are confident to say that the patients in two subgroups are 
comparable, and observable confounding factors between the two groups were 
eliminated. 
The illustration of the matching patients after intervention introduced can be seen in 
Figure 5-3.  
 
Figure 5-3 The result of PSM for stage of after intervention 
In the above figure, the blue areas (“Untreated” defined by statistics software 
automatically) indicate the 724 paired patients out of 1,330 CI patients ingroup of 
“After/Treatment”, who are managed by CP approach after the intervention was 
introduced. The red areas (“Treated: on support” defined by statistics software 
automatically) indicate the 724 paired patients out of 728 CI patients in group of 
“After/Control”, which means the intended patients were not eligible to be managed 
by CP approach after intervention introduced. The green area (“Treated: off support” 
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defined by statistics software automatically) means the unpaired patients in the group 
of “After/Control”. In general, we can see symmetry between the blue and red areas, 
which indicates the effectiveness of matching.  
5.3.1.2. Results of DID analysis 
Using the PSM samples, DID analysis was undertaken on the outcome variables listed 
in section 2.3.2 . The summary of DID results are shown in Table 5-9 to Table 5-16. 





Control group difference 
Before 4495.66 3499.11 996.55 
After 4447.79 4400.85 46.94 
difference 47.87 -901.74 949.61 
As shown in the above table, for the control group, hospitalization expenses 
increased by 901.74 YUAN. In contrast, for the CP managed patients, hospitalization 
expenses decreased by 47.87 YUAN after the intervention was introduced. We cannot 
say that all the differences may be attributed to the intervention. Employing DID to 
offset the natural trend in the control group before and after intervention, we can state 
that the absolute difference attributed to CP intervention is estimated at 949.61 
YUAN, which means the patients managed by CP approach will save 949.61 YUAN 
per patient on average, compared to non-CP managed patients. The next investigation 
is how the difference in total expenses breaks down among the five expenditure 
components of total hospitalization expenses. 
 
 




Control group difference 
Before 2225.88 1624.81 601.07 
After 2136.68 1983.96 152.72 
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difference 89.20 -359.15 448.35 
As shown in the above table, for the control group, medication expenses would 
increase by 359.15 comparing the period before and after the intervention. In 
comparison, for the treatment group medication expenses would decrease by 89.20 
YUAN comparing the period before and after the intervention. We cannot say that all 
the differences may be attributed to the intervention. Employing DID to offset the 
natural trend in the control group before and after intervention, we can state that the 
absolute difference attributed to CP intervention is estimated at 448.35 YUAN, which 
means the patients managed by CP approach will save 448.35 YUAN per patient on 
average, compared to non-CP managed patients.  




Control group difference 
Before 307.4 317.84 -10.44 
After 354.85 383.73 -28.88 
difference -47.45 -65.89 18.44 
As shown in the above table, for the control group, radiology expenses would 
increase by 65.89 comparing the period before and after the intervention. In 
comparison, for the treatment group radiology expenses would increase by 47.45 
YUAN comparing the period before and after the intervention. We cannot say that all 
the differences may be attributed to the intervention. Employing DID to offset the 
natural trend in the control group before and after intervention, we can state that the 
absolute difference attributed to CP intervention is estimated as 18.44YUAN, which 
means the patients managed by CP approach will save 18.44YUAN per patient on 
average, compared to non-CP managed patients. 
Table 5-12 DID result of laboratory test expenses (YUAN) 
Laboratory test expenses 
Treatment 
group 
Control group difference 
Before 460.59 411.76 48.83 
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After 666.32 750.12 -83.8 
difference -205.73 -338.36 132.63 
As shown in the above table, for the control group, laboratory test expenses 
would increase by 338.36 comparing the period before and after the intervention. In 
comparison, for the treatment group laboratory test expenses would increase by 
205.73YUAN comparing the period before and after the intervention. We can state 
that the absolute difference attributed to CP intervention is estimated as 132.63 
YUAN, which means the patients managed by CP approach will save 132.63 YUAN 
per patient on average, compared to non-CP managed patients.   




Control group difference 
Before 601.35 406.31 195.04 
After 483.5 469.92 13.58 
difference 117.85 -63.61 181.46 
As shown in the above table, for the control group, consultation expenses would 
increase by 63.61 comparing the period before and after the intervention. In 
comparison, for the treatment group consultation expenses would decrease by 117.85 
YUAN comparing the period before and after the intervention. We can state that the 
absolute difference attributed to CP intervention is estimated at 181.46 YUAN, which 
means the patients managed by CP approach will save 181.46 YUAN per patient on 
average, compared to non-CP managed patients. 




Control group difference 
Before 413.08 361.27 51.81 
After 392.7 400.96 -8.26 
difference 20.38 -39.69 60.07 
As shown in the above table, for the control group, diagnostic expenses would 
increase by 39.69 comparing the period before and after the intervention. In 
comparison, for the treatment group diagnostic expenses would decrease by 20.38 
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YUAN comparing the period before and after the intervention. We can state that the 
absolute difference attributed to CP intervention is estimated at 60.07 YUAN, which 
means the patients managed by CP approach will save 60.07 YUAN per patient on 
average, compared to non-CP managed patients.  
In term of expenses, the saving of total hospitalization expenses for the 
intervention group can be broken down into following subjects, visually in a pie chart 
as: 
 
Figure 5-4 Proportion of total hospitalization expenses savings 
The most saving of hospitalization are due to saving of medication expenses, 
accounting for 47.21%. The consultation expenses, laboratory test expenses were also 
reduced significantly. In contrast, the diagnostic expenses and radiology expenses did 
not change noticeably, accounting for 6.33% and 1.94% respectively. See Figure 5-4. 
Table 5-15 DID result of LOS (days) 
Length of stay 
Treatment 
group 
Control group difference 
Before 12.83 9.27 3.56 
After 11.18 9.89 1.29 















As shown in the above table, for the control group, LOS would increase by 0.62 
day comparing the period before and after the intervention. In comparison, for the 
treatment group medication expenses would decrease by 1.65 days comparing the 
period before and after the intervention. We can state that the absolute difference 
attributed to CP intervention is estimated as 2.27 days, which means the patients 
managed by CP approach will save 2.27 days per patient on average, compared to 
non-CP managed patients.   




Control group Difference 
Before 0.3490  0.2475  0.1015 
After 0.4500  0.2503  0.1997 
difference -0.1010 -0.0028 -0.0982 
As shown in the above table, for the control group, average utility score would 
increase by 0.0028 comparing the period before and after the intervention. In 
comparison, for the treatment group utility score would increase by 0.1010 comparing 
the period before and after the intervention. We can state that the absolute difference 
attributed to CP intervention is estimated as 0.0982, which means the patients 
managed by CP approach will obtain more utility score of 0.0982 on average, 
compared to non-CP managed patients. 
5.3.2. Results of ITS 
As described in chapter3, ITS was used to explore the intervention impact using 
monthly equal-interval data. According to the grouping of patients in Table 5-2, all 
patients before and after the intervention (including those not managed by the CP) 
were analyzed so that the sample size of the “Before” group is 475 (12 months data), 
and the sample size of the “After” group is 2,058 (36 months of data). Patient data 
before intervention were grouped into 12 monthly interval subgroups based on 
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patients’ discharge date, and 36 monthly interval subgroups after intervention, which 
is from 1st June 2014 to 31st May 2017.To investigate the relatively short impact of 
CP, the comparison between 12 months before and after was conducted as well, 
results can be provided upon request. In addition, patients in “Before/Treatment” was 
informed by clinical guideline, which is considered a confounding factor of CP. 
Therefore, the group of patients refer to “Before/Control” and “After/Treatment” were 
compared, and results are positive which implies that CP treatment save money and 
improves quality of care. Such results can be provided upon request. This chapter will 
only discuss about results of ITS for all patients before and after CP intervention, to 
investigate the overarching impact of CP.  
Un-matched patient level data was used in ITS as PSM cannot be applied to 
monthly patient-level subgroup data. In addition, the ITS is workable on continuous 
variables, thus the outcome measures which are continuous variables are included in 
the following analysis: LOS, total hospitalization expenses, medication expenses, 
radiology expenses, laboratory test expenses, consultation expenses, diagnostic 
expenses and EQ-5D-3L based utility values. In each monthly timepoint, mean value 
of each outcome measure is calculated to process the ITS analysis.  
Before developing the multiple linear regression model described in section 
4.4.3, model assumptions should be examined This was done using diagnostic plots, 
which are based on the estimated residuals. 
Length of Stay  
In general, the CP intervention had a positive impact on LOS by reducing 
average LOS and variations. This is consistent with aforementioned DID result. As 
indicated in Figure 5-5, there is increasing trend of LOS before CP intervention and 
 
103 
decreasing trend after CP intervention. Meanwhile, the variability of the plots shown 
in Figure 5-5 was reduced after intervention. According to  
Table 5-17, we can see the p value is <.0001, which is statistically significant 
using 0.05 as standard. However, none of the parameters are statistically significant. 
Statistical results show limited effect of CP. 
 
Figure 5-5 Linear regression graph of LOS 
 
Table 5-17 Linear regression simulation test result of LOS 
Variables Estimated Parameter Standard Deviation P value 
Intercept 11.79 0.49 <.0001 
X1 0.04 0.07 0.584 
X2 0.82 0.64 0.2051 
X3 -0.10 0.07 0.1398 
R2 0.5527  <.0001 
X1: slope prior to the intervention (Baseline trend) 
X2: change in the level immediately after the intervention (level change)      
X3: change in the slope from the pre-to-post intervention periods (trend change) 
 
EQ-5D-3L based utility value 
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In general, the index utility value after CP intervention is higher than before, which is 
in line with the DID result. However, index scores appear to decline over time to 
levels prior to the introduction of the CP (see Figure 5-6). The increase in index value 
on introduction of the CP was 0.1366 (p<.0001) compared with before. The 
decreasing trend is statistically significant (see Table 5-18). Patients were getting a lot 
of attention early on because of the introduction of the CP (the physicians and 
hospitals wanted to make it a success – maybe there were also getting more 
standardized treatment, medicines, necessary laboratory test etc.) This relative 
attention to patient needs may have declined over time as the CP became more 
routine. 
 
Figure 5-6 Linear regression graph of EQ-5D-3L based utility value 
 
Table 5-18 Linear regression simulation test result of EQ-5D-3L based utility 
value 
Variables Estimated Parameter Standard Deviation P value 
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Intercept 0.3119 0.0119 <.0001 
X1 0.0018 0.0016 0.2665 
X2 0.1366 0.0155 <.0001 
X3 -0.0042 0.0016 0.0154 
R2 0.7435  <.0001 
X1: slope prior to the intervention (Baseline trend) 
X2: change in the level immediately after the intervention (level change)      
X3: change in the slope from the pre-to-post intervention periods (trend change) 
 
Total hospitalization expenses 
CP impact on the total hospitalization expenses is not clear based on the results. 
As indicated in Figure 5-7, there is an abrupt increase after CP intervention. The total 
hospitalization expenses decreased in 2015, and increased again in 2016. However, 
the trend is decreasing in general. All parameters are not significant according to 
Table 5-19. Statistical results show limited effect of CP. 
 
Figure 5-7 Linear regression graph of total hospitalization expenses 
 




Variables Estimated Parameter Standard Deviation P value 
Intercept 4242.68 238.65 <.0001 
X1 15.53 32.43 0.6344 
X2 377.17 311.66 0.2327 
X3 -22.48 33.02 0.4995 
R2 0.0377  0.6345 
X1: slope prior to the intervention (Baseline trend) 
X2: change in the level immediately after the intervention (level change)      
X3: change in the slope from the pre-to-post intervention periods (trend change) 
 
Medication expenses 
As shown in Figure 5-8, findings are similar to the analysis undertaken on 
hospitalization expenses, there is an abrupt increase after CP intervention, and 
decrease in 2015, it goes up again in 2016. However, the trend is decreasing in 
general. Table 5-20 shows that the p value of regression is 0.3251, which is 
considered to be not significant under the standard of 0.05. It indicates limited 




Figure 5-8 Linear regression graph of medication expenses 
 
Table 5-20 Linear regression simulation test result of medication expenses 
Variables Estimated Parameter Standard Deviation P value 
Intercept 2136.08 153.75 <.0001 
X1 4.30 20.89 0.838 
X2 135.45 200.79 0.5035 
X3 -10.61 21.27 0.6205 
R2 0.075  0.3251 
X1: slope prior to the intervention (Baseline trend) 
X2: change in the level immediately after the intervention (level change)      
X3: change in the slope from the pre-to-post intervention periods (trend change) 
Radiology expenses 
Radiology expenses are higher than that before the CP intervention, but the trend 
is decreasing after the CP intervention (Figure 5-9). Table 5-21 shows that the p value 
of regression is 0.0356, which is considered to be significant under the standard of 
0.05. Changes in level and slope, were however not statistically significant. It 




Figure 5-9 Linear regression graph of radiology expenses 
 
Table 5-21 Linear regression simulation test result of radiology expenses 
Variables Estimated Parameter Standard Deviation P value 
Intercept 309.50 28.08 <.0001 
X1 1.38 3.81 0.7187 
X2 56.80 36.66 0.1285 
X3 -1.44 3.88 0.7131 
R2 0.1752  0.0356 
X1: slope prior to the intervention (Baseline trend) 
X2: change in the level immediately after the intervention (level change)      
X3: change in the slope from the pre-to-post intervention periods (trend change) 
 
Laboratory test expenses 
The results show that laboratory test expenses continue to increase after CP 
introduction; the post intervention slope suggests that it is at a slower rate rather than 
before the CP, but this is not statistically significant (see Figure 5-10 and Table 5-22). 
Table 5-22 shows R2 to be 0.83 (p<.0001). Laboratory test expenses increased 118.58 




Figure 5-10 Linear regression graph of laboratory test expenses 
 
Table 5-22 Linear regression simulation test result of laboratory test expenses 
Variables Estimated Parameter Standard Deviation P value 
Intercept 359.59 35.74 <.0001 
X1 13.48 4.86 0.008 
X2 118.58 46.67 0.0147 
X3 -6.62 4.94 0.1874 
R2 0.8308  <.0001 
X1: slope prior to the intervention (Baseline trend) 
X2: change in the level immediately after the intervention (level change)      
X3: change in the slope from the pre-to-post intervention periods (trend change) 
Consultation expenses 
As shown in Figure 5-11, fitted trend line appears to show a change in slope post 
the introduction of CP, the variation of scatters are less after the CP intervention. In 
general, it shows CP intervention generally decreases consultation expenses. Table 5-
23 shows that the p value of regression is 0.0007, which is considered to be 
statistically significant under the standard of 0.05. However, other parameters in the 
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regression are not statistically significant. Statistical results show limited effect of CP.
 
Figure 5-11 Linear regression graph of consultation expenses 
 
Table 5-23 Linear regression results on consultation expenses 
Variables Estimated Parameter Standard Deviation P value 
Intercept 590.54 48.35 <.0001 
X1 -6.02 6.57 0.3643 
X2 -6.89 63.14 0.9136 
X3 2.19 6.69 0.7453 
R2 0.3186  0.0007 
X1: slope prior to the intervention (Baseline trend) 
X2: change in the level immediately after the intervention (level change)      
X3: change in the slope from the pre-to-post intervention periods (trend change) 
 
Diagnostic expenses 
As shown in Figure 5-12, the fitted trend line showed the change in slope after 
the introduction of CP intervention. There was an increasing trend before CP 
intervention and a decreasing trend after intervention. The distribution of scatters is 
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similar with that of total hospitalization expenses and medication expenses. However, 
from the statistical point of view, all parameters of regression are not statistically 
significant, which indicates the effect is limited, see  
Table 5-24. 
 
Figure 5-12 Linear regression graph of diagnostic expenses 
 
Table 5-24 Linear regression simulation test result of diagnostic expenses 
Variables Estimated Parameter Standard Deviation P value 
Intercept 375.77 32.06 <.0001 
X1 3.49 4.36 0.4271 
X2 42.66 41.87 0.3139 
X3 -4.05 4.44 0.3664 
R2 0.0247  0.7739 
5.3.3. Markov Modeling of intervention 
Clinical inputs 
The clinical model inputs are transition probabilities between outpatient and inpatient 
status, and mortality rate.  
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Transition probabilities between states 
To identify probabilities between different states, a keyword search was 
conducted in MEDLINE (09/2018) using the keywords “clinical pathway*”, “care 
pathway*”, “critical path*”, “care implementation*”, “cerebral infarction”, “stroke”, 
“economic evaluation”. The goal was to find population-based data that described the 
transition probabilities in CI patients at acute or stable stages. Of the 6 search results, 
one paper was screened in full. It was from China (Tu, 2016) which provided 
rehospitalization rate at population level. Rehospitalization rate was considered as 
probabilities from outpatient to inpatient in the model describing patients at stable 
stage. 
Probabilities of inpatient to outpatient are directly calculated using data after the 
PSM (Table 5-8). For patients at acute stage, the discharge rates were calculated by 
day and considered as transition probabilities from inpatient to outpatient, the 
calculation equation is as follows: 
Daily discharge rate =
Number of discharged patient in specific day
Total number of inpatients
 
All patients are assumed to be discharged within one year when they are at stable 
stage. Transition probabilities can be found in Appendix C3. 
Mortality rate 
Chinese natural mortality data are available for males and females over the 
lifetime (Statistics, 2015). The general mortality rate was used as the natural mortality 
rate for outpatients in stable stage. Annual mortality rates from age of 60 and above 
were used in each cycle accordingly.  
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Daily mortality rates of inpatients at acute stage were calculated using the data 
from pilot hospital, calculation equation can be seen as below.  
p = 1 − 𝑒−𝑟𝑡 
Probability p is a measure of likeliness that an event will occur (over a specified time period) 
Rate r is number of events per unit time in a defined population (epidemiology) 
Mortality rates of outpatients at acute stage for CP and non-CP arms were derived 
from literature (Chen, Gao, & Liu, 2017), see Table 5-25. Mortality rate of outpatients 
at stable stage for CP and non-CP arms were derived from China’s Population and 
Employment Statistical Yearbook 2015 (Statistics 2015). The mortality rate of 
inpatients at both acute and stable stages were derived from real world data collected 
from the pilot site.  
Table 5-25 Mortality rates used in two models 
Stage Intervention State Mortality rate Source 
Acute 
CP 
Outpatient 0.000453 (Chen et al., 2017) 
Inpatient 0.0000004056 Real-world data 
Non-CP 
Outpatient 0.000453 (Chen et al., 2017) 
Inpatient 0.0000024389 Real-world data 
Stable 
CP 
Outpatient Appendix C4 (Chen et al., 2017; 
Statistics, 2015) 
Inpatient 0.0001480604 Real-world data 
Non-CP 
Outpatient Appendix C4 (Statistics, 2015) 
Inpatient 0.0008902087 Real-world data 
Health related quality of life 
Health related quality of life data (based on the EQ-5D-3L) for patients in the 
acute stage was directly collected from patients in the pilot hospital. Patients 
completed the questionnaire on the day of discharge. Utility data at admission stage  
was excluded due to data quality, primarily incompleteness of questionnaires at time 
of admission. Lack of utility data upon admission may lead to bias, which may cause 
the overestimate of the intervention effect. For the economic analysis, the Chinese 
EQ-5D-3L value set was applied to calculate the utility values (G. G. Liu et al., 2014). 
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One paper from the UK (Hunter et al., 2018) provided utility value of outpatients 
measured by Barthel Index at population level, see Table 5- 26. 
Table 5- 26 Health state utility values after intervention 
Intervention State Utility 
(Mean value) 
Standard error Source 
CP 
Outpatient 0.558 0.0156 (Hunter et al., 2018) 
Inpatient 0.4284 0.0504 Real-world data 
Non-CP 
Outpatient 0.558 0.0156 (Hunter et al., 2018) 
Inpatient 0.2500 0.0299 Real-world data 
Cost inputs 
Cost means the actual expenses charged by hospital. The cost inputs incurred in 
the outpatient state consist of medication costs, radiology expenses, laboratory test 
expenses and consultation costs. In the inpatient state, diagnostic expenses were 
introduced in inpatient cost beyond outpatient expenses. Only inpatient costs can be 
directly derived from HIS, detailed analysis of results can be found in section 5.3.1.1 
(Table 5-8). For costs incurred in the outpatient state, expert consultation was 
conducted for data collection. In addition, the initial project investment, accounting 
for 10,000 YUAN, was also included. But the initial investment will be amortized 
over a longer time horizon.  
All costs are converted to 2014 base year using the prices index from the 
National Bureau of Statistics (Statistics). 
Outpatient costs 
In the absence of cost data from either the pilot hospital or from published 
literatures, estimates of outpatient costs were based on expert consultation from pilot 
hospital. The clinicians were asked about their individual experiences and treatment 
practices refer to volume, frequency, and unit costs of prescription items. It is 




Data on drugs used by outpatients and the unit cost for each kind of drug were 
obtained from clinician consultation (see Table 5-27). Aspirin and Atorvastatin 
Calcium are two drugs used frequently by local physicians for CI patients after 
discharge. The combination of these two drugs could be an alternative option for 
some patients based on their symptoms. Total drug cost per cycle was calculated 
based on the proportion of patients allocated into various therapy utilization 
patterns,Table 5-28. Total drug cost for outpatient per year is ¥1,908.04. 














30 100 ¥15.3 100 ¥0.51  ¥186.15  
Atorvastatin 
Calcium  
7 20 ¥39.48 20 ¥5.64  ¥2058.60  
 
Table 5-28 Cost of outpatients per year 
Therapy of utilization % of patients Costs 
Aspirin Enteric-coated+Atorvastatin Calcium  70.00 ¥1571.33  
Aspirin Enteric-coated 15.00 ¥27.92  
Atorvastatin Calcium  15.00 ¥308.79  
 Total cost ¥1,908.04  
Medical resource use 
Frequencies and the proportion of patients using medical resources in each cycle, 
such as consultation, laboratory test and radiology services are presented in Table 5-
29. Total medical resource use for outpatient per cycle is ¥ 2,320.68.  
Table 5-29 Medical resource use 
  % of patients Frequency per cycle 
Consultation 
Oncologist-junior 55% 12 
Oncologist-senior 45% 12 




Biochemistry 5.95% 4 
Blood test 60% 4 
Stool test 8% 2 
Urine test 40% 1 
Total costs ¥ 60.24 
Radiology 
Ultrasound  50% 1 
CT scan 50% 2 
MRI scan 33% 1 
Total costs ¥ 365.84 
Total cost per cycle ¥ 2,320.68 
Total cost per day ¥ 6.36 
Unit costs for medical resource use were taken from pilot hospital and converted 
to 2014 prices using the data from National Bureau of Statistics(Statistics),see Table 
5- 30. 
Table 5- 30 Medical resource use unit costs 
Cost item 
Consultation 
Oncologist-junior ¥ 3.00 
Oncologist-senior ¥ 5.00 
Laboratory test 
Biochemistry ¥ 65.00 
Blood test ¥ 18.00 
Stool test ¥ 1.30 
Urine test ¥ 3.40 
Radiology 
Ultrasound  ¥ 60.00 
CT scan ¥ 170.00 
MRI scan ¥ 320.00 
Costs at acute stage (Inpatients) 
Inpatient costs are calculated using data collected as part of the CP 
implementation from the pilot hospital (see section 5.3.1.1, Table 5-8). The total 
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average inpatient cost for CP managed patients is ¥4,447.79 and for Non-CP patients 
¥4,400.85 (see Table 5- 31). 









Drug costs ¥191.14 46.08 ¥206.40 68.38 
Radiology costs ¥354.85 218.96 ¥383.73 238.59 
Laboratory test costs ¥666.32 245.28 ¥750.12 341.57 
Consultation costs ¥483.50 395.01 ¥469.92 401.70 
Diagnosis costs ¥392.70 172.54 ¥400.96 222.36 
Total costs ¥4,447.79 1287.62 ¥4,400.85 1545.32 
Validation 
Face validity and peer review 
The development of the model included in this report was undertaken with 
support from various stakeholders and experts; these included stroke specialists from 
the China National Clinical Research Center of Neurological Diseases and senior 
modelers from the China Health Economic Association. Feedback on model structure 
and input data was obtained through various rounds of consultation, dissertation 
review, national/international scientific conferences, and commentary from experts. 
Their inputs led to the development of a model that defined ‘acute’ and ‘stable stages’ 
following a CI disease management progress.  
5.3.3.1. Cost-effectiveness analysis results 
Base-case analysis 
The base case analysis undertaken in two stages: cost-effectiveness estimates were 
generated for the acute and stable stages separately. An overall estimate of the 
incremental cost-effectiveness was then estimated (see section 4.4.4 for more detail 
on the methodology) 
Cost-effectiveness results for acute stage:  
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The mean average hospitalization cost was ¥3,678.57 per patient in the 
intervention arm compared with ¥3,400.23 in the control arm, yielding a cost 
difference of ¥278.34 in favor of the Non-CP group instead of the CP group. CP 
treatment results in 0.031 QALY versus 0.028 QALY of Non-CP treatment, resulting 
in an intervention difference of 0.003 QALY. The incremental cost-effectiveness ratio 
was determined to be ¥103,450.45/QALY, which means that the administration of CP 
intervention resulted in an extra 1 QALY at an additional cost of ¥103,450.45(Table 
5-32). As stated, the Shannxi GDP per capita in 2014 is ¥46,929.00. As recommended 
by Ochalek or Woods et al (Revill et al., 2015), if we set the threshold value as 1 
times of 2014 Shannxi local GDP, equivalent to ¥46,929.00, the intervention strategy 
is not cost-effective compared to Non-CP treatment, because the ICER is much higher 
than the threshold value.  
Table 5-32 Base-Case analysis of acute stage 
Strategy Costs  ∆Costs QALYs ∆ QALYs ICER 
Non-CP 
group 
¥3,400.23  0.028   
CP group ¥3,678.57 ¥278.34 0.031 0.003 ¥103,450.45/QALY 
Cost-effectiveness results for stable stage:  
The annual mean average outpatient cost was ¥42,365.38 per patients in the 
intervention arm compared with ¥32,223.84 on the control arm, yielding a cost 
difference of ¥10,141.54 in favor of the Non-CP group instead of the CP group. CP 
treatment results in 6.755 QALY versus 6.411 QALY of Non-CP treatment, resulting 
in an intervention difference of 0.344 QALY. The incremental cost-effectiveness ratio 
was estimated to be ¥29,497.55/QALY, which means the administration of CP 
intervention resulted in an extra of 1 QALY at an additional cost of ¥29,497.55 (Table 
5-33). As stated, the Shannxi GDP per capita in 2014 is ¥46,929.00. If we set the 
threshold value as 1 times of 2014 Shannxi local GDP, equivalent to ¥46,929.00, the 
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intervention strategy is cost-effective compared to Non-CP treatment, because the 
ICER is lower than the threshold value.  
Table 5-33 Base-Case analysis of stable stage 
Strategy Costs ∆Costs QALYs ∆ QALYs ICER 
Non-CP 
group 
¥32,223.84  6.411   
CP group ¥42,365.38 ¥10,141.54 6.755 0.344 ¥29,497.55/QALY 
Cost-effectiveness results overall:  
The overall mean average cost was ¥46,043.94 per patient in the intervention 
arm compared with ¥35,624.06 in the control arm, yielding a cost difference of 
¥10,419.88 in favor of the Non-CP group instead of the CP group. CP treatment 
results in 6.786 QALY versus 6.440 QALY of Non-CP treatment, resulting in an 
intervention difference of 0.347 QALY. The incremental cost-effectiveness ratio was 
estimated to be ¥30,071.79/QALY, which means the administration of CP 
intervention resulted in an extra of 1 QALY at an additional cost of ¥30,071.79 (Table 
5-34). As stated, the Shannxi GDP per capita in 2014 is ¥46,929.00. As recommend 
by Ochalek or Woods et al (Revill et al., 2015), if we set the threshold value as 1 
times of 2014 Shannxi local GDP, equivalent to ¥46,929.00, the intervention strategy 
is cost-effective compared to Non-CP treatment, because the ICER is lower than the 
threshold value.  
Table 5-34 Base-Case analysis overall 
Strategy Costs ∆Costs QALYs ∆ QALYs ICER 
Non-CP 
group 
¥35,624.06  6.440   
CP group ¥46,043.94 ¥10,419.88 6.786 0.347 ¥30,071.79/QALY 
In the short run (acute stage), CP intervention of CI patients was not cost-
effective, since the ICER value was higher than the pre-defined threshold value. 
However, the intervention of CP provided a better quality of life as indicated by 
higher QALYs. In the long run (acute stage), CP intervention of CI patients was cost-
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effective, since the ICER value was lower than the pre-defined threshold value. In the 
both phases combined, CP intervention of CI patients was cost-effective, whose ICER 
was lower than the pre-defined threshold. In addition, the intervention of CP 
introduced the better quality of life as indicated by higher QALYs. To sum up, the 
impact of CP intervention was observed to be not cost-effective in short term (acute 
stage), but tending to be cost-effective in long term (acute and stable stage combined) 
5.3.3.2. Sensitivity analysis 
One-way sensitivity analysis 
Results of one-way sensitivity analysis (OWSA) for combined case are presented in 
Figure 5-13. The top ten most influential parameters were identified by using OWSA, 















Probabilistic sensitivity analysis (PSA) 
The results of 1,000 PSA simulations were plotted on the CEP (Figure 5-14) and 
a CEAC was generated (Figure 5-15). Detailed distribution of parameters can be 
found in Appendix C5. 
In the comparison with Non-CP, the average incremental costs were ¥10,401.01, 
and the average incremental QALYs were 0.353; this is consistent with the findings of 
the deterministic analysis of incremental costs and QALYs: ¥ 10,419.88 and 0.347, 
respectively. Almost all of the plots are located in the Northeast quadrant with results 
of higher cost and higher effectiveness compared with Non-CP. The proportion of 
simulations which was considered cost-effective at a threshold of ¥46,929 (2014 per 
capita GDP of Shannxi Province) per QALY was 88.90%. 
 
 








Chapter 6  Discussion 
Summary of Chapter 
Translating research evidence into practice remains a persistent challenge because of 
diverse and idiosyncratic application settings. This chapter aims to outline 
interpretations of the analytical results, potential causal factors attributable to research 
findings, implications for future studies and the strengths and limitations of this 
impact evaluation study. The comments outlined in this chapter were generated after 
mapping a review of the literature and proposals by local practitioner and project 
staffs generated by site investigations. In line with the pre-defined study rationales, 
this discussion was seen as an additional way to understand CP effectiveness and 
facilitate scaling up CP intervention in China.  
6.1. Interpretation of research findings 
In term of the data analysis, we employed three major methodologies to examine the 
efficacy and cost-effectiveness of the intervention in a rural Chinese setting. The 
application of DID in support of PSM aims to explore the aggregated effectiveness of 
intervention through comparing subgroups, given balanced patient baseline 
characteristics. The application of ITS aims to explore the change in trend and 
intercept before and after acting on primary outcomes. The application of the Markov 
model aims to examine the cost-effectiveness of interventions covering both the 
hospitalization stage and the post-discharge stage. 
In term of the research findings, DID in support of PSM indicates there is more 
likely a positive net effect attributed to CP intervention using the aggregated mean 
values; ITS results imply that effects of CP intervention on intercept and change in 
trend are limited. The coefficients of most regression models seem statistically 
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insignificant, but the intercept and trend change can be shown in the figures. The 
results of the Markov models in defining disease management show that CP 
intervention is cost effective combining the short and long-term models. The result of 
the short-term model indicates that the CP intervention is not cost-effective using one-
time per capita GDP as a threshold, while the results of the long-term and 
combination models are cost effective. 
Per analytical progress, there are some comments as follows:  
6.1.1. Influence of incomplete data set 
The quantitative study employed data extracted from the pilot hospital information 
system, focusing mainly on expense rather than clinical outcomes. Therefore, given 
the limitation of dataset records, the impact of intervention can only be interpreted by 
expenses data, LOS and utility value. In terms of the PSM analysis, the inclusion of 
covariates in estimation of propensity scores was limited, resulting in reduced 
accuracy in score matching. In term of the Markov models, the structure of the model 
was simplified into three disease management states rather than following the 
trajectory of the clinical outcome of disease progressions. In addition, some of input 
parameters in modeling were supported by literature and expert consultations rather 
than the recorded clinical data taken directly from pilot hospital information system.   
6.1.2. Diluted effect of ITS analysis 
The introduction of CP is a complex intervention affecting the entire population in the 
pilot site. Given the absence of a control hospital, the ITS comparison study used 
patient groups before and after intervention to assess the overall intervention impact.  
Because of the mixture of treated and untreated patients, the effectiveness of CP 
intervention was diluted during the intervention period. Comparisons between 
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subgroups, such as “treatment before” versus “treatment after” and “control before” 
versus “control after,” were conducted to strengthen the exploration of intervention 
effectiveness. Study results of ITS focusing on subgroups as per above will be shared 
upon request.  
6.1.3. Potential alternatives to optimize the ITS regression 
As seen in ITS results, the values of R2 referring to certain primary outcomes were 
relatively low, which means the regression simulation showed limited representation 
of scatter plots. The primary outcomes included total hospitalization expenses, 
medication expenses and diagnostic expenses. According to the illustration of the ITS 
scatter plot, there is a common pattern of change in the three primary outcomes 
mentioned before, after introduction of the CP. Therefore, the introduction of 
additional dummy variables in existing regression models could be used to provide a 
better fitting model, for example, the covariate of disease severity, or the period of 
time since the intervention. 
6.1.4. Markov models covering short-term and long-term 
In treatment of CI, the development of the Markov model should take consideration of 
both the acute stage and the stable stage. Building the Markov model was done with 
assistance from and in consultation with clinical experts. Given the limited variables 
in relation to disease prognosis, the disease states were defined in connection with 
type of medical services and disease progression. This design model is in line with a 
study conducted in the United Kingdom (Hunter et al., 2018). The cycle length of the 
acute model is one day, since the CP prescriptive items were allocated into days and 
the transition probabilities (inpatient to outpatient and inpatient mortality) can be 
accessed based on data collected from the pilot hospital. The time horizon of the acute 
model is 21 days, which is consistent with the maximum LOS required by CP. The 
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cycle length of the stable model is one year, as recommended by clinicians. Most of 
the parameters in the stable model, except inpatient mortality, are derived from 
literature rather than data from the pilot hospital. Considering lifetime disease 
management and Chinese life expectancy, the time horizon of the stable model is 20 
years.  
6.1.5. Implication of quality of life measurement 
Using the EQ-5D-3L as a measurement questionnaire to evaluate patient quality of 
life has been widely accepted around the world and this study introduced it in the 
hospitalization stage to evaluate patient quality of life. Taking advantage of the 
Chinese utility value set, the quality of life measurement in this study is most likely 
representative of the preferences of the Chinese population. Detailed analysis 
focusing on each domain of EQ-5D-3L can be done in the future to accommodate the 
specific effectiveness of CP intervention in regards to mobility, self-care, normal 
activities, pain/discomfort, and anxiety/depression. However, the sensitivity of EQ-
5D-3L to measure patients with certain, specific diseases raises controversy. Given 
the absence of a disease-specific measurement questionnaire for stroke patients in 
China, the generic measurement questionnaire is a practical choice to assist this 
impact evaluation study.  
6.2. Practical causal factors supporting CP intervention 
This section aims to outline the causal factors that come with the process of CP 
implementation, which can also be seen as approaches to ensure implementation 
success at the pilot site and hospital. 
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6.2.1. Motivation of CP intervention 
According to the results of the literature review, we can see that the original 
motivation for the intervention is a key factor resulting of disparate levels of 
effectiveness in different studies. In this study, the CP intervention initiated in the 
pilot hospital, along the progression of healthcare reform nationwide in China, 
provides a solid and feasible macro environment for CP implementation. In a 
centralized country as China, political will is an important precondition and powerful 
motivator. Taking advantage of ongoing national healthcare reform, the intervention 
got good coordination from local healthcare authorities in the pilot county. This not 
only allowed local authorities to meet political requirements in local healthcare 
reform, but also allowed them to use CP intervention to clean-up and standardize 
behavior of local healthcare practitioners, for example, profit-seeking over-
prescription of medications. Thus, CP was recognized as a useful tool for 
standardization of practice, which was particularly needed in rural hospitals in China. 
6.2.2. Rising awareness of evidence-based medicine (EBM) 
Over-prescription and under-prescription caused by physician behavior has been 
criticized as the biggest driver of unreasonable and fast-growing healthcare 
expenditures. But because of the asymmetric levels of information on the demand and 
supply sides of healthcare services, this difficulty was hard to understand for a long 
time in China. With the progression of healthcare reforms, awareness of EBM has 
strengthened and achieved a broad level of support among various stakeholders. In 
dealing with the fast-growing of local health expenditures, the medical insurance 
agency can control unreasonable expenditures using CP as a standardized guide and 
quality control indicator. Given the distrustful relationship between patients and 
physicians in rural hospitals in China, the clinical practitioners in county hospitals can 
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offer better healthcare services, improve clinical capacities in a way that patients will 
understand and respect. This also can reduce strong patient concerns about their 
hospital bills. In short, evidence-based CP can be seen a standard tool to balance the 
interests of various stakeholders. 
6.2.3. Flexibility of CP content 
In some literatures, the CP was sarcastically referred to by clinical practitioners as a 
“cooking menu” because of the conflict between CP-required standardized treatments 
and the complexity and peculiarities of the needs of individual patients. CP should be 
tailored in consideration of the treatment setting and practitioner capacity. In this 
study, using current clinical practices in the pilot hospital as the basis for CP content 
development, a consensus was reached using amendments to existing practices 
following comments from top national stroke experts. Therefore, CP was developed 
by both senior neurology physicians from tertiary hospitals and the clinical 
practitioners from the pilot county hospital. The bilateral engagement likely ensures 
the feasibility of CP mapping within the local hospital setting that doesn’t vary far 
from treatment principles defined by national stroke experts. The feasibility and 
flexibility of CP content is important in achieving local clinical practitioner support, 
which in turn ensures their willingness to use CP. Frankly, the evolution progress of 
behavior change of clinicians was not easy. Initially, physicians would include 
“optional” factors consistent with previous practice, but this gradually died out. 
Gradually, CP became a useful tool for standardization of practice – something that 
was particularly needed in rural reginal county-level hospitals.  In order to ensure the 
basic quality of service and improve physician adherence to CP, the detailed 
prescribed items were defined into mandatory and optional ones, according to their 
importance and specific needs of individual patients. In addition, in order to increase 
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the feasibility and inclusion rate of the CP, common complications and comorbidities 
were included. The sub-pathways do not intend to cure complications and morbidities, 
but accommodate and stabilize them within the treatment of CI. The finalization of 
proposed items was reviewed iteratively by local physicians and senior clinical 
consultants together based on their views of EBM and the practical capacities of local 
physicians. In addition, as a dynamic intervention, the CP has been optimized 
continuously to match the changing of local setting (for example, improved capacity 
of local physicians, or greater oversight on prescriptions) and interaction with other 
confounding factors, such as implementation of essential drug policies, etc. The 
ultimate goal of these efforts was to obtain physician recognitions and increase the 
flexibility of CP.  
6.2.4. Supportive information system 
CP management modules embedded into hospital information systems can improve 
working efficiency and change prescription behavior. In an environment in which all 
patient-oriented data can be tracked down, the information systems can also record 
prescription activities in a timely manner and facilitate the monitoring, evaluation and 
auditing of same. This can help support healthcare decision-making and the formation 
of a clinical, decision-supporting system based on the amount and quality of available 
data. It can bridge the gap between knowledge and practice and ensure that the right 
treatment can be offered to patients.     
6.2.5. Capacity building for CP practitioners 
Capacity building is a crucial factor, a precondition even, to ensure the success of 
project implementation in pilot hospitals. This intervention involved various types of 
medical staffs in the hospital who were not quite familiar with the content of CP, their 
role in a multi-disciplinary team (MDT), or with the working mechanisms at the 
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beginning of the intervention. Round after round of training workshops were offered 
with the aim of helping them understand the concept of evidence-based disease 
management, intervention objectives, rationales for prescriptive items and 
demonstration of practical skills in operating the information system. The workshops 
were delivered by project experts and local trainers involved in the design and 
development of earlier projects. Peer experience is highly effective in motivating, 
educating and influencing the understanding of those just learning CP. 
6.2.6. Incentive mechanism 
In order to motivate involvement by physicians and other medical staffs, hospital 
management introduced a series of supportive management measures to accommodate 
the implementation of CP. These included integrating medical staffs’ salaries with the 
volume of patients managed by CP, setting bonus payments for outstanding 
physicians and nurses in CP, and implementing regulations on internal supervision 
and accountability. The incentive mechanism delivered a clear signal from hospital 
management and brings about positive reinforcement for practitioners who were 
coping with the changeover from the prescription-based system. Standardized clinical 
behaviors replaced unconscionable profits gained from inappropriate behavior. 
6.2.7. Identification of confounding factors alongside the intervention 
After introduction of CP intervention, changing patterns were observed in scatter plots 
of total hospitalization expenses, medication expenses and diagnostic expenses. There 
is an abrupt expense increase in the first five months after introducing CP to a pilot 
hospital, then a decreasing expenditure trend which reaches lowest rate one year after 
implementation. An increase in expenditures is observed again in the second year 
after intervention. Based on the consultation with local policy makers and 
practitioners, the following reasons were identified: 1) Reasonable and necessary 
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prescriptive services, not previously provided, had been included into the CP service 
package. This induced the abrupt increase in corresponding expenses shortly after 
introducing CP intervention. 2) A common prescribed and expensive drug, 
Edaravone, was delisted from the local medical insurance reimbursement scheme 
because of negative clinical evidence. This change caused a significant decrease in 
medication and total hospitalization expenses. Meanwhile, as the process of 
healthcare reform moves along, the awareness of EBM has been heavily strengthened 
and it’s become mandatory for local health authorities. 3) Within one year of 
introducing of CP intervention, CP was optimized dynamically and more evidence-
based prescriptive services and drugs were incorporated into the CP service package. 
Then an increasing trend was observed afterwards.  
6.3. Implications for future studies 
Based on the study findings and experiences gained from CP implementation at the 
pilot hospital, some academic and practical comments can be summarized to aid 
future studies and facilitate the dissemination of the study within the country and 
between China and other countries. 
6.3.1. Payment reform 
The CP intervention in this study did not integrate with payment reform. When we 
have seen payment reform in other parts of China, it has been a powerful tool to 
mitigate inappropriate behavior. Based on the lessons learned from other counties in 
China, it can be noted that there were spillover effects from the intervention to the 
control group due to the payment reform and evidence-based CP approach. Because 
the out-of-pocket payment of patients was reduced in taking celling case payment 
approach, but health status of CP patients improved significantly,, the CP 
management approach integrated with case payment is becoming more popular in 
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such areas (CNHDRC, 2015). If future studies can incorporate both payment reform 
and CP intervention, the general effectiveness of CP will be strengthened, for 
example, with stroke, replacing a fee-for-service scheme with a case payment scheme. 
With payment reform as part of the general scope of healthcare reform, local medical 
insurance agencies and healthcare providers can negotiate to set standards for case 
payment based on the actual cost of CP content. And the yearly adjustment 
mechanism can be set up to factor in inflation and clinical setting changes to form a 
dynamic and sustainable approach. To be sure, the case-based payment method 
should couple with quality indicators to control for quality of health outcomes. 
Ideally, the common comorbidities can also be considered for inclusion in the 
payment scheme. In addition, the case-based global budget is an alternative option for 
payment reform, in which a total annual budget is set to reach the aim of cost 
containment beyond cost controls for each, individual case.    
6.3.2. Use of billing data 
Billing data is the detailed, day-to-day record of expenses for all prescriptive items 
and resource consumed. In this study, only the general information presented by 
medical records was available, and not the billing data of prescribing behaviors by 
physicians and the services received by hospitalized patients, Taking advantage of 
billing data will allow later studies to observe prescription and service pattern 
changes. Such analysis can describe CP effectiveness in more detail and identify 
specific targets for CP optimization.   
6.3.3. Key quality control indicators 
Beyond the incentive measurements adopted in this study of CP intervention, key 
quality indicators should be created to monitor clinical practice performance. The 
original concept of CP development is to standardize clinical behavior. Following up 
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with a quality control indicator is a powerful way to monitor adherence to CP clinical 
practices and to correct unreasonable behaviors in a timely fashion. In addition, 
quality control indicators can be connected with medical insurance payouts to 
promote appropriate services for patients.  
6.3.4. The integrated care pathway beyond acute stage treatment 
The CP in this study focuses on the treatment protocol offered in the hospitalization 
stage. For stroke as a chronic disease, the CP concept can be extended into integrated 
care pathways covering prevention and rehabilitation. The adoption of integrated care 
pathways can be supported by township health centers and village clinics affiliated 
with the pilot county hospital. This provides an alternative option for improving the 
tiered medical services system in the current rural health setting, as proposed by 
national health authorities towards the lifelong management on chronic disease.  
6.3.5. Initiate CP management of surgical disease 
In the initiation stages of the introduction of CP management in county hospitals, the 
local practitioners can start with surgical procedures, such as acute simple 
appendicitis, elective surgery for benign gallbladder lesions, oblique inguinal hernia, 
and caesarean section. These kinds of conditions are diagnostically straightforward, 
rarely have comorbidities and have standardized treatments. CI is a complex disease 
with high possibility of comorbidities and variations in disease prognosis. With 
patient safety as the priority, patients were removed from CP management when very 
individual treatment needs arose. Initiating CP management on simpler surgeries can 
help practitioners get experience before heading to CP management of more difficult 
chronic diseases.  
If complex diseases are chosen for CP management techniques, a balance must 
be struck between treatment principles and personalized issues. 
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6.3.6. Methodology recommendation 
This study adopted three methodological approaches in this evaluation study: (1) DID 
in support of PSM, (2) ITS and (3) the Markov model. Choosing the right 
methodology depends on the data available in the project setting; there is no one 
method that is always right. If cost data and more clinical data is available, such as for 
stages and the severity of the disease, and on transitions in health status, the 
development of the Markov model seem more practical to simulate the trajectory of 
disease progress. (And estimation of propensity scores is more accurate in subsequent 
analysis.) If longitudinal data is available, the ITS analysis is recommended, given the 
removal of outlying data. If the control arm available, DID analysis is a 
straightforward and feasible approach for examining the effectiveness of intervention.  
6.4. Strength of study 
There are three strengths in terms of the study design and implications of the study 
results. One is the application of the PSM approach, the second is the introduction of 
the Markov model to explore the cost-effectiveness of CP intervention, and the third 
is the conclusion that the study created solid evidence to support healthcare decision-
making in future iterations.  
6.4.1. Application of PSM approach 
The application of PSM aims to balance the variation of exposed, baseline factors 
towards improving the comparability between the treatment and control arms. Using 
the method of nearest neighbor matching, the age, gender, type of comorbidities, 
rather than number. of comorbidities, were matched on patients in the intervention 
and control arms. After the PSM, all the outlined indicators were not statistically 
different (using a P value of 0.05). The cost of matching is a reduction in sample size, 
but the refined, new sample increases the accuracy and reliability of research findings. 
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In the setting of real world and retrospective data, given the impossibility of RCT 
design, the PSM is a feasible and practical alternative solution in a quasi-experimental 
study. In the literature, the baseline data was not processed using the PSM normally 
used in observational studies. Thus, the conclusion of some similar studies outlines 
the significant difference in demographic baseline as a study limitation.  
6.4.2. Building the Markov model 
In the literature, there are fewer papers which focus on the cost-effectiveness of CP 
intervention. In this study, a group of complete Markov models was built to examine 
the cost-effectiveness of intervention impacts based on the practical treatment process 
within the Chinese rural healthcare system. In addition, most of the data input in the 
Markov model was collected from the pilot hospital so that reliable results could be 
obtained to benefit of local and national healthcare policy makers. The result of the 
Markov model provides visual and easily understood results to deliver to policy 
makers.  Thus, the Markov model analysis was not only to address knowledge gaps in 
the literature regarding the effectiveness and cost-effectiveness of CP intervention for 
CI, but also to demonstrate the real-world impact of CP intervention in rural China 
and identify contextually appropriate solutions towards enabling continuous 
improvement.  
6.4.3. Identification of causal factors attributed to CP intervention 
The causal factors attributed to observed effects can be identified and explained better 
in a practical setting. In fact, the identification and understanding of causal factors is 
more important than observed results. In this discussion, the causal factors attributed 
to CP intervention included application setting, a supportive hospital information 
system, capacity building and incentive mechanisms. The identification of these 
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factors can facilitate the amending and improvement of CP intervention, aid CP 
dissemination on a larger scale and inform policy-making with evidence.  
6.5. Limitations of study 
6.5.1. Potential selection bias in patient grouping 
In terms of grouping of patients before intervention, the local physicians, relying on 
the inclusion criteria defined by CP, reviewed patient health records to group patients 
before interventions into two subgroups, “before treatment” and “before control.” 
This sorting can facilitate DID analysis in the usual way, but it also introduces the 
possibility of subjectivity. In medical record reviews, the physician focuses on the 
treatment received by patients, but not patient baseline characteristics. The utilization 
of PSM can improve the accuracy and reliability of DID analytical results, as the 
baseline characteristics of patient data were balanced. But when applying the PSM in 
DID analyses, there is a concern about the sacrifice of sample size in the process of 
matching.  
6.5.2. Absence of control subject 
Another limitation in the analysis here is the lack of a control hospital. In ITS theory, 
a control subject better detect highlights the effectiveness of an intervention. In 
reality, all the Chinese hospitals, whether county- or upper-level, are experiencing 
different types of healthcare reform actions, e.g., payment reform, pricing reform, 
fiscal input reform and human resources reform. In this analysis, the neighboring pilot 
hospital in Hanbin county did not meet the requirements of a control subject, since 
their ongoing reform trials introduce confounding factors. This is why this study 




In addition, data on individual patients’ previous experience of CI would be 






Chapter 7  Conclusions 
A consistent conclusion in term of the impact of CP on health outcomes is difficult to 
generate using only a review of literature. But based on the impact evaluation of CI 
CP intervention in this study, the effectiveness of CP intervention in supporting of 
pre-defined primary outcomes in the pilot hospital is positive in comparison with the 
control group in the observation period. In terms of cost effectiveness, the CP 
intervention is not cost effective in the short run compared to non-CP practices. But in 
the long run, the CP intervention is a cost-effective intervention. Generally, the ICER 
of the combined Markov model is 30,071.79 YUAN/QALY, which is cost-effective 
under the threshold of one times local per capita GDP (46,929 YUAN).  
In conclusion, the CP intervention is a practical solution to bring changes in 
standardized prescription behavior and contain unreasonable hospitalization expenses 
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A1: General principles of clinical pathway 
 
脑梗死临床路径 
Clinical pathway of cerebral infarction 
一、脑梗死临床路径标准住院流程 








Diagnosis should be made on the basis of the China guideline for Neurologic 
Diseases (Compiled by the Chinese Medical Association and published by the 
People’s Medical Publishing House) 
1.临床表现:急性起病，出现局灶症状和体征，伴或不伴意识障碍。 
i. Clinical manifestations: acute onset, focal neurologic signs or symptoms 
along with headache and/or dysfunction of consciousness; 
2.头颅 CT 证实颅内无出血改变。 
ii. No hemorrhage confirmed with brain scan. 
（三）选择治疗方案。 
(3) Treatment options and basis 
1.整体治疗: 
i. General treatment:  
（1）卧床休息，维持生命体征和内环境稳定，预防感染等并发症； 
a) Bed rest, stabilize vital signs and clinical status, prevent and treat infection 
（2）维持呼吸道通畅，鼻导管吸氧； 




c) Patients who can not be fed orally should have nasal feeding to maintain the 
nutrition, aspiration pneumonia should be avoided. 
（4）控制血压； 
d) Control blood pressure 
（5）降低颅内压。存在颅内压升高的征象时，采取降颅压措施，药物可选
用 20%甘露醇，严重时可考虑去骨瓣减压； 
e) Decreasing intracranial pressure: when patients manifest increased 
intracranial pressure, lowering the pressure is recommended, and 20% 
mannitol is the optional medicine. If patients have severe conditions, 
decompressive craniectomy is recommended. 
（6）控制体温在正常水平，38℃以上应给予物理和药物降温； 
f) Maintain the temperature at the normal level, physical and drug cooling is 
recommended if patients’ temperature is above 38℃. 
（7）防治应激性溃疡； 
g) Prevent and treat stress ulcer 
（8）早期康复治疗。 
h) Early rehabilitation care 
2.特殊治疗： 
ii. Special treatments: 
（1）溶栓治疗（发病 3-6 小时之内）； 
a) Thrombolytic therapy (within 3-6 hours after the onset) 
（2）抗凝治疗； 
b) Anticoagulation therapy 
（3）抗血小板治疗； 
c) Antiplatelet therapy 
（4）降纤治疗； 
d) Defibrate therapy 
（5）神经保护治疗； 
e) Neuroprotective therapy 
（6）中药治疗。 
f) Traditional Chinese Medicine (TCM) treatment 
（四）临床路径标准住院日为 8-21 天。 
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(4) Standard length of stay: 8-21 days. 
（五）进入路径标准。 
(5) Criteria for CP management 
1.第一诊断必须符合 ICD-10:I63 脑梗死疾病编码。 
i. Primary diagnosis must be cerebral infarction (ICD10: I63); 
2.当患者同时具有其他疾病诊断，但在住院期间不需要特殊处理也不影响
第一诊断的临床路径流程实施时，可以进入路径。 
ii. Those patients with secondary diagnosis can be covered by the current CP if 
they do not need special treatment for their secondary diagnosis and if the 
secondary diagnosis does not have any impact on the implementation of 




i. Essential tests: 
( 1 )血常规、尿常规; 
a) Blood and urinalysis 
( 2 )肝肾功能、电解质、血糖、凝血功能； 
b) Liver and renal function, electrolytes, blood glucose, coagulation function 
( 3 )头颅 CT、胸片、心电图。 
c) Brain and skull CT, chest X-ray, ECG 
2.根据具体情况可选择的检查项目：心肌酶谱、血脂、双颈动脉加双椎动
脉彩超、TCD、头颅 MRI。 
d) Optional tests according to patients’ conditions: cardiac enzymes, lipids, 





i. Diuretics: mannitol, furosemide .etc; 
2.降压药物：收缩压大于 180mmHg 或舒张压大于 110mmHg 时，可选用卡
托普利、依那普利、尼群地平、硝苯地平等 
ii. Anti-hypertensives: If patients’ SBP is above 180mmHg or DBP is above 
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110mmHg, medicines such as captopril, enalapril, nitrendipine, and 




iii. Antibiotics referred to the Guidelines for Clinical Application of 
Antibacterial (Department of Medical Administration (2004) NO.285). 
Patients without infection do not need to use antibiotics, while patients 
confirmed to be infected should take antibiotics on the basis of bacterial 
drug sensitivity. 
4.溶栓治疗：尿激酶等。 
iv. Thrombolytic therapy: urokinase 
5.抗凝治疗：低分子肝素、肝素等。 
v. Anticoagulation therapy: Low molecular weight heparin (LMWH), heparin 
6.抗血小板治疗：可选用阿司匹林、氯吡格雷等。 




viii. Prevent and treat stress ulcer: ranitidine, famotidine 
9.纠正水、电解质紊乱药物。 
ix. Medicines for fluid and electrolyte imbalance 
10.中药治疗。 
x. TCM treatment 
（八）监测神经功能和生命体征。 
(8) Monitoring neurological function and vital signs (VS). 
1.生命体征监测。 
i. Monitoring VS 
2.监测神经系统定位体征。 
ii. Monitoring focal neurological signs 
（九）出院标准。 




i. Patient is in stable condition 
2.没有需要住院治疗的并发症。 
ii. There are no complications that require further inpatient care 
（十）变异及原因分析。 
(10) Special considerations 
1.脑梗死病情危重者需转入 lCU，转入相应路径。 
i. Cerebral infarction patients in a critical condition should be transferred to 
ICU and managed by correspondent CP; 
2.辅助检查结果异常，需要复查，导致住院时间延长和住院费用增加。 
ii. For abnormal diagnostic test results, reexamination is required and the 
cause of the abnormality needs to be analyzed, esp. those concerning 
prolonged length of stay and increased hospitalization costs. 
3.住院期间病情加重，出现并发症，需要进一步诊治，导致住院时间延长
和住院费用增加。 
iii. Worsening condition, with complications that require for further diagnosis 




iv. Cerebral infarction may cause worsening conditions of previous 
comorbidities, which requires more care and may result in prolonged 




A2: Detailed prescribed items 
脑梗死疾病临床路径表单 Cerebral infarction    Clinical pathway 
疾病编码：ICD-10：I63 Code of disease：ICD-10：I63 
最短住院天数：8 天最长住院天数：21 天 平均住院天数：12 天    Shortest hospital stay：8 days    Longest hospital stay：21 days  





































              
评估基本生命体征
Initial assessment 
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医患沟通，交待病
情 Communicating 
with patients about 
their conditions 
              












          
  




          
  
或二级护理 or 








Low-fat and low-salt 








































做 1 次） catheter 
(optional in the first 
day and only once 
during hospital 
stay ） 
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(二)检查（2）tests 血常规 Blood 
临时医嘱
SOS 
          
  尿常规 Urine 
临时医嘱
SOS 
          
  大便常规 Stool 
临时医嘱
SOS 












          
  电解质 Electrolyte 
临时医嘱
SOS 
          
  血糖 Blood glucose  
临时医嘱
SOS 
          
  血脂 Blood lipid 
临时医嘱
SOS 
          
  
心肌酶谱
Myocardial enzymes  
临时医嘱
SOS 






























hepatitis B or C） 
临时医嘱
SOS 
          
  胸片 chest X-ray 
临时医嘱
SOS 
          
  心电图 ECG 
临时医嘱
SOS 
          
  
头颅 CT （可选）
Skull CT (optional) 
临时医嘱
SOS 
      
加复查不超
过 3 次 less 












      
加复查不超
过 3 次 less 










      
加复查不超
过 3 次 less 










      
加复查不超
过 3 次 less 

















          




                


























only once in the first 
day during the stay) 
            
  1.尿激酶 urokinase   






























alternative or both) 





















75mg 75mg 口服 oral qd   



















































Drugs for improving 
cerebral perfusion 
(optional, use 1 type 
out follow 3 one) 











qd   
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  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  










qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  











qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  
  250ml 250ml       





            
  
1.5%葡萄糖液 5% 














































































qd   
                
(五)其他               








Health education on 
admission 




              
患者检查指导
Instruct patients on 
tests 
              
住院基础护理 
Basic nursing care 
on admission 
              
脑血管病的健康宣
教，戒烟宣教
Advise on smoking 




              
饮食指导
Instruction on diets 









搏 Measuring blood 
pressure,temperatur
e and pulse 
              































录 Ward round by 
chief physician  
and keep record 
senior doctors  

















              
开始康复治疗               
需手术者转神经外





              
记录会诊意见
Keeping record of 
consultation 
              














          
  

















Low-fat and low-salt 








































          











          
  
复查头 CT 或 MRI
（必要时）
reexamine skull CT 




      
加复查不超
过 3 次 less 































alternative or both) 























75mg 75mg 口服 oral qd   













20mg 20mg 口服 oral qd   





































Drugs for improving 
cerebral perfusion 
(optional, use 1 type 
out follow 3 one) 











qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  










qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  













qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  
  250ml 250ml       





            
  
1.5%葡萄糖液 5% 














































































qd   
                
(五)其他(5) Others               







              
基础护理 Basic 
nursing care 
              
脑血管病的健康宣
教，戒烟宣教
Advise on smoking 




              
饮食指导               
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round by chief 
physician  
and keep record 
senior doctors  














prevent and treat 
complication 





              
开始康复治疗               
需手术者转神经外





              












          
  




          
  
或二级护理 or 










Low-fat and low-salt 








































          
                
    
临时医嘱
SOS 









          


























alternative or both) 





































20mg 20mg 口服 oral qd   





































Drugs for improving 
cerebral perfusion 
(optional, use 1 type 
out follow 3 one) 











qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  










qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  











qd   
  生理盐水 0.9% NS   250mg 250mg       
  或 5%葡萄糖 5%   250ml 250ml       
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Glucose liquid  





            
  
1.5%葡萄糖液 5% 






























































                













qd   
                








              
基础护理 Basic 
nursing care 
              
脑血管病的健康宣
教，戒烟宣教
Advise on smoking 




              
饮食指导
Instruction on diets 





              
































Ward round by 
physicians 
























康复治疗               
                
通知患者及其家属
出院 Inform 
patients and his/her 
relatives of the 
discharge day 




patients on do's and 
don’ts upon 














reasons if patients 
can not be 
discharged 











          
  




          
  
或二级护理 or 








Low-fat and low-salt 





























          






      
加复查不超
过 3 次 less 










      
加复查不超
过 3 次 less 











      
加复查不超
过 3 次 less 
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(三)处置与手术               






alternative or both) 





















75mg 75mg 口服 oral qd   













20mg 20mg 口服 oral qd   





































Drugs for improving 
cerebral perfusion 
(optional, use 1 type 
out follow 3 one) 











qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  












qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  











qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  
  250ml 250ml       





            
  
1.5%葡萄糖液 5% 














































































qd   
                



















































Educate patients on 
do's and don’ts, 
treatments and 
family health care 
after discharge 





              
                














          
  




          
  
或三级护理 or 




          
  
低盐低脂饮食或流
质饮食 Low-fat and 




          
  今日出院 Discharge              












skull CT or MRI 
临时医嘱
SOS 
      
加复查不超
过 3 次 less 











              






alternative or both) 





















75mg 75mg 口服 oral qd   



















































Drugs for improving 
cerebral perfusion 
(optional, use 1 type 
out follow 3 one) 











qd   
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  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  










qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  











qd   
  生理盐水 0.9% NS   250mg 250mg       
  
或 5%葡萄糖 5% 
Glucose liquid  
  250ml 250ml       





            
  
1.5%葡萄糖液 5% 














































































qd   
                














special nursing care 
              
告知复诊时间和地
点 Tell patients 
time and place of 
reexamination 






              
嘱其定期门诊复诊
Inform patients 
about  regular 
follow-up visit 
              





B1: Search strategy 
a. Medline—Ovid—1288 papers 






critical path*.mp.  
care map*.mp. 
care plan*.mp. 





interdisciplinary OR Integrated) 
AND care*).mp.  
managed care.mp. 
(integrated AND system*).mp.  

































patient care planning/ 
critical pathways/  
case management/  
managed care programs/ 
delivery of Health Care, 
Integrated/ 
patient care management/ 
















b. Medline—Pubmed—15 papers 






care pathway*.tw.  
critical path*.tw.  
care map*.tw. 
care plan*.tw. 



























critical pathway [Mesh] 
patient care planning [Mesh] 
(inclusive of case 





















controlled clinical trials as 
topic[Mesh] 
clinical trials*[Mesh] 
Intention to Treat 
Analysis[Mesh] 
random allocation[Mesh] 
c. Cochrane Library—236 papers 
Concepts Clinical Pathways Acute Cerebral Infarction RCT 
Author 
Keywords: 
(Clinical pathway* or Care 
pathway* or Critical 
pathway* or Care path 
method or Care map$ or 
care plan$) :ti,ab,kw 




























MeSH descriptor: [Cerebral 
Infarction] explode all trees 
MeSH descriptor: [Brain 
Ischemia] explode all trees 
MeSH descriptor: [Cerebral 
Hemorrhage] explode all trees 
MeSH descriptor: [Cerebral 
Infarction] explode all trees 
MeSH descriptor: 
[Randomized Controlled 
Trial] explode all trees 
MeSH descriptor: 
[Randomized Controlled 
Trials as Topic] explode all 
trees 
d. EMBASE—OVID—339 papers 






critical path*.mp.  
care map*.mp. 
care plan*.mp. 





interdisciplinary OR Integrated) 
AND care*).mp.  
managed care.mp. 
(integrated AND system*).mp.  

















(double blind or double 
masked).mp.  
 









nursing care plan/ 
clinical pathway/  
exp cerebrovascular 
accident/  
exp brain hemorrhage/  
exp brain infarction/  





double blind procedure/ 
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terms single blind procedure/ 
 
CINAHL—6 papers 
Concepts Clinical Pathways Acute Cerebral Infarction RCT 
Author 
Keywords: 
(Clinical pathway* or Care 
pathway* or Critical pathway* or 
Care path method or Care map$ or 
care plan$).  






























PubMed: Cost-effectiveness search strategy 
Search Query Results 
1 "Stroke"[Mesh] 122097 
2 
("Critical Pathways"[Mesh]) AND ("Cost-Benefit 
Analysis"[Mesh]) 
217 




B2: Summary of study characteristics 
Author,  
Country& Year 
Method Duration Sample size Intervention Controls Outcomes Conclusion/Discussion 















Overall processes of care (PoC) 
adherence rates was 75% in 
SU,65% in MS,52% in CC. The 
adjusted odds of participants 
being alive at discharge (aOR 
3.63; 95% CI: 1.04 to 
12.66;p=0.043). 28 weeks after 
stroke, trends at home (aOR 
3.09; 95% CI: 0.96 to 
9.87;p=0.058) and independent 
(aOR 2.61; 95% CI: 0.96 to 
7.10;p=0.061). 
 
1)Better adherence to key 
PoC in SUs 2)better 
adherence was associated 
with improved mortality at 
discharge and insignificant 
trends found with 















training) for the 








to 25.4), P=0.002], functional 
dependency (Barthel 
index≥95:95%CI(-0.5 to 
19.5),p=0.07  Barthel 
index≥60:95%CI(-3.6to 
8.6),p=0.44), and SF-36 (PCS 
score:95%CI(1.2 to 5.5), 
P=0.002; MSCscore:95%CI(-1.9 
to 2.8), P=0.69). Fever: 
95%CI(8.3% to 24.6%), 
P<0.0001, Glucose: 95%CI(0.08 
to 1.01), P=0.02, Swallowing 
screening:95%CI(22% to 
36.4%), P<0.0001, Length 
ofhospital stay: 95%CI(-0.5 to 
3.5), P<0.144. 
Adoption of protocals favor 








6 months 2547 Emergency Clinical 
Pathways (ECP) 




(ER),with adoption of 




training in line with 
the experiential 
learning tradition   
conventional 
EMS and ER 
treatment 
1) Eligible patients referred to 
SU: ITT analysis: aRR=2.01, 
95% CI(0.79, 4.00);PP analysis: 
aRR 3.21, 95% CI (1.62, 4.98). 
2) Eligible stroke patients 
receiving thrombolysis in SU 
tested by Fisher's exact tests: 
ITT analysis P=0.02, PP 
analysis: P=0.001.  3) The EMS 
treatment/travel mean time 
(SD) from dispatch to hospital 
(minutes) in metropolitan area: 
Intervention group :31.8 (15.1); 
control group: 35.8 (13.8). 4) 
The ER transferred mean time 
(SD) in metropolitan area: 
Intervention group: 193 (176); 
control group 228 (216).    







8 months TIA:426;ICH:332 Fine tune 
recommended 
protocols for TIA and 




1) TIA: length of hospital 
stay(p<0.01), hospitalization 
cost (p=0.02), drug cost 
(p=0.04), Incidence of stroke 
within 90 days (p=0.16) 2) ICH: 
length of hospital stay(p<0.01), 
hospitalization cost (p<0.01), 
drug cost (p<0.01), 
mortality(p=0.72), infection 
(p=0.07)3) The NIHSS between 
groups  at admission (p=0.48); 
14 days after admission 
(p=0.10). 4) The Barthel Index  
between groups  at admission 
(p=0.60); after 90 days (p=0.12).  
1) Both TIA and ICH clinical 
pathways decreased the 
length of hospital stay and 
overall healthcare costs. 2) 
no sacrifice of treatment 
quality was observed.  
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training) for the 







1)more patients admitted to 
hospitals allocated to the 
intervention group received care 
according to the fever 
(95%CI(7.9 to 22%), P < 0.001), 
hyperglycemia ( 95%CI(0.8 to 
6.3%),P = 0.01), and swallowing 
dysfunction protocols 
(95%CI(5.5 to 21%), P ≤ 
0.001).2)Significantly more 
patients in intervention stroke 
units received four-hourly 
temperature monitoring (37% 
vs. 19%, P < 0.001) and six-
hourly glucose monitoring 
(32% vs. 9.5%, P < 0.001) within 
72 hours of admission to a stroke 
unit, and a swallowing screen 
(46% vs.6.8%, P ≤ 0.0001) 
within the first 24 hours of 
admission to hospital.3) No 
difference between the groups in 
the treatment of patients with 
fever with paracetamol (21% 
vs.29%, P = 0.78) or their 
hyperglycemia with insulin (40% 
vs.30%, P = 0.49). 
1)significantly more patients 
were managed, 
demonstrating a clear 
positive influence of  
intervention on behavior 
change. 2)There was no 
difference between the 
groups in the treatment of 
fever and hyperglycemia, 
which was unable to explain 
definitively the large 
improvements in death and 
dependency found in the 
main trial results. 
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249 acute stroke unit care 
integrated with 
geriatric wards in 
term of treatment 
principles, training 
and work procedures 
conventional 
treatment in acute 
stroke unit  
1) No significant difference in 
mortality rates after 1 year by 
discharge  [80% vs 72%, 95 CI (-
4%-18%)]. 2) No significant 
difference in proportion of 
patients at home after 3 weeks 
[46% vs 44%, 95 CI (-11%-
16%)], 3 months  [68% vs 61%, 
95 CI (-7%-19%)]and 12 months  
[61% vs 59%, 95 CI (-11%-
15%)].3) No significant 
differences between the groups 
in the neurological score or in 
the ADL scores, and in mean 
total Nottingham Health 
Profile scores. 4)  In patients 
with concomitant cardiac 
disease, there was a reduction in 
death or institutional care after 
3 months (28% versus 49%, 
95% CI -40% to -3%).  4)The 
mean length of stay after the 
index hospitalization was 28.3 
(median 15) days in the acute 
stoke units integrated with a care 
continuum and 35.8 (median 10) 
days in the general ward group 
(P=NS).  
Limited short-term benificial 
effect was found, no 
significant difference on the 
healthoutcome after 1 year. 
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2 years 476 a trained 
multidisciplinary 
team  developed 
practical CPs and 
reviewd by regional 
EBM (evidence-based 
medicine) unit 
usual care  1) lower risk of mortality at 7 
days(OR = 0.10; 95% CI[0.01 to 
0.95],p=0.04).No significant 
differences in mortality at 30 
days(OR = 0.30; 95% CI [0.06 
to 1.39], p=0.12) .2) Lower rate 
of not returning to pre-stroke 
function (OR = 0.42; 95% CI 
[0.18 to 0.98],p=0.04). 3) less 
but non-significant length of 
staymean(SD): intervention 
(11.78±6.6) v.s.control 
(10.88±7.9, p=0.19). 4) Plenty of 
process of care performed better 
in CP arm.  
CPs can significantly 
improve the outcomes of 
patients with ischemic 
patients with stroke 
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team care (MTD) 
1) No differences in mortality 
rates (13% vs 8%, OR=0.6, 
95%CI[0.3;2.3]), 
institutionalization (13% vs 
21%, OR=01.5, 95%CI[0.5;2.8]), 
or length of hospital stay 
(50±19 vs 45±23 days) between 
two groups. 2) median change 
in BI score between 4 and 12 
weeks improved sigificantlt in 
control group  6 versus 2; 
P<0.01. 3) control group had 
higher Quality of Life scores at 
26 weeks: 72 versus 63; 
P<0.005.4) There were no 
significant differences in the 
mean duration of 
physiotherapy (42.8±41.2 
versus 39.4±36.4 hours) or 
occupational therapy (8.5±7.5 
versus 8.0±7.5 hours) received 
between the 2 groups. 
ICP management offered no 









2 years 198 interdisciplinary 
stroke team focusing 
on personal 
continuous discharge 
planning in order to 
reduce functional loss 
after discharge 
standard aftercare 1) No significant difference in 
terms of length of hospital 
admission (35.2 versus 39.8 
days, 95%CI[-12.4 days; 3.1 
days]). 2) No 
signficantdifferneces in 
readmission,GP-visits, and 
primary health care services 
and in functional scores or 
patient satisfaction. 3) No 
significant differences were 
found as regardsBI, Mini mental 
state examination, SF-36. 
Interdisciplinary stroke team 







B3: Detailed statement for the assessment of risk of bias 




Incomplete outcome data Selective 
outcome 
reporting 
Other potential threats to validity 
Dominique A et 
al,2004,Australia 
High risk of Bias: 
Cohort design, 
allocation by 
availability of the 
intervention 
Uncertainty: the method of 
concealment is not described. 
Low risk of Bias: 
researchers collecting 
follow-up data were 
blinded to the model of 
care.  
Low risk of Bias:1) Although only 
15 of the 21 PoCs were used in the 
analysis, the selection criteria 
included consideration of reliability, 
robustness and importance regarding 
outcome.2) The outcome data were 
available on 96% of selected 
patients.  
High risk of bias: 
no detailed 
reporting on the 
selected PoCs 
High risk of bias: 1)potential for 
contamination and crossovers 
among groups;2) The thorough and 
complete care rates may have been 
overestimated. 
 Middleton S. et 
al,2011,Australia 




stratified by category;  
Low risk of Bias: Stratifcation with 
allocation concealed until provided 
to the project officer who assigned 
ASUs to groups.  
Low risk of 
bias:1)Research 
assistants were masked 
to trial design enrolled 
patients, trial aims, 
design and group 
allocation. The 
statistician was masked 
to group allocation.  2) 
Single blind: clinician 
delivering the 
intervention were not 
blinded.  
Low risk of bias: 1)The patients with 
severe strokes might be 
underestimated, but the subgroup 
analyses has showed significant 
outcomes accordingly. 2) 48 out of 
735 patients were lost to follow-up.  
Low risk of bias: 





Low risk of bias:the study appears 
to be free of other sources of bias.  
Assunta De Luca et 
al,2009,Italy 
Low risk of Bias: 
Utilized the Italian 
lottery number 
extracted on the 6th of 
November 2004 as 
seed numbers for 
generating the random 
sequences.  
High risk of bias: just health 
professionals in the control group 
were not aware of being part of the 
study.  
High risk of bias:the 
EMS intervention arm 
had a lower rate of 
confirmed strokes than 
the control arm, 
suggesting possible 
over-diagnosing by the 
trained EMS personnel 
High risk of Bias:1) Direct access to 
CT which, according to the protocol, 
together with time of onset was 
necessary to define the eligible 
stroke patients, was not available in 
the whole study population. 2)The 
province of Viterbo did not complete 
the study, meaning that 10 entities 
with 1086 patients withdrew, 985 
from the intervention and 100 from 
the control arm.  




High risk of Bias:Strong non 
homogeneity among clusters and 
withdrawal of some important 
participantingcentres reduced the 
power of the study. Low rsk of 
Bias:"stopping rules": the study 
strictly monitored the study in aim 
to detect any unexpected events.   
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information about the 
sequence generation 
process to permit 
judgement.  
Uncertainty: insufficient 
information about the sequence 
generation process to permit 
judgement.  
Uncertainty: insufficient 
information about the 
sequence generation 
process to permit 
judgement.  
Low risk of bias: no mssing outcome 
data 
Low risk of bias: 






information to assess whether an 
important risk of bias exists.   
Drury P et 
al,2013,Australia 




stratified by category;  
Low risk of Bias: Stratifcation with 
allocation concealed until provided 
to the project officer who assigned 
ASUs to groups.  
Low risk of 
bias:1)Research 
assistants were masked 
to trial design enrolled 
patients, trial aims, 
design and group 
allocation. The 
statistician was masked 
to group allocation.  2) 
Single blind: clinician 
delivering the 
intervention were not 
blinded. 3) 4 auditors 
blind to study design 
conducted audit.  
Low risk of bias: 1)The patients with 
severe strokes might be 
underestimated, but the subgroup 
analyses has showed significant 
outcomes accordingly. 2) .2) Of the 
1861 eligible patients across the 
entire study period, medical records 
were unavailable for 57 
patients(3.6%)[17(2.4%) from the 
preintervention cohort and 40(3.7%) 
from the postintervention cohort.] 
Low risk of bias: 





High risk of Bias:"attitudes and 
beliefs" or leadership style may 
have affected the success uptake of 
the intervention. 
Fagerberg B et al,2000, 
Sweden 
Low risk of Bias: 
randomized the 




information about the sequence 
generation process to permit 
judgement.  
High risk of Bias: the 
internist or neurologist 
on call conduct the 
patient randomization.  
Low risk of bias: Only 7 out of 83 
patients did not complete the follow-
up in control branch. Only 6 out of 
166 patient were missing in follow-
up in intervention group.  
Low risk of bias: 





High risk of bias: Different degrees 
of severity of stroke among the 
studied patients may influence the 
results, since such patients 
constituted a minority and the 
favorable effect may have been 
overshadowed by the patients with 
less severe stroke. . 
Panella M et al,2012, Italy Low risk of bias: 
patient randomization 
was carried out using 
a computer-generated 
sequence 
Low risk of bias: the randomization 
works with allocation concealment 
High risk of bias: 1) the 
selection of units and 
the final randomization 
was based on the 
comparability of their 
location, patient 
population and volume, 
facilities and teaching 
status. 2) Blinding of 
patients and clinicians 
was not possible 
(Hawthorne effect).  
Uncertainty: insufficient reporting of 
attrition/exclusions to permit 
judgement 
Low risk of Bias: 





High risk of bias:1) Selection bias 
may have occurred both at the 
individual and cluster levels;2) CPs 
used in the study were not 
completely identical because of 




Sulch D et al,2000, UK Low risk of bias: on 
the basis of a 
computer-generated 
list of random number 
Low risk of bias: the responsible 
physician called the randomization 
office, which conformed eligibility 
and allocation independently.  
Low risk of Bias: No 
blinding of service 
providers is less likely 
to introduce the bias.  
Low risk of bias: 1) the rates of 
incomplete records were lower than 
12%;  
Low risk of 




are of interest in 
the study have 
been reported in 
the pre-specified 
way.   
Low risk of Bias: 1) three-month 
piloting was conducted in advance 
to reduce the practice bias.2) 
Crossover of intervention s was 
minimized by using 2 different 
teams in 2 different wards areas to 
implement the 2 different strategies.  
Torp CR et 
al,2006,Denmark 
Low risk of Bias: 
cluster allocation with 
computer-generated 
random number 
High risk of bias: patients were 
prerandomized according to address 





close contact to the 
patients. Comparison of 
baseline data showed 
that the randomization 
was successful.  
Low risk of Bias: the 37 out of 410 
patients were not examined 
attributable to clerical errors. But the 
comparison of the excluded and 
included patients showed no 
significant differences regarding age 
and gender.  
Low risk of 




are of interest in 
the study have 
been reported in 
the pre-specified 
way. 
Uncertainty: 1) the term “standard 
aftercare” conceals many different 
treatment and rehabilitation 
programs. The effects of some 
standard aftercare are clearly 
underestimated and not 
comparable.2)Although the groups 
were rather comparable at baseline, 
it of course cannot be ruled out that 
the lack of 







C1:Histogram of selected variables 
Age 
 
Figure C1-1 Distribution of age for general patient cohort 
 
 
Figure C1-2 Distribution of age for control arm (upper) and treatment arm (lower) 
The histogram of age in general group of patients appears to be a normal 
distribution, with one clear center that the data are clustered around. Around 95% of 
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the values lie within two standard deviations of the mean value of 66.06 years old. In 
the control arm, the histogram appears to be a roughly normal distribution roughly 
with the center value of 67.97 years old. In the treatment arm, the similar trend was 
observed, with a slightly higher frequency around 64 years old.  
 
 
Figure C1-3 Distribution of consultation expenses (YUAN)for general patient cohort 
 
Figure C1-4 Distribution of consultation expenses (YUAN)for control arm (upper) 
and treatment arm (lower) 
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The histogram of consultation expenses in general group of patients appears to 
be a skewed right distribution, in which the tail on the right side of the histogram is 
longer than the left side. This means the data is generally clustered around a small 
mean value of 480.39YUAN and larger values are fewer. In the control arm, the 
histograms appear to be skewed right distribution as well with a continuously 
decreasing tendency along the x-axis. In the treatment arm, a similar trend was 
observed, with a higher frequency around 100 YUAN. 
 
 




Figure C1-6 Distribution of diagnostic expenses (YUAN)for control arm (upper) and 
treatment arm (lower) 
 
The histogram of diagnostic expenses in general group of patients appears to be a 
skewed right distribution, in which the tail on the right side of the histogram is longer 
than the left side. This means the data is generally clustered around a small mean 
value of 399.74 YUAN and larger values are fewer. In the control arm, the histograms 
appear to be skewed right distribution as well with the decreasing tendency along the 
increased value on x-axis. In the treatment arm, the similar trend was observed, but 




Figure C1-7 Distribution of laboratory test expenses (YUAN) for general patient 
cohort 
 
Figure C1-8 Distribution of laboratory test expenses (YUAN)for control arm (upper) 
and treatment arm (lower) 
The histogram of laboratory test expenses in general group of patients appears to 
be a skewed right distribution, in which the tail on the right side of the histogram is 
longer than the left side. This means the data is generally clustered around a small 
mean value of 640.24 YUAN and larger values are fewer. In the control arm, the 
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histograms appear to be skewed right distribution as well with the decreasing 
tendency along the increased value on x-axis. In treatment arm, the similar trend was 
observed, but the values around 525YUAN accounts for a relative higher frequency.  
 
Figure C1-9 Distribution of LOS (DAY) for general patient cohort 
 




The histogram of LOS in general group of patients appears to be a normal 
distribution, with one clear center that the data are clustered around. Around 95% of 
the values lied within two standard deviations away from mean value of 10.88days, 
while the more extreme values on either side of the center become less rare as the 
distance from the peak center. In control arm, the histogram appears to be an 
approximate normal distribution with the center value of 10.5 days, but the frequency 
trend seems fluctuated. In treatment arm, the skewed right distribution was observed 
in which the tail on the right side of the histogram is longer than the left side, and the 
larger values tends to decrease in a bigger range on x-axis.  
 
 





Figure C1-12 Distribution of medication expenses (YUAN)for control arm (upper) 
and treatment arm (lower) 
The histogram of medication expenses in general group of patients appears to be 
a proximate normal distribution, with one clear center that the data are clustered 
around. Around 95% of the values lied within two standard deviations away from 
mean value of2085.70YUAN, while the more extreme values on either side of the 
center become less rare as the distance from the peak center. Visually, the histogram 
appears to be a skewed right distribution, in which the tail on the right side of the 
histogram is longer than the left side, and the larger values are fewer in right tail. In 
the control arm, the histogram states a light skewed right distribution, where the left 
side of distribution follows an apparent uniform pattern has approximately the similar 
number of values in each frequency group. In the treatment arm, an obvious skewed 




Figure C1-13 Distribution of radiology expenses (YUAN) for general patient cohort 
 
Figure C1-14 Distribution of radiology expenses (YUAN)for control arm (upper) and 
treatment arm (lower) 
The histogram of radiology expenses in general group of patients appears to be a 
skewed right distribution, in which the tail on the right side of the histogram is longer 
than the left side. This means the data is generally clustered around a small mean 
value of 355.76 YUAN and larger values are fewer. In the control arm, the histograms 
appear to be skewed right distribution as well with the decreasing tendency along the 
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increased value on x-axis. In treatment arm, the similar trend was observed, but the 
values around 240YUAN accounts for a relative higher frequency.  
 
Figure C1-15 Distribution of total hospitalization expenses (YUAN) for general 
patient cohort 
 
Figure C1-16 Distribution of total hospitalization expenses (YUAN)for control arm 
(upper) and treatment arm (lower) 
The histogram of total hospitalization expenses in general group of patients 
appears to be a proximate normal distribution, with one clear center that the data are 
clustered around. Around 95% of the values lie within two standard deviations away 
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from mean value of 4379.65 YUAN, while the more extreme values on either side of 
the center become less rare as the distance from the peak center. Visually, the 
histogram appears to be a light skewed right distribution, in which the tail on the right 
side of the histogram seems longer than the left side, and the larger values are fewer 
in right tail. In the control arm, the histogram states a light skewed right distribution, 
where the left side of distribution follows an apparent uniform pattern has 
approximately the similar number of values in each frequency group. In the treatment 
arm, the distribution shape of the data in the histogram is skewed right distribution 
apparently, and the bi-mode occurs, as there are two peaks for the data item. 
 




Figure C1-18 Distribution of utility score for control arm (upper) and treatment arm 
(lower) 
The distribution shape of the utility score for general population in the histogram 
is skewed left distribution slightly, and the bi-mode occurs, as there are two peaks for 
the data item. The data is generally clustered around a mean value of 0.369 and the 
higher scores are more than the lower ones. In the control arm, the histograms appear 
to be skewed right distribution as well with the decreasing tendency along the 
increased value on x-axis. In treatment arm, a significant skewed left distribution was 
observed. In addition, we can see that the two-peak distribution for general population 
can be explained by the two adverse sub groups.  
C2: Results of Diagnostic Plots in ITS 
Length of Stay  
Referring to Figure C2-1, looking at the studentized residuals vs. predicted 
values, the points appear to be randomly scattered about zero, suggesting that mean 
does equal zero. There appears to be no difference in spread across the residuals, this 
suggests that the assumption of constant variance is met. There does not appear to be 
any systematic trend suggesting that independence is met. There appear to be some 
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outliers, which are highlighted by the leverage and Cook’s distance (Cook’s D) plots. 
Generally, the assumptions of multi-linear regression are met.  
 
Figure C2-1Diagnostic Plots for LOS 
EQ-5D based utility value 
Referring to Figure C2-2, looking at the studentized residuals vs. predicted 
values, the points appear to be randomly scatted about zero, suggesting that mean 
does equal zero. There appears to be no difference in spread across the residuals, this 
suggests that the assumption of constant variance is met. There does not appear to be 
any systematic trend suggesting that independence is met. There appear to be some 
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outliers, which are highlighted by the leverage and Cook’s distance (Cook’s D) plots. 
Generally, the assumptions of multilinear regression are met. 
 
Figure C2-2 Diagnostic Plots for EQ-5D based utility value 
Referring to Figure C2-3, looking at the studentized residuals vs. predicted 
values, the points appear to be randomly scatted about zero, suggesting that mean 
does equal zero. There appears to be no difference in spread across the residuals, this 
suggests that the assumption of constant variance is met. There does not appear to be 
any systematic trend suggesting that independence is met. There appear to be some 
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outliers, which are highlighted by the leverage and Cook’s distance (Cook’s D) plots. 
Generally, the assumptions of multilinear regression are met.  
 
 
Figure C2-3 Diagnostic Plots for total hospitalization  expenses 
Medication expenses 
Referring to Figure C2-4, looking at the studentized residuals vs. predicted 
values, the points appear to be randomly scatted about zero, suggesting that mean 
does equal zero. There appears to be no difference in spread across the residuals, this 
suggests that the assumption of constant variance is met. There does not appear to be 
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any systematic trend suggesting that independence is met. There appear to be some 
outliers, which are highlighted by the leverage and Cook’s distance (Cook’s D) plots. 
Generally, the assumptions of multilinear regression are met.  
 
Figure C2-4 Diagnostic Plots for medication expenses 
Radiology expenses 
Referring to Figure C2-5, looking at the studentized residuals vs. predicted 
values, the points appear to be randomly scatted about zero, suggesting that mean 
does equal zero. There appears to be no difference in spread across the residuals, this 
suggests that the assumption of constant variance is met. There does not appear to be 
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any systematic trend suggesting that independence is met. There appear to be some 
outliers, which are highlighted by the leverage and Cook’s distance (Cook’s D) plots. 
Generally, the assumptions of multilinear regression are met. 
 
Figure C2-5 Diagnostic Plots for Radiology expenses 
Laboratory test expenses 
Referring to Figure C2-6, looking at the studentized residuals vs. predicted 
values, the points appear to be randomly scatted about zero, suggesting that mean 
does equal zero. There appears to be no difference in spread across the residuals, this 
suggests that the assumption of constant variance is met. There does not appear to be 
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any systematic trend suggesting that independence is met. There appear to be some 
outliers, which are highlighted by the leverage and Cook’s distance (Cook’s D) plots. 
Generally, the assumptions of multilinear regression are met.  
 
Figure C2-6 Diagnostic Plots for laboratory test expenses 
Consultation expenses 
Referring to Figure C2-7, looking at the studentized residuals vs. predicted 
values, the points appear to be randomly scatted about zero, suggesting that mean 
does equal zero. There appears to be no difference in spread across the residuals, this 
suggests that the assumption of constant variance is met. There does not appear to be 
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any systematic trend suggesting that independence is met. There appear to be some 
outliers, which are highlighted by the leverage and Cook’s distance (Cook’s D) plots. 
Generally, the assumptions of multilinear regression are met.  
 
Figure C2-7 Diagnostic Plots for consultation expenses 
Diagnostic expenses 
Referring to Figure C2-8, looking at the studentized residuals vs. predicted 
values, the points appear to be randomly scatted about zero, suggesting that mean 
does equal zero. There appears to be no difference in spread across the residuals, this 
suggests that the assumption of constant variance is met. There does not appear to be 
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any systematic trend suggesting that independence is met. There appear to be some 
outliers, which are highlighted by the leverage and Cook’s distance (Cook’s D) plots. 
Generally, the assumptions of multilinear regression are met.  
 
Figure C2-8 Diagnostic Plots for Diagnostic expenses 
C3: Transition probabilities between outpatient and inpatient 
applied in models 
Intervention State Probability Cycle Source 
CP 
Inpatient to outpatient  
(Acute stage) 
0.000  1 
Real-world 
data 
0.001  2 
0.003  3 
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0.000  4 
0.003  5 
0.010  6 
0.072  7 
0.088  8 
0.156  9 
0.169 10 
0.135  11 
0.086  12 
0.042  13 
0.051 14 
0.082 15 
0.040  16 
0.024  17 
0.013  18 
0.010 19 
0.010  20 
0.000 21 
0.000  22 
Outpatient to inpatient  0.157 -- (Tu, 2016) 
Non-CP 
Inpatient to outpatient  
(Acute stage) 
0.000  1 
Real-world 
data 
0.028  2 
0.031  3 
0.049  4 
0.066 5 
0.057  6 
0.067  7 
0.067  8 
0.105 9 
0.166 10 
0.095  11 
0.055 12 
0.082 13 
0.052  14 
0.045  15 
0.041  16 
0.017 17 
0.012 18 
0.007  19 
0.008  20 
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0.000  21 
0.000  22 
Outpatient to inpatient  0.157 -- (Tu, 2016) 
 
C4: Mortality rates used in outpatient at stable stage 


























































































U_CP_inpatient（per year） beta 
U_NCP_inpatient（per year） beta 
U_outpatient（per year） beta 
U_dead（per year） fixed 
 
